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Within this investigation a robust ILC identification method was used to identify ILCs and their 
subsets, comparing them across non-lymphoid and lymphoid tissues. ILCs were distributed 
differently across the analysed tissue and it was identified that surface marker expression, 
used to identify ILCs, was varied depending on location. The importance of digestion protocols 
was also highlighted, observing reduced expression of identification markers under harsher 
digestion protocols. Upon identifying ILCs, the role of the co-stimulatory molecule, inducible 
co-stimulator (ICOS), in their homeostasis was assessed. ILCs were not perturbed in the 
absence of ICOS:ICOSL interactions, suggesting a redundant role in ILC maintenance. This 
directed the aim of the investigation towards assessing ILC migration between non-lymphoid 
and lymphoid tissues. Photoconvertible Kaede mice were used to observe ILCs migration into 
peripheral LNs, with ILC1s likely entering in from the blood, in a CCR7-dependent manner. ILCs 
egressed from the LN in an S1P-dependent manner and recirculated through contralateral 
LNs. Minimal ILC migration through the lymphatics was detected from the ear to the draining 
LN, however, was modestly increased under skin inflammation. Combined these data reveal 
fundamental new insight into the biology of ILCs at barrier sites and LNs, identifying a 
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Chapter 1.   INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The immune system is the body’s mechanism for dealing with the invasion of harmful 
microorganisms, termed pathogens, preventing them from causing disease. Barrier sites such 
as the lung, gastrointestinal tract and skin provide the first line of defence against pathogen 
entry, with a physical and chemical barrier, involving the production of anti-microbial proteins 
and mucins (1-3). These barrier sites are constantly exposed to a variety of pathogens but are 
also colonised by commensal bacteria, which whilst helping protect against pathogens under 
certain conditions may themselves become pathogenic (4). The immune system evolved to 
discriminate between pathogenic and non-pathogenic microorganisms, achieved by the 
development of a two sided immune system, the innate and adaptive (5, 6). The innate 
immune system is the first response to pathogen invasion, detecting non-self/danger signals, 
with a plethora of cells being recruited to the point of entry to combat infection (6). Under 
certain circumstances this initial response alone, is insufficient in the eradication of 
pathogens, in which the adaptive response is then involved to effectively combat pathogen 
invasion in an antigen-specific manner (5, 7, 8). Adaptive immunity also possesses the ability 
to develop memory, which upon pathogen re-invasion activates a quick response and a faster 
clearance of infection (9).  
A key factor in the development of an effective immune response is the regulation of the 
migration and/or retention of innate and adaptive immune cells. This enables the recruitment 
of innate immune cells to the site of infection followed by the induction of adaptive immunity. 
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1.2 THE INNATE IMMUNE SYSTEM 
1.2.1 Recruitment of innate immune cells to the site of infection 
Pathogen invasion, through penetration of the protective epithelial cell barrier, requires the 
initiation of a quick response to control and prevent pathogen dissemination. Leukocytes 
residing within the tissue at the area of infection are principal for an effective localised 
immune response, which is controlled by the cells of the innate immune system. 
Barrier sites contain innate monocyte-derived macrophages and dendritic cells (DCs) which 
contribute to the initial line of defence, recognising microbial ligands via pathogen recognition 
receptors (PRRs) (1, 2, 10-12). These cells aid pathogen clearance via the process of 
phagocytosis alongside the production of cytokines and chemokines initiated by the activation 
of specific PRRs called toll like receptors (TLR) (10, 12-17). Cytokines and chemokines are both 
small soluble proteins which elicit their effects by binding to their specific receptors on other 
cells (10, 12, 17). Cytokines act in an autocrine or paracrine manner, affecting the behaviour 
of cells, either by supressing or enhancing their activation level, whereas chemokines are 
important in driving the directional migration of cells towards highly concentrated chemokine 
areas (18, 19). TLR driven activation of innate immune cells results in their release of 
chemokines, such as C-C motif Chemokine Ligand (CCL) 2, driving the recruitment of innate 
immune cells such as neutrophils, natural killer (NK) cells, monocytes and DCs towards the site 
of infection, aiding pathogen clearance (20, 21). Production of the cytokines interleukin 
(IL)- 1b, tumour necrosis factor (TNF)-a and IL-12, also produced by epithelial cells, are 
important in the activation of the vascular endothelium, aiding cell recruitment and activating 
lymphocytes, such as NK cells (2, 22-24). Innate lymphoid cells (ILCs) are also described as an 
 3	
innate population residing at barrier sites that contribute to the early innate cell cytokine 
production and therefore the regulation of pathogen clearance (25-28). Efficient pathogen 
clearance relies on macrophages and DCs to recruit innate cells to the site of infection, driving 
inflammation. 
1.2.2 Migratory properties of the innate immune system 
Innate cells are mainly located within barrier sites and it is now understood that some 
populations are completely tissue-resident, including tissue-resident macrophages that 
remain within the tissue throughout the immune response (29). These cells are important in 
the rapid recruitment of innate lymphocytes, such as neutrophils, from the blood into certain 
tissues (29). In addition to DCs function in driving the clearance of pathogens via phagocytosis 
within the inflamed tissue, they are able to uptake, process and present antigen via the major 
histocompatibility complex (MHC) (11, 30-32). Within the infected tissue, combined TNF-a 
and TLR stimulation drives DCs to develop into a mature phenotype, polarizing MHC-peptide 
expression to the plasma membrane and the upregulation of co-stimulatory molecules cluster 
of differentiation (CD) 80 and CD86 (31-33). The role of co-stimulatory molecules in the 
activation of the adaptive immune system will be discussed later. DC maturation is further 
accompanied by the downregulation of chemokine receptors associated with tissue-residency 
and upregulation of C-C chemokine receptor (CCR) 7, which enables mature DCs to become a 
migratory population (34, 35). This maturation process of tissue-resident DCs into mature 
migratory antigen presenting cells (APCs), enables them to leave the site of infection via the 
lymphatics and migrate into draining secondary lymphoid tissue (SLTs) with processed antigen 
from the site of infection. This maturation is key to the activation of the adaptive immune 
response.   
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1.3 THE ADAPTIVE IMMUNE SYSTEM 
Activation of the adaptive immune system is required to mount a sufficient antigen-specific 
response to resolve infection, with a lack of adaptive immunity leading to a fatal outcome 
upon pathogen exposure (7, 8). The adaptive immune system comprises of T cells and B cells 
which, unlike innate immune cells, express the antigen specific receptors T cell receptor (TCR) 
and immunoglobulin (Ig) B cell receptor respectively (5, 36). This enables the development of 
a response specific to the invading pathogen. During cell development the receptor undergoes 
somatic gene recombination, which gives rise to a multitude of receptors on individual cells, 
specific to a range of pathogens (36, 37). This mechanism of specific receptor domain 
rearrangement is dependent on recombination activation genes (RAG) 1 and RAG2 (36-38). 
These genes have been  targeted in murine models to study the immune system, creating RAG 
deficient mice which lack adaptive immunity (36-38). The antigen specificity of T and B cells 
enables a tailored immune response separating adaptive immunity from innate, which instead 
responds in a similar manner independent of the invading pathogen. Whilst B cell activation 
and development is required for the production of antigen specific Ig release and the 
resolution of inflammation, the pathway involved in the activation of T cells will be focused 
on throughout this report. 
1.3.1 T cells 
T cells are subdivided into multiple groups based on their phenotype and functional 
contribution to the immune response. The TCR is comprised of two glycoproteins chains, 
either a and b chains (ab TCR) or g and d chains (gd TCR) (39). The majority of T cells are ab T 
cells, which are abundant in SLTs (6). This is compared to gd T cells which are fewer and mainly 
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reside at epithelial and mucosal barrier sites, possessing innate abilities blurring the lines 
between the innate and adaptive responses (6, 40). Within both ab and gd T cells the TCR is 
associated with the CD3 module, termed the TCR-CD3 complex, which is paramount in the 
efficient transduction of TCR signalling and T cell activation (41). The TCR-CD3 complex only 
recognises cognate antigen when presented by MHC, in which there are two subsets, MHC 
class I (MHCI) and class II (MHCII) (39, 42-44). ab T cells can be further subdivided based on 




 T cells 
are activated by their TCR-CD3 complex initiating their development into effector T cells 
eliciting their functions immediately, or their development into memory T cells which upon 
pathogen re-encounter can rapidly produce an antigen specific response (45). CD8
+
 T cells are 
the cytotoxic branch of the ab T cell subset, able to recognise peptide presented my MHCI 
and function in the protection against intracellular bacteria, viruses and tumorigenic cells (44). 
Cytotoxic CD8
+
 T cells elicit their functions through the release of interferon-g (IFN-g), TNF-a, 
cytotoxic granules and are able to signal through the TNF family proteins, inducing cell death 
(42, 45, 46). CD4
+
 T cells, however, do not function as cytotoxic cells and are referred to as T 
helper (Th) cells, restricted to activation via MHCII (42). Upon recognition of the MHCII-antigen 
complex naïve CD4
+
 T cells develop into mature effector T cells and elicit their functions by 
producing effector cytokines, contributing to regulating the immune response (42, 47). 
1.3.2 Activation of the adaptive immune system 
Naïve T and B cells are highly migratory populations, recirculating through the blood and SLT 
(48). T cells migrate through SLT in search of processed antigen presented via MHC (44, 48). 
Processed antigen can be presented by MHCII on APCs such as DCs, which as discussed earlier, 
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mature within the site of infection developing the ability to migrate and leave via the 
lymphatics (31-33). Due to the low frequency of TCRs that are specific to the invading 
pathogen, and the small number of APCs expressing specific cognate antigen, the probability 
of TCR recognition of MHCII-antigen is low (9). To overcome this APCs are directed to SLT, such 
as the lymph node (LN) in which naïve T cells recirculate, increasing the chance of TCR:MHCII-
antigen interactions between naïve T cells and APCs (9). This emphasises the importance of 
the migratory properties of innate immune cells to link these two sides of the immune system. 
LNs are vascularised structures with direct drainage from the lymphatic system providing a 
niche microenvironment in which circulating naïve T cells from the blood and innate APCs, 
from the draining peripheral tissues, become concentrated and their interactions facilitated 
(49). The blood and lymphatics provide a constant influx of lymphocytes to the LN, which are 
segregated upon entry into T cell zones and B cell follicles (49-51). This is tightly controlled by 
the stromal network producing key chemokines such as CCL19, CCL21 and C-X-C motif ligand 
(CXCL) 13, controlling lymphocyte entry and migration to specific zones (49-52). Naïve T and 
B cells are thought to spend up to 12 hours and 24 hours, respectively, scanning the LN for 
cognate antigen, in which they leave the LN and re-enter the circulation if none is found (53). 
Upon antigen encounter within the LN a series of steps occurs leading to the activation of the 
naïve T cells via the TCR. 
1.3.3 CD4+ T cell Activation 
Activation of naïve CD4
+
 T cells is a well-regulated multi-step process which requires the TCR 
on naïve CD4
+
 T cells to recognise and bind MHCII-antigen complex on APCs (54). This 
interaction alone stimulates the naïve T cell out of a quiescence phase, however, is insufficient 
for the effective generation of mature effector T cells, which requires further stimulation 
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through co-stimulatory molecules expressed on mature APCs (55-57). The receptor CD28 is 
constitutively expressed on naïve T cells and post TCR:MHCII-antigen interactions binds to its 
ligands CD80 and CD86 on mature APCs initiating T cell proliferation, IL-2 production and cell 
survival (55-57). As a regulatory mechanism, cytotoxic T lymphocyte-associated molecule-4 
(CTLA-4) is upregulated on T cells post activation and competes with CD28 (58, 59). This 
controls and limits the proliferation process of T cells, stopping the immune response when 
appropriate (58, 59). CD28 co-stimulation is not the only, although is the most robust, manner 
in which T cell activation is assisted. Signalling through CD28 regulates the expression of other 
co-stimulatory molecules expressed on activated T cells including inducible co-stimulatory 
(ICOS), tumour necrosis factor receptor superfamily, member 4 (OX40) and CD40L (54, 55, 57). 
ICOS binds to ICOS ligand (ICOSL) which can be expressed on immune and stromal cells, 
promoting survival, proliferation and maturation of T cells (60-62). The expression of OX40 
ligand (OX40L) is induced on APCs, with OX40:OX40L interactions, in conjunction with 
CD28:CD80/86 stimulations, elongating proliferation of activated T cells and promoting 
cytokine production (63, 64). CD40, the receptor for CD40L is expressed on B cells with these 
interactions promoting B cell survival and maturation alongside the formation of germinal 
centres, required for the effective development of B cells and their antibody response (65, 
66). 
1.3.4 Effector T helper cells  
Efficient activation of naïve CD4
+
 T cells via TCR:MHCII-antigen and co-stimulatory 
interactions, leads to the differentiation into effector Th cells which are subdivided into 
different subsets based on their expression of transcription factors (TF) and cytokine 
production (47). Pioneering work profiling effector T cells, initially identified two subsets Th1 
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and Th2 cells, with Th1s expressing the T-box TF (T-bet) producing IFN-g and TNF-a and Th2s 
being GATA binding protein 3 (GATA-3)
+
 and producing the cytokines IL-4, IL-5, IL-9 and IL-13 
(47, 67). The differentiation of Th cells is determined by multiple factors including cytokine 
signalling and strength of TCR interactions, which are regulated by the type of pathogen 
invasion (47, 68, 69). Th1s are induced under IFNg, IL-2 and IL-12 signalling and the effector 
cytokines produced are involved in immune responses against intracellular pathogens, 
including bacteria and viruses (69-71). Th2s cytokine production is important in the expulsion 
and protection against helminth infections, with their differentiation and function being 
driven by IL-4, IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) (68, 69, 72-74). In addition 
to the protective roles of these Th cells, they have also been associated with disease 
development, including multiple sclerosis and rheumatoid arthritis by Th1s and allergic 
responses and atopic diseases by Th2s (47, 75, 76). Following the discoveries of Th1 and Th2 
cells, the identification of additional subsets was discovered, including Th17 cells, T regulatory 
cells (Tregs), T follicular h (Tfh) cells and the more recently described Th9 cells (47, 68). The TF 
retinoic acid receptor-related orphan receptor-gt (ROR-gt) drives Th17 cell development and 
the production of IL-17A, IL-17F and IL-22, which are important in the clearance of 
extracellular pathogens (77-79). Tregs are involved in the suppression and control of the 
immune response through different mechanisms. For example, they use inhibitory receptors 
and produce anti-inflammatory cytokines including IL-10, and transforming growth factor b 
(TGFb), alongside IL-35, regulating the proliferation of antigen-stimulated T cells, including to 
self-antigen (80-82). The development and function of Tregs depends on the expression of the 
TF forkhead box P3 (Foxp3) and in addition to differentiating from naïve CD4
+
 T cells within 
the periphery, Tregs also develop within the thymus which are termed natural Tregs (82, 83). 
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Tfh cells are important in the development of the humoural B cell response. They are required 
for the maturation and function of germinal centres which are paramount for B cell affinity 
maturation and survival signals to developing B cells (84-86). As discussed, IL-9 is a cytokine 
related to Th2 cells and is involved in stimulating the production of mucus and activation of 
innate immune cells (87-89). However, recent publications have identified a separate source 
of IL-9 by Th9 cells which require TGF-b and IL-4 signalling for their development, either 
directly from naïve T cells or from Th2 cells (88, 90, 91).  
Upon development and expansion of the effector CD4
+
 Th cell populations, which takes about 
2 days, clearance of infection is dependent on the migration of particular Th cell subgroups to 
the inflamed tissue (9, 47). Th cells leave the LN via the lymphatics and enter the blood 
travelling to the site of infection (9). Post infection, the majority of effector Th cells die, 
however some develop into memory T cells which migrate within the blood and non-lymphoid 
tissue in a similar manner to Th cells (9). Memory T cells are crucial in the efficient induction 
of adaptive memory responses upon pathogen re-invasion (9). Furthermore, within recent 
years tissue-resident memory T cells have also been identified, contributing to the quick 
response against reinvading pathogens at the site of infection (92-94).  
There is clear evidence that effector populations can switch function and fate indicating 
plasticity. Th17 cells can adopt the characteristics of Th1s, producing both IL-17 and IFN-g (95, 
96). In some situations, Th17s can fully convert from their original subset into Th1s, as 
demonstrated by Hirota et al., through the use of fate mapping cells (95). Under experimental 
autoimmune encephalomyelitis Th17 cells downregulated their expression of RORgt and 
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upregulated T-bet enabling their production of IFN-g and their shut off of IL-17 production 
becoming ex-Th17 cells (95).  
1.4 INNATE LYMPHOID CELLS  
ILCs are a recently classified subgroup of innate immune cells which are distributed 
throughout the body in lymphoid and non-lymphoid tissues (97). ILCs share similarities with 
effector Th cells in their ability to produce effector Th cytokines upon activation and their 
developmental pathways, with both differentiating from common lymphoid progenitors (CLP) 
in an IL-2 dependent manner (98-102). However, ILCs are a distinct population of lymphocytes, 
separate to T cells and were originally identified based on their lack of lineage marker 
expression, differentiating them from common innate cells (25, 103). Furthermore, their 
effector Th cytokine production occurs within the early innate stages of pathogen infection, 
compared to the later adaptive Th cell response (25, 28, 97, 103, 104). Confirming that ILCs 
are not part of the adaptive immune response, the lineage negative population were still 
functionally present and able to produce effector cytokines upon stimulation in Rag-/- mice 
(25, 103, 105-108). This also shows that ILCs are not dependent upon the RAG recombinase 
complex to generate antigen specific receptors. Instead it was discovered that ILCs typically 
rely on soluble factors produced by cells such as myeloid cells and epithelial cells, for their 
activation and function (97, 109). 
ILCs ability to rapidly produce effector cytokines alongside their positioning at barrier sites 
makes them an important early source of Th cytokines, upon pathogen invasion (25, 103). ILCs 
are now an established population with their functions being defined in multiple tissues 
contributing to the clearance of pathogen invasion, regulation of commensal microorganisms, 
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repair of damaged tissue and maintenance of epithelial barriers (26, 28, 97, 104, 108, 110, 
111). However, dysregulated ILC cytokine production has also been linked to the development 
of particular inflammatory diseases (104, 112). 
Effector Th cytokine production by ILCs enables them to be divided into subgroups similar to 
Th1s, Th2s and Th17 cells. According to their cytokine profile and TF expression ILCs are 
classified into group 1 ILCs, group 2 ILCs and group 3 ILCs (101). Recently a fourth subset of 
ILCs has been proposed, named regulatory ILCs (ILCregs), however, these are only described 
in one publication and remain controversial within the literature (113). 
1.4.1 Group 1 ILCs 
Group 1 ILCs are identified according to their expression of the TF T-bet and their ability to 
produce the cytokines TNF-a and IFN-g upon stimulation, similar to effector Th1 cells (108, 
114). Group 1 ILCs are further subdivided into conventional natural killer (cNK) cells and innate 
lymphoid cell group 1 (ILC1) (28, 101). cNK cells were initially identified in 1975 as an innate 
lymphocyte population that were  similar to cytotoxic T cells, with the ability to travel within 
the blood, surveying and killing tumour cells and viral or intracellular bacterial infected cells 
(115-117). However, cNK cells do not respond in an antigen specific manner and can be 
activated via cell surface receptors, such as the natural cytotoxic receptor (NCR) NKp46 (118). 
This is why upon recent ILC nomenclature, cNK cells have been classified within this group 
(101). cNK cells elicit their cytotoxic abilities through the release of perforin and granzymes 
alongside the expression of the TNF-related apoptosis-inducing ligand (TRAIL) (115, 118-125). 
Additionally, cNK cells release IFN-g and TNF-a which have anti-viral, -tumour and -bacterial 
functions such as stimulating macrophage phagocytosis (23, 24, 126). Due to the cytotoxic 
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capability of cNK cells, they are classified separately from other ILCs as cytotoxic ILCs, with the 
remaining ILCs, across all other groups, being termed helper ILCs (28, 101). A distinct feature 
of cNK cells, compared to ILC1s, is the expression of eomesdermin (EOMES) which is required 









) (27, 127, 128). In addition, ILC1 development 
is dependent on IL-7 signalling, with IL-7 being redundant in the development of cNK cells (27, 
128). IL-7 dependency is a common factor amongst all helper ILCs, therefore expression of 
IL- 7 receptor a (IL-7Ra) is used as a hallmark in the identification of Lineage- helper ILCs (27, 
28, 101). Similar to cNK cells, stimulation of NKp46 on ILC1s upregulates TRAIL expression and 
the ability to induce cell apoptosis on cells expressing TRAIL receptors (124, 129). Further to 
NKp46, depending on their function and location, ILC1s can be activated by IL-12, IL-18 or 
IL- 15 to produce their effector cytokines including IFN-g and TNF-a (104, 129-132). The 
identification of cNK and ILC1 subsets is currently being developed in the group 1 ILC field, 
with different ILC1s being identified within the salivary glands and liver (133). cNKs functions 
are well described within the literature, partly due to their early discovery (134). The recent 
identification of ILC1s, as a distinct population from cNK with a similar cytokine profile and 
innate ability, raises the possibility that ILC1s may contribute to the previously described 
functions of cNK cells. With the current ability to identify cNK cells and ILC1s separately, 
through TF expression, further research is required into the specific functions of ILC1s and cNK 
cells to determine whether they elicit distinct or combined effects (135).  
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1.4.2 Group 2 ILCs 
Innate lymphoid cell group 2 (ILC2s), before the establishment of a uniformed nomenclature, 
were initially identified as a variety of cells termed nuocytes, natural helper cells and innate 
helper 2 cells (25, 102, 103). Albeit having different names, all cell populations were identified 
within the same year on their basis of lacking lineage markers, producing an innate source of 
Th2 cytokines, being activated by IL-25 and IL-33 and providing protection against helminth 
infections (25, 102, 103). These publications were central in the establishment of ILCs as a 
separate population to Th cells, with ILC2s being able to produce IL-13 in the early innate 
phases of the immune response to helminths in the absence of an adaptive immune system 
(25, 103). Nuocytes, natural helper cells and innate helper 2 cells were later classified into one 
group with their development and maintenance being dependent on the TF GATA-3 and 
signalling through the IL-7Ra (25, 102, 103, 136). More recently, alongside IL-25 and IL-33, 
TSLP, produced by epithelial cells, has also been identified as another cytokine important in 
the activation of ILC2s (25, 103, 112). ILC2s have further been subdivided into two groups 
based on their sensitivity to IL-25 and IL-33 (108). IL-25 sensitive ILC2s, which lack the IL-33 
receptor (ST2), termed inflammatory ILC2s (iILC2s), express high levels of killer-cell lectin like 
receptor G-1 (KLRG1), and although barely detectable in the lung under steady state, their 
proliferation is increased upon IL-25 but not IL-33 stimulation (108). Comparatively, natural 
ILC2s (nILC2s) are found in the steady state lung and are responsive to IL-33 rather than IL-25  
(108). Upon helminth infection, iILC2s expand within the lung prior to nILC2s, providing the 
main source of IL-13, upregulating ST2 expressing and developing into a nILC2 phenotype 
(108). In addition to the production of interleukins, ILC2s also elicit their functions through the 
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release of epidermal growth factor amphiregulin, which is important in the maintenance and 
repair of epithelial barriers (110).  
1.4.3 Group 3 ILCs 
Innate lymphoid cell group 3 (ILC3s) are similar to effector Th17 cells in that they express the 
TF RORγt and produce the cytokines IL-22 and/or IL-17A (108, 114). The first subgroup of ILC3s 
discovered were lymphoid tissue inducer cells (LTi cells), which are located within the embryo 
and are paramount in the organogenesis of LNs (111, 137, 138). Before the identification and 
classification of ILCs, RORgt+ NKp46+ innate immune cells were identified to produce IL-22 
within the gut (26, 105). These cells were classified as a separate population to cNK cells and 
T cells on the basis of lacking cNK cell effector functions, CD3 expression and their successful 
development and identification in Rag-/- mice (26, 105). The development and function of 
RORgt+ NKp46+ cells was dependent on the presence of intestinal commensal bacteria, with 
germ free mice lacking RORgt+ NKp46+ cells (26, 105). Such cells are now confirmed as RORgt 
expressing ILC3s that lack lineage markers associated with common innate immune cells and 
adaptive immune cells (130, 139). 

















 ILC3s (130, 139). 
Interestingly, ILC1s are not the only ILC subgroup that depend on T-bet for their function. NCR
+
 
ILC3s also depend on T-bet and are absent in T-bet deficient mice (130). This joint expression 
of T-bet and RORgt enables them to also produce IFN-g in response to IL-12 (127, 130). 
Although all group 3 ILCs can be stimulated by IL-23, LTi-like cells are able to produce IL-17 




 ILC3s which both produce IL-22 (139).  
 15	
1.4.4 Regulatory ILCs 
Since the definition of a universal nomenclature in 2013, the functional relevance of ILCs has 
been explored in multiple tissues under homeostatic and inflammatory conditions (101). More 
recently, in 2017, a fourth ILC subset was proposed, termed ILCregs (113). ILCregs were 
described as negative for lineage markers but express IL-7Ra and deoxyribonucleic acid (DNA) 
binding protein inhibitor 2 (Id2), defining them as ILCs and are identified through the 
production of IL-10 (113). ILCregs were shown not to express any typical ILC TF such as T-bet, 
GATA-3 or RORgt and were therefore identified as a distinct subgroup from ILC1s, ILC2s and 
ILC3s (113). ILCregs share similarities with Tregs as upon stimulation they produce TGFb and 
IL-10, yet ILCregs lack Foxp3 expression (113). ILCregs respond to TGFb in an autocrine manner 
and are suggested to play a role in the regulation of inflammation, directly supressing ILC1 
and ILC3s (113). In the same year, IL-10 production was also linked to IL-33 responsive ILC2s 
within the lung, involved in reducing the chronic papin dependent recruitment of eosinophils 
(140). Currently the source of IL-10 production by ILCs is under debate within the literature 
and further research into this area is required. A summary of ILC and Th cell subgroups and 
their cytokine expression is shown in Figure 1.1. 
1.4.5 ILC Plasticity 
The establishment of a uniformed nomenclature facilitates the clear identification of ILC 
subsets based on their TF and cytokine profile. However, similar to Th cells, ILCs possess a 
level of plasticity and dependent on environmental stimuli, appear to be able to change their 
phenotype, including TF expression and cytokine profile and function, shifting from being 
identified in one subgroup to another (141-143). The shift in TF expression usually results in 
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Figure 1.1. Th cell and ILC subsets and cytokine production 
Th cells, on the left hand side and ILCs, on the right hand side, are subdivided into different 
subgroups based on their expression of cytokines. Th1 and ILC1s both express IFN-g and TNF-
a, Th2 and ILC2s both produce the type 2 cytokines IL-4, IL-5, IL-9 and IL-13. ILC2s further 
possess the ability to release amphiregulin. Th17 and ILC3s are able to release IL-17 and IL-22 
upon activation and Tregs alongside the newly suggested population of ILCregs produce IL-10 
and TGFb.  






























the ILC changing their cytokine production to that driven by the TF, however, a change in TF 
expression doesn’t always amount in a change of cytokine production, with ILC3s production 
of IL-17 and IL-22 being unaffected by inhibition of RORgt (144). NCR- ILC3s can upregulate T-
bet expression and co-express RORgt and T-bet, enabling the production of IFN-g (130, 141). 
NCR
+
 ILC3s are further able to downregulate RORgt becoming RORgt- T-bet+ NCR+ ILC1s (ex-
ILC3s) shown by Vonarbourg et al., using genetically tagged ILC3s (141). This plasticity is 
dependent on the microbiota, which stabilises RORgt expression for the development of NCR+ 
ILC3s from NCR
-
 ILC3s, and the absence of IL-7 signalling enabling the downregulation of RORgt 
and therefore development into ex-ILC3s (130, 141).   
Similar to ILC3s, ILC2s also possess the ability to acquire an ILC1 phenotype (142). During viral 
infections ILC2s are able differentiate into an ILC1 phenotype, with IL-12 and IL-18 driving the 
downregulation of GATA-3 and upregulation of T-bet, alongside the ability to produce IFN-g 
(142). However, direct fate cell mapping specific to ILC2s has not been used to show direct 
evidence of cellular conversion. ILC1s are the dominant ILC subset involved in the clearance of 
viral infections, potentially explaining the conversion of ILC2®ILC1s (142). Under certain 
conditions dysregulated ILC2 differentiation into ILC1s is believed to play a role in the 
development of chronic obstructive pulmonary disease, with an increase in ILC1s correlating 
with disease severity (142). 
1.5 ILC DEVELOPMENT 
ILC development occurs within the foetal liver during embryonic development and within the 
bone marrow (BM) in adults (136, 145, 146). Similar to T and B cells they arise from the CLP, 
which differentiate from multipotential hematopoietic stem cells, then undergo several 
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developmental stages before complete maturation (97, 127). Nuclear factor IL-3 regulated 
(NFIL3) and inhibitor and Id2, which is regulated by NFIL3, are required alongside IL-7 to 
promote the differentiation of CLPs into α4β7
+ 
α-lymphoid precursors (α-LP) (25, 97, 127, 147-
150). Id2 is essential for the development of all ILCs via inhibiting the TFs E proteins that are 
required for the development of T and B cells (102, 136, 145, 149, 151-154). This drives the 
commitment of the α-LP to an ILC lineage (102, 136, 145, 149, 151-154). α-LP differentiate 
into early innate lymphoid progenitors (EILP) which under IL-15 signalling upregulate EOMES 
and commit to the EOMES
+





 cNK cells (128, 131, 149, 155, 156). EILP that do not commit to the cNK lineage 
depend on GATA-3, which drives the upregulation of IL-7Ra, for differentiation into the 
common helper innate lymphoid progenitor (CHILP) committing the lineage fate to all helper 
ILCs (127, 136, 151, 157). GATA-3, although associated with ILC2s, is required for the 
development of all helper ILC subsets, with conditional knock outs deficient in GATA-3 
expression in hematopoietic stem cells, lacking the development of helper ILCs (136, 151, 
157). The maturation of CHILP into innate lymphoid cell precursor (ILCP) via the upregulation 
of the TF promyelocytic leukaemia zinc finger (PLZF) commits the development of ILCPs into 
ILC1s, ILC2s and NCR
-
 ILC3s only (98, 127). Similar to cNK cells, the development of LTi-like 
cells occurs from a higher developmental stage and differentiates from CHILP rather than ILCP. 
ILCP and CHILP both follow similar developmental pathways to give rise to LTi-like cells and 
NCR
-
 ILC3s, respectively, with both pathways being dependent on IL-7Ra signalling alongside 
expression of RORgt and the aryl hydrocarbon receptor (AHR) (127, 137, 141, 155, 158). As 
discussed, the upregulation of T-bet in NCR
-
 ILC3s results in their differentiation into NCR
+
 
ILC3s (130, 141). Differentiation of ILCPs into ILC1s or ILC2s is driven by IL-15 or IL-7 signalling, 
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respectively (127, 136, 156, 159). ILC1 development depends on the upregulation of T-bet 
whereas ILC2s require the combined upregulation of GATA-3 and retinoid-related orphan 
receptor a (RORa) alongside Notch signalling to develop into mature ILC2s (127, 136, 156, 
159). ILCs developmental pathway is summarised in Figure 1.2. 
1.6 FUNCTIONS OF ILCS 
ILCs function through a range of mechanisms within lymphoid and non-lymphoid tissues. ILCs 
rapid production of cytokines was important in the identification and classification of ILCs, 
within earlier studies and elicits many of their functions in a similar manner to Th cells (25, 
104, 105). More recent publications have additionally attributed their mechanism of action to 
their expression of cell surface proteins. LTi cells and LTi-like cells express lymphotoxin (LT) 
a1b2, which interacts with cells expressing the LTb receptor (LTb) R (111, 160, 161). 
Furthermore, subsets of ILC2s and ILC3s express MHCII which augments their interactions with 
the antigen specific TCR:CD3 complex on T cells, providing a direct mechanism of regulating 
the adaptive immune system (162-164). Under healthy conditions ILCs in these areas are able 
to support the normal function of tissues, however, upon dysregulation ILCs have also been 
associated with inflammatory diseases (28). The role of ILCs in the regulation and protection 
of non-lymphoid and lymphoid tissue will be discussed below. 
1.6.1 Gastrointestinal tract 
The gastrointestinal tract is the largest mucosal barrier and has developed alongside 
commensal bacteria to allow the absorption of nutrients from the diet whilst preventing the 
unwanted invasion of pathogens (2). The gut is lined with a number of specific lymphoid 
structures including Peyer’s patches (PP), which develop before birth, and solitary intestinal  
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Figure 1.2. ILC Development 
ILC development occurs within the BM developing from the CLP. Upon IL-7 signalling and 
upregulation of NFIL3 and Id2 the CLP develops into the aLP and subsequently the EILP which 
is committed to the ILC lineage. EILP upregulate EOMES and T-bet in an IL-15 dependent 
manner to develop into cNK cells, whereas IL-7 signalling and GATA-3 expression drives the 
development of the CHILP. Upregulation of RORgt, AHR and IL-7 signalling drives the 
development of LTi cells. This is similar for the development of NCR
-
 ILCs, which initially 
requires CHILP to upregulate PLZF differentiating into an ILCP. NCR
-
 ILC3s are able to 
upregulate T-bet expression driving the expression of NKp46 becoming an NCR
+
 ILC3s. The 
ILCP finally gives rise to both ILC1s, which required IL-15 stimulation and T-bet expression and 
ILC2s which development requires GATA-3, RORa, Notch and IL-7 signalling.  













































lymphoid tissues (SILT) which develop after birth (165). SILTs consist of small cryptopatches 
(CP) and isolated lymphoid follicles (ILF) which largely comprise of LTi-like cells (165). LTi-like 
cells are also found outside SILTs within the lamina propria (LP), however NCR
+
 ILC3s are more 
abundant within these areas (26, 105). All ILC3s are important producers of IL-22, which within 
SILTs, promotes the growth and proliferation of intestinal stem cell (ISC) niches which 
maintain a normal epithelial integrity post epithelial damage (166, 167). This was 
demonstrated by the absence of ILC3, in RORgt deficient mice, resulting in augmented damage 
within the intestine in response to i.p administration of methotrexate (167). Within the LP 
ILC3s production of IL-22 promotes a protective role against extracellular bacteria by 
promoting epithelial cell release of anti-microbial peptides (26, 168). Early production of IL-22 
in Citrobacter rodentium infections, promotes the production of the anti-microbial 
regenerating gene family proteins, (Reg)IIIb and RegIIIg, aiding clearance of infected mice and 
repair after epithelium damage (169-172). IL-22 production by ILC3s is controlled by IL-23, 
with recognition of microbial ligands stimulating the release of IL-23 by macrophages and DCs, 
regulating ILC3 function (173-175). Alongside the clearance of pathogens, ILC3s production of 
IL-22 plays a role in the regulation of commensal bacteria (162, 176). The removal of ILCs in 
Rag1 knock out (-/-) mice resulted in the peripheral propagation of commensal bacteria, to 
areas such as the spleen and liver, resulting in systemic inflammation (176). Administration of 
IL-22 reduced bacterial load within these sites, suggesting that ILC3s production of IL-22 may 
prevent commensal bacteria dissemination (176). However, these experiments were 
conducted in Rag-/- mice, suggesting that ILC3s may play a redundant role in the presence of 
a functioning adaptive immune system (176). ILC3 production of IL-22 and LTa1b2 expression 
have also been shown by Goto et al., to induce fucosyltransferase 2 (Fut2) expression in 
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intestinal epithelial cells (168). Fucosylation results in the production of fucose which is 
important in the survival and maintenance of commensal bacteria, aiding the protection 
against Salmonella typhimurium (168). 
Additional functions of ILC3s within the gut are dependent on specific mechanisms unique to 
different subsets. Alongside IL-22, LTi-like cells are able to produce IL-17 which also regulates 
extracellular pathogens by stimulating epithelial cells to produce and release anti-microbial 
proteins (177-179). Furthermore, LTi-like cells provide LTa1b2 signals to ISCs contributing to 
the recruitment of B cells and DCs into ILFs, promoting the release of IgA required in the 
protection against mucosal pathogens (160, 180).  
Cytokine production by ILC3s has already been suggested to play a role in suppressing the 
dissemination of commensal bacteria (176). Hepworth et al., discovered an additional role of 
NCR
-
 ILC3s in regulating commensal bacteria by direct interactions with CD4
+
 T cells. (162, 
163). NCR
-
 ILC3s express high levels of MHCII and exhibit antigen processing and presenting 




 ILC3s lack the co-stimulatory molecules, CD80, CD86 
and CD40 and are consequently unable to stimulate naïve T cells through TCR:MHCII-antigen 
interactions (162). This results in TCR:MHCII-antigen interactions between CD4
+
 T cells and 
ILC3s, limiting the proliferation and expansion of CD4
+
 T cells that are specific to commensal 
bacteria as well as inducing cell death of activated commensal bacteria-specific T cells (162, 
163). This was shown through the selective deletion of MHCII expression on ILCs resulting in 
an increase in CD4
+
 T cell proliferation and production of commensal bacteria specific IgG 
(162). This indicates a homeostatic role of ILC3s in the direct suppression of the adaptive 
immune response by preventing a CD4
+
 T cell response against commensal bacteria. 
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Alongside ILC3s, ILC2s are also important in the homeostasis of the gut (181). The epithelium 
under steady state produces IL-25 via tuft cells, maintaining a constant level of IL-13 
production by ILC2s (181). Upon infection with Heligmosomoides polygyrus, tuft cell 
hyperplasia resulted in an increased production of IL-25, further activating ILC2s production 
of IL-13, aiding pathogen clearance (181). IL-4 production by ILC2s is also important in the 
expulsion of enteric helminth infections, contributing to the clearance of Heligmosomoides 
polygyrus infection in a manner independent of IL-2 signalling (182). Within the gut type 2 
cytokines have been associated with the ‘weep and sweep’ process. IL-4, IL-5, IL9 and IL-13 
have been shown to increase helminth expulsion through increasing goblet cell mucus 
production and by promoting intestinal smooth muscle contractions in conjunction with 
enteric nerve stimulation, resulting in the mechanical expulsion of worms (183, 184).  
The recent identification of ILC1s as a distinct population from cNK cells means that their 
specific functions, separate to cNK cells, within inflammation are still currently being 
investigated (135). Upon infection with Salmonella, Toxoplasma gondii and Clostridium 
difficile ILC1s are suggested to be the main contributors of early IFN-g production (27, 130, 
185). It is, however, difficult to determine the individual roles of ILC1s, cNK cells and plastic 
ex-ILC3s contribution to IFN-g production due to overlapping phenotypic markers. Klose et al., 
established the identification of an ILC1 subset distinct from cNK cells and ex-ILC3s, however 
when determining their functionality upon Toxoplasma gondii infection, due to the lack of 
transgenic mice solely lacking ILC1s, T-bet deficient mice were examined concluding that ILC1s 
provided protection against infection (27). Although Tbx21-/- mice lack ILC1s, they also have 




 ILCs and ex-ILC3s, presenting a caveat to these findings (27, 130, 186). 
Within the gut, IFN-g production provides protection against Salmonella infections, with 
exogenous administration of IFN-g preventing death upon mice being challenged with a lethal 
dose of Salmonella (187). IFN-g, elicits its protective functions by playing an important role in 
the stimulation of other immune cells such as macrophages, enhancing their phagocytotic 
abilities (187, 188). 
Under certain conditions the functional properties of ILCs can contribute to the development 
of inflammatory bowel disease (IBD). Inappropriate activation of ILCs can result in their 
unwanted production of cytokines, driving inflammation and autoimmunity. IBD effects 
around 2.5 million people and includes Crohn’s disease and ulcerative colitis (UC) (189, 190). 
It can be caused by many genetic and environmental factors resulting in a dysregulated 
immune response leading to chronic inflammation of the gastrointestinal tract (189-191). 
Gastrointestinal ILCs have also been associated with the development of IBD with genome-
wide association studies identifying genes related to ILCs, mainly the ILC3 subset, as a risk of 
loci for IBD, suggesting a role of ILCs in its pathogenesis (190).  
The increased production of IFN-g has been associated in many studies with the development 
of human Crohn’s disease (192). It is currently under debate, within the field, as to the exact 
source of innate IFN-g, with Crohn’s disease patients having increased numbers of cNK cells 
and ILC1s (104, 193). To examine the role of ILC1s in Crohn’s disease, the murine anti-CD40 
IBD model was established in Rag-/- mice, examining the innate contribution to development 
of disease (104). An increase in ILC1s and their production of IFN-g was observed and the 
development of colitis was prevented upon blocking ILC1s with anti-NK1.1 (104). As discussed 
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previously the identification between ILC1s, ex-ILC3s, NCR
+
 ILC3s and cNK cells is blurred and 
anti-NK1.1 will also deplete these described cells (101, 104, 194). Furthermore, lacking 
adaptive immunity may exaggerate the contribution of ILCs (194). 
ILC3s have also been implicated in the development of IBD, with increased production of IL- 22 
by ILC3s being detected in human IBD patients (195). Dysregulated production of IL-22 leads 
to the increase in the permeability of the intestinal epithelial barrier, a hallmark of IBD, 
resulting in decreased protection against pathogen invasion (168, 196). Powell et al., conclude 
that in Rag2-/- mice lacking T-bet expression, Helicobacter typhlonius drives the development 
of UC in an ILC3 dependent manner (197, 198). Increased levels of IL-23 and DCs were shown 
to contribute to the activation of ILC3s and their production of IL-17 and IL-22, with in vivo 
blocking of these cytokines reducing the development of colitis (197, 198).  Furthermore, 
within the murine UC model induced by anti-CD40 in Rag-/- mice, ILC3s, in an IL-23 dependent 
manner,  produce IL-22, with in vivo neutralisation of IL-22 protecting the mice from 
developing colitis (199). Although these studies both indicate a role for IL-22 producing ILC3s 
in the development of IBD, similar to the previous in vivo studies assessing ILCs role in IBD, 
Rag-/- mice were used. As well as exaggerating the ILC response, it has been established that 
the homeostasis of ILCs is perturbed in Rag-/- mice with increased numbers of ILC2, ILC3 and 
their respective cytokine production (106, 200). This is potentially due to the excess of 
cytokines, which would normally be involved in T cell proliferation and survival, such as IL-7, 
influencing ILCs (201, 202).  
Another model of IBD, induced in Rag-/- mice by Helicobacter hepaticus, is characterised by 
the IL-23 dependent production of IL-17 and IFN-g by ILC3s (175). This study combines the 
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importance of ILC1 and ILC3 cytokine production in IBD, with ILC3s developing into an ILC1 
phenotype, producing IFN-g, but maintaining the ability to produce IL-17 (175). Although 
Rag- /- mice are not the most appropriate model to assess IBD development by ILCs, these in 
vivo models do suggest that disturbances in ILC regulation and function may contribute to the 
development of chronic inflammation. 
ILC1s and ILC3s both seem to play an important role in the development of inflammation via 
their production of IFNg, IL-17 and IL-22. Interestingly, the new subgroup of ILCs, termed 
ILCregs, are shown to regulate intestinal inflammation (113). Inflammatory signals driven by 
the infection with Salmonella typhimurium and Citrobacter Rodentium induces ILCregs to 
produce TGF-b1, which maintains their own expansion during inflammation, and the 
production of IL-10 (113). IL-10 supresses the activation and cytokine production of ILC1s and 
ILC3s, protecting against the development of inflammation (113).  As discussed previously, 
there is currently debate within the literature surrounding the source of ILC derived IL-10 and 
the functionality of these described ILCregs (140).   
1.6.2 Lung 
ILCs reside within the lungs of humans and mice, with ILC2 being the dominant subset playing 
a role in the repair and remodelling of damaged tissue (28, 110, 203). Under homeostatic 
conditions ILC2s contribute to the maintenance of the epithelial barrier, expressing multiple 
genes associated with tissue remodelling, including amphiregulin, which were comparatively 
not expressed in splenic ILC2s (110). Influenza viral infection elicits damage to the epithelium, 
resulting in the release of alarmins including IL-33, which in turn stimulates ILC2s production 
of amphiregulin (110, 204). Depleting ILCs with anti-CD90 resulted in a decrease in epithelial 
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integrity and an impairment in tissue remodelling, which was reversed upon administration 
of amphiregulin (110).  
The initial descriptions of ILC2s identified that both nuocytes and innate helper 2 cells played 
a role in the expulsion of helminth infections from the lung (25, 103, 108). Helminths such as 
Nippostrongylus brasiliensis, stimulate epithelial cells, macrophages and DCs to produce IL-25 
and IL-33, which in turn induces the recruitment, expansion and activation of ILC2s (108, 205, 
206). Mice lacking IL-25 and/or IL-33 are unable to efficiently clear Nippostrongylus brasiliensis 
infections due to a decrease in ILC2s and therefore type2 cytokine production (25, 205). IL-13 
production by ILC2s, is essential for the expulsion of helminth infections and it has been 
established, through the transfer of nuocytes into mice deficient in IL-4 and IL-13, that even if 
ILC2s are the only source of IL-13, helminth clearance still occurs (25). Even with ILC2s 
providing the main source of IL-13, effective expulsion is still dependent on the presence of 
the adaptive immune system, with Rag2-/- mice being unable to clear infection, suggesting 
ILC2s interact directly or indirectly with T or B cells, promoting their production of IL-13 (25, 
103). Lung ILC2s may communicate with T cells through the expression of MHCII (164). They 
possess the ability to uptake and process antigen in vitro, however, when cultured with T cells, 
were unable to elicit T cell proliferation (164). Other type 2 cytokines produced by ILC2s, such 
as IL-5 and IL-9, are important in the recruitment of eosinophils alongside IL-4 and IL-13 which 
contribute to the initial hyperplasia of goblet cells and therefore the increase in mucus 
production and effective expulsion of helminth infections (103, 184, 207-211). The production 
of IL-9, alongside having an autocrine function in promoting cytokine production also 
promotes B cell survival (212-215).  
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ILC1s and ILC3s are much smaller populations within the lung compared to ILC2s, with ILC3s 
contributing roughly 2% of total lung ILCs (216). Furthermore, as discussed previously, ILC1s 
role in inflammation is currently being investigated, partly due to the lack of clarity in the 
discrimination between cNK cells and other IFN-g producing cells. Consequently, little is 
known about ILC1s function within the lung. However, under infection with influenza virus 
ILC2s are able to develop into IFN-g producing ILC1s (142). IFN-g production is important in 
the clearance of pathogens by activating macrophage phagocytosis, as shown in 
Mycobacterium bovis infected lungs (126). Although ILC3s are a small population within the 
healthy lung within obese murine models, mice developed airway hyperreactivity which was 
linked to an increase in LTi-like cells within the lung, contributing to IL-17A production (217). 
LTi-like cell activation was driven by IL-1b, produced by macrophages, which upon blockage 
reduced the number of LTi-like cells and obesity induced airway hyperreactivity (217). 
Furthermore, ILC3s residing within the lung also play a role in combating bacterial infections 
such as  Streptococcus pneumonia, by producing large amounts of IL-22 (107). Interestingly, 
within human lungs Carrega et al., identified IL-22 producing NCR
+
 ILC3s in being important in 
the development of tertiary lymphoid structures, which are important in the early stages of 
protection against tumours (218).  
The lung is continuously exposed to airborne antigens, some being pathogenic and others 
being allogenic which unnecessarily stimulates an immune response in the lung, driving the 
inflammatory lung disease, allergic asthma (219, 220). Asthma is characterised by airway 
hyperreactivity and can be activated upon viral or fungal challenge (110, 221-224). Under 
these conditions ILC2s can be activated in a similar manner to helminth infections, via alarmin 
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release from epithelial cells, however, this unwanted activation results in the development of 
airway hyperreactivity (219, 221-224). Fungal, allergen and viral induced airway 
hyperreactivity has been shown to be independent of the adaptive immune system with 
eosinophil recruitment and mucus hyperproduction being induced by papain administration 
in Rag-/- mice but not  Rag-/- mice lacking ILCs (110, 219, 221). 
1.6.3 Skin 
The skin provides a thick mechanical and chemical barrier to the outside world, preventing 
the entry of pathogens whilst controlling the colonisation of commensal bacteria (1). It is 
comprised of an outer epidermis layer and an inner dermis layer, each containing a plethora 
of immune cells (1). ILCs play an important role in the homeostasis of the skin barrier, with 
ILC2s continuously producing IL-13 which is involved in the anti-inflammatory functions via 
the suppression of mast cells trafficking through the skin (200). IL-13 also functions in the 
repair and maintenance of the epithelial barrier with mice lacking IL-13 being more 
susceptible to epithelial carcinogens (225). ILCs have also recently been discovered to be 
important in the maintenance of Tregs within the skin with a select group of CCR10
+
 skin ILCs 
being required for the effective reconstitution of Tregs into the skin in Rag-/- host wild type 
(WT) BM chimeras (226).  
ILCs are also involved in the maintenance of the skin epithelial barrier, with ILC2s being 
activated in an IL-33 dependent manner, upon skin damage, promoting wound repair via the 
production of amphiregulin (227, 228). In the absence of ILCs, using anti-CD90 depleting 
antibodies, the skin showed delayed wound healing, however, due to the deletion of all ILCs, 
this cannot be solely attributed to ILC2s (228). Upon skin injury, Notch1 signalling drives the 
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production of TNF-a by epithelial cells recruiting CCR6+ NKp46low/- ILC3s to dermis of the skin 
(229). Increased levels of IL-17 and IL-22 are also involved in skin repair and maintenance and 
were detected at skin damage sites with wound closure being delayed in Rorc-/- mice (79, 229, 
230). 
Dysregulation of ILCs has also been reported to cause unwanted inflammation within the skin. 
ILC2s are found within the lesions of atopic dermatitis (AD) patients and AD murine models 
potentiating the type 2 response via cytokine production (227, 231). Rora-/- BM reconstituted 
WT hosts failed to develop induced AD, compared to controls, suggesting the importance of 
ILC2s in disease development (227). Psoriatic lesions within patients show an enrichment in 
ILC3s, similar again to murine models, contributing to the development of psoriasis through 
the production of IL-22 and IL-17 alongside gd T cells (232-234). These diseases will be 
discussed in more detail later within this investigation. 
1.6.4 Secondary lymphoid tissue 
During embryogenesis, LTi cells are required for the formation of LNs (111, 235). They are 
recruited to the LN anlagen early in embryonic development providing essential signals to 
LTbR+ mesenchymal cells via surface LTa1b2 for further LN development, with LTbR-/- and 
LTb  - /- mice being unable to develop LNs or PP (137, 161, 236). Id2-/- and Rorc-/- mice, lacking 
ILCs and ILC3s respectively, have a deficiency in the development of both LNs and PP, 
supporting that LTi cells are the key cellular provider of LTa1b2 (237-239). The interactions 
between LTi and mesenchymal cells are further enhanced by the expression of receptor 
activator of nuclear factor κ B Ligand (RANKL) on LTi cells, which interacts with receptor 
activator of nuclear factor κ B (RANK), expressed on mesenchymal cells (240, 241). RANK 
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signalling in LTi cells increases their expression of LTa1b2 required for the accumulation of LTi 
cells at the LN anlagen with Rank-/- mice lacking the development of peripheral LNs (240-242). 
LTi cells stimulate mesenchymal cells to upregulate vascular cell adhesion molecule 1 (VCAM-
1) and intercellular adhesion molecule 1 (ICAM-1) which are important in the recruitment and 
arrangement of cells, including monocytes, T cells and B cells, enabling the full development 
of the LN (235, 240). LTa1b2 signals are also required for the organisational development of 
the spleen, with mice lacking these signals loosing normal T cell and B cell segregation (161, 
236). 
Within the adult, an LTi-like cell population is identified clustered within the interfollicular 
areas between T cell and B cell zones and contributes to the repair and maintenance of SLTs 
(243, 244). Upon lymphocytic choriomeningitis virus (LCMV) infection stromal cells are 
destroyed within the spleen, disrupting T and B cell zones, however, LTi-like cells provide a 
source of LTa1b2 signalling which contributes to the rebuilding of the SLT stromal framework 
(244). This suggests that LTi-like cells function in promoting the repair of tissues, with 
restoration being delayed within Rorc-/- mice (244). Furthermore, ILC3s play an important role 
in the maintenance and function of LNs in an IL-7 dependent manner, with the absence of IL- 7 
signalling resulting in a decrease in ILC3 numbers and  impaired migration of T and B cells into 
the LN (245). 
Although ILC3s within the gut have an inhibitory effect on CD4
+
 T cells, controversially within 
the spleen ILC3s have been suggested to prime CD4
+
 T cell responses (114, 162). Von Burg et 
al., show that upon IL-1b and TLR stimulation ILC3s upregulate cytokine production, MHCII, 




 T cell activation and proliferation, with mice lacking MHCII on RORgt expressing cells 
observing reduced proliferation of ovalbumin (OVA) specific T cells upon OVA immunization  




 ILC3s within the spleen and gut suggest a 
differential role for these subgroups depending on location and potentially a further 




ILC3 subgroup into cells that possess the ability to upregulate 
co-stimulatory molecules and those that don’t. However, within the publication by von Burg 
et al., the florescent activated cell sorting (FACS) data, showing an increase in CD80, CD86 and 
CD40, is dubious (114). Further experiments would need to be conducted to determine 
whether ILCs required CD80, CD86 and CD40 to efficiently activate T cells, potentially through 
the use of genetically modified mice lacking the expression of these co-stimulatory molecules 
exclusively on ILC3s. 
Similar to intestinal and splenic ILC3s, a population of ILC2s within the mesenteric LN (mLN) 
has been identified to express MHCII (25, 164). Alongside MHCII they also express CD80, CD86 
and possess the ability to process and present antigen (25, 164). In vitro studies showed that 
MHCII-antigen TCR-CD3 complex mediated interactions between ILC2s and CD4
+
 T cells 
mutually supports both populations, promoting ILC2 proliferation and production of IL-13 
alongside T cell maintenance and cytokine production (164). The importance of this cross talk 
was demonstrated in vivo with mice lacking ILC2s being unable to effectively clear 
Nippostrongylus brasiliensis worm burden (164). This supports previous publications by Neill 
et al., who showed that although IL-13 production by ILC2s was important in the expulsion of 
helminth infections, mice lacking adaptive immunity were unable to efficiently expel 
Nippostrongylus brasiliensis infections (25). In comparison to B cells, mLN ILC2s have a lower 
expression of MHCII which is lost upon short term culture (164). This raises the debate as to 
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whether ILC2s are true professional APCs or whether they just provide additional signals 
promoting T cell and their own maintenance. As discussed previously the strength of TCR 
interactions can influence the development of Th cells. It is suggested that this lower 
expression of MHCII, CD80 and CD86 may be important in skewing CD4
+
 T cells towards a Th2 
response (246). Together this indicates a mutual relationship between the innate and adaptive 
immune system with ILC2s and ILC3s within SLT promoting T cell responses. 
In conjunction with cell surface protein interactions, ILCs are able to elicit their functions 
through the productions of cytokines within SLTs. Upon enteric pathogen infections, alongside 
increased activation and accumulation of ILCs at the site of infection, some reports have 
identified an increase in ILCs within the mLN (185). Clostridium difficile infections did not only 
induce ILC1s and ILC3 cytokine production, in the small intestine (SI) but also in the mLN (185). 
Similarly, in Heligmosomoides polygyrus infected mice, ILC2s and their production of IL-4 was 
increased within the SI and mLN (182). Through the use of BM chimeras Pelly et al., showed 
that mice lacking ILC2s or IL-4 producing ILC2s had fewer Th 2 cells within the mLN and spleen 
(182). Although it was not determined whether this was a direct or indirect effect of ILC2s, it 
indicates a relationship for ILCs in promoting Th cell development, potentially via cytokine 
production (182). Supporting this, circulatory cNK cells have been shown by Martin-Fontecha 
et al., to migrate into LNs in a C-X-C chemokine receptor (CXCR) 3 dependent manner on 
activation via mature DCs (116). cNK cells were shown to provide an early source of IFNg, 
promoting the differentiation of effector Th1 cells (116). As discussed earlier, Th 
differentiation can be skewed dependent on the cytokine environment, together, these 
publications suggests a role for cNK cells and helper ILCs in the direct regulation of the 
adaptive immune system (116, 182, 185). 
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1.7 MIGRATORY PROPERTIES OF ILCS 
The positioning of ILCs at barrier sites allows for the efficient early production of effector 
cytokines upon pathogen invasion and in the regulation of epithelial barriers. Within SLTs ILCs 
cytokine production is involved in the structural repair post infection and is also believed to 
influence the differentiation of Th cells. More recently ILCs have been shown to express 
antigens via MHCII, with the largest MHCII expression being located on ILCs residing within 
SLT, posing the question as to how ILCs are able to gain access to antigen from the site of 
infection and present it within the draining LN (114, 164). Oliphant et al., has shown the ability 
of ILC2s to acquire MHCII expression via trogocytosis, so potentially ILCs gain their antigen 
expression from migratory APCs such as DCs. However, another potential mechanism is that 
helper ILCs may be able to acquire antigen at the site of infection and then migrate to 
lymphoid tissues in a similar manner to DCs (247). This raises the question as to whether ILCs 
are tissue-resident or possess migratory abilities, similar to cNK cells (116). Currently the 
prevailing view on helper ILCs migratory properties within the field is that they are tissue-
resident within lymphoid, including the spleen and mLN, and non-lymphoid tissue evident by 
the inability of ILC exchange within parabiotic mice (248, 249). Gasteiger et al., suggests that 
ILCs are replenished through local differentiation from progenitor populations rather than 
seeding with mature ILCs that have migrated from the BM (249). Upon acute helminth 
infection ILC populations expanded via proliferation within the tissue and not via migration 
from the blood (249). cNK cells are a well-established migratory ILC population, surveying 
tissues via migration from blood into LNs occurring in a similar manner to T cells (116, 249). 
Within the blood cNK cells express L-selectin (CD62L) and CCR7, which are required for the 
exit of lymphocytes from the blood and into the LN, with intravenously injected splenic cNK 
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cells migrating to the draining LN within 12 hours (116, 250, 251). It is, however, becoming 
apparent that cNK cells may not be the only migratory ILC population, with recent publications 
arguing against a solely tissue-resident helper ILC population (226, 243, 252). Although it was 
concluded, using parabiotic mice, that helper ILCs were tissue-resident within the assessed 
tissues, ILC1s were present within the blood and were found to equilibrate between the 
parabiotic mice, although they didn’t enter the assessed tissues (249, 253). The migration of 
ILCs from barrier sites to draining LNs was also not assessed within the parabiotic mice (249). 
Supporting the theory of a migratory population of helper ILCs, Mackley et al., used Kaede 
transgenic mice to show that ILC3s possess the ability to migrate from the gut to the draining 
mLN in a CCR7 dependent manner (243). Further ILC migration within the gut and gut 
associated LNs was suggested by Kim et al., who indicated that helper ILCs possessed the 
ability to migrate to the gut upon the upregulation of gut homing molecules, such as a4b7+, 
in a retinoic acid dependent manner with ILC1s and ILC3s originating from SLT and ILC2s from 
the BM (252). Injected ILCs into the skin draining LNs are able to acquire expression of the skin 
homing receptor CCR10 and migrate into the skin to promote the homeostasis of skin resident 
T cells (226). A recent publication has further explored the migratory abilities of the iILC2 
population detected initially within the intestine (108, 254). Through the use of parabiotic 
mice and Nippostrongylus brasiliensis infections they show that iILC2s are able to undergo 
proliferation within the intestine, upon IL-25 stimulation, drain into the lymph and then blood 
in a sphingosine-1-phosphate (S1P) dependent manner and disseminate into peripheral 
tissues including the lung, spleen, liver and mLN (254). These studies clearly challenge the 
theory of a solely tissue-resident ILC population, however, the relationship of ILCs between 
non-lymphoid and lymphoid tissues is still unclear.  
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1.8 AIMS OF THIS INVESTIGATION 
The aim of this investigation was to explore and compare ILCs across lymphoid and non-
lymphoid tissues and to develop a clearer understanding of the relationship between these 
different cellular compartments. Although ILC function has been investigated in multiple non-
lymphoid tissues their function within LNs and their communication with the adaptive 
immune response remains unclear. Furthermore, ILCs express co-stimulatory molecules that 
are critical for interactions between cells of the adaptive immune system such as members of 
the B7 family. Thus, it was sought to investigate the requirement for key co-stimulatory 
molecules for ILC function in both lymphoid and non-lymphoid tissue. It was hypothesised 
that ICOS:ICOSL interactions were required for normal ILC2 homeostasis. To further assess 
whether the ILC populations within non-lymphoid tissue and the SLT that drain them were 
related, novel models of cellular migration were used to directly test the hypothesis that ILCs 
migrate from non-lymphoid to lymphoid tissue.  
In summary, the key aims of this investigation were: 
1. Characterise and compare ILCs within lymphoid and non-lymphoid, determining 
whether ILC subgroups phenotype differs depending on location. 
2. Explore the importance of the co-stimulatory molecule ICOS expression on the 
homeostasis of ILC2s and ILC3s within lymphoid and non-lymphoid tissue. 
3. Investigate whether ILCs are a solely tissue-resident population within peripheral LNs, 
or whether they are able to migrate into, or egress from the SLT and the mechanisms 
behind this. 
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4. Begin to explore the migration of ILCs between the skin and draining LN under steady 




Chapter 2.   MATERIALS AND METHODS 
2.1 MICE STRAINS 
The mice models used in this project were maintained at the University of Birmingham 
Biomedical Serviced Unit (BMSU) and used in accordance with Home Office guidelines (Table 
2.1). Within these experiments’ WT mice and conditional knock outs were used to assess ILCs 
under normal and genetically manipulated conditions, respectively, in a variety of tissues. 
Photoconvertible Kaede mice were used to track the migration of cells in vivo from sight 
specific labelled areas and Kaede conditional knock outs used to assess the mechanisms 
controlling migration. In all experiments mice were age matched between 6-11 weeks of age.  
Table 2.1. Mouse strains used within this investigation 
Strain  Formal strain 
name 
Background Phenotype  Source  
C57BL/6  C57BL/6J Used as a WT control BMSU 
Ccr6-/-  B6.129P2-
Ccr6tm1Dgen/J 
C57BL/6J CCR6 knock out; Absence of 
CCR6:CCL20 interactions 
JAX (original reference 
not provided by JAX) 
Ccr7-/- 
 
Ccr7tm1Rfor/J C57BL/6J CCR7 knock out; Absence of 






C57BL/6J ICOS knock out; Absence of 






C57BL/6J ICOSL knock out; Absence of 






 C57BL/6J eGFP was inserted into the 3’ 







tm3.1Anjm C57BL/6J These mice are an eGFP 
knock in at exon 1 of IL-13, 





C57BL/6J Ubiquitous expression of a 
photoconvertible Kaede 
green protein 




2.2 MEDIUMS AND REAGENTS 
2.2.1 Mediums 
These mediums were used throughout various experiments. 
Table 2.2. Staining buffer 
Media and Reagents Manufacture 
Final 
Concentration 
Dulbecco's Phosphate-Buffered Saline (DPBS) 
[+] MgCl (1000 mg/L) and CaCl (100 mg/L) Life technologies   
Ethylenediaminetetraacetic Acid Solution (EDTA) Sigma-Aldrich 2.5 mM 
Foetal Bovine Serum (FBS) Heat Inactivated  Sigma-Aldrich 2% 
 
Table 2.3. Culture media 
Media and Reagents Manufacture 
Final 
Concentration 
Roswell Park Memorial Institute 1640 Medium  
[+] L-Glutamine Life Technologies   
Penicillin Streptomycin Solution 
Invitrogen (Life 
Tech) 0.98% 
L-Glutamine Sigma-Aldrich 0.98% 
FBS Heat Inactivated Sigma-Aldrich 9.80% 
 
Table 2.4. Staining solution for immunofluorescence microscopy 
Media and Reagents Manufacture 
Final 
Concentration 
PBS Sigma-Aldrich   
Bovine Serum Albumin (BSA) Heat Inactivated  Sigma-Aldrich 1% 
 
2.2.2 Gey’s solution 
Gey’s solution is a red cell lysis buffer made within the laboratory (Table 2.5) samples are 
incubated in Gey’s solution to lyse and remove red blood cells. Solution A and B are made up 
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to 1 L within distilled water and autoclaved. Gey’s solution consists of 10 mL of Solution A, 2.5 
mL of Solution B, 2.5 mL of Solution C and 35 mL of distilled water and kept at 4°C. Gey’s 
solution is then run through a 0.2 µm filter to use in sterile conditions. 
Table 2.5. Gey’s solution 
Solution Additive Quantity 
A 
NH₄Cl 35 g 
KCl 1.85 g 
Na₂HPO₄.12H₂O 1.5 g 
KH₂PO₄ 0.119 g 
Glucose 5.0 g 
Gelatin 25.0 g 
1% Phenol red 1.5 mL 
B 
MgCl₂.6H₂O 4.2 g 
MgSO₄.7H₂O 1.4 g 
CaCl₂ 3.4 g 
C NaHCO₅ 22.5 g 
 
2.3 PREPARING CELL SUSPENSIONS 
Tissues were prepared similar to methods previously published by Dutton et al., and 
Mackley et al. (216, 243). 
2.3.1 Lymph nodes and spleen 
Tissue was isolated from the mouse and cleaned using a dissection microscope and forceps, 
removing the fat and blood vessels, in Roswell Park Memorial Institute (RPMI) 1640 Medium 
(Life Technologies). Where large amounts of fat were removed, the tissue was transferred into 
3 mL of fresh RPMI before being teased apart using forceps. For digestion, collagenase dispase 
(final concentration, 0.25 mg/ml) (Roche Life Sciences) and DNase (0.025 mg/ml) (Roche 
Diagnostics) were added and the cells were incubated at 37°C for 20 minutes. Digestion was 
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stopped through the addition of EDTA (0.01 M) (Sigma-Aldrich) and the tissues were crushed 
through a 70 μm filter into a falcon tube using a 2 mL syringe plunger. Samples were 
centrifuged (5 minutes, 1,500 revolutions per minute (rpm), 4°C) and the supernatant 
removed. Lymph nodes (LN) were resuspended in an appropriate amount of staining buffer, 
however, spleen samples were resuspended in 5 mL of Gey’s red blood cell lysis buffer and 
incubated for 5 minutes on ice. Spleens were diluted with RPMI, centrifuged and re-suspended 
in the appropriate amount of staining buffer. 
2.3.2 Lung 
To isolate the lungs, mice were perfused with Dulbecco's Phosphate-Buffered Saline (DPBS) 
(Life Technologies), the right atrium of the heart was pierced with a needle and the left 
ventricle was forcefully injected with 10 mLs of DPBS. This causes inflating of the lungs and 
the blood to be flushed out. The lung was removed and cleaned in a petri dish containing 
culture media, teased apart with dissection forceps and transferred to a falcon tube. Lungs 
were agitated at 37°C for 45 minutes in an overall volume of 5 mL of culture media containing 
Liberase thermolysin medium concentration (TM) (42.4 μg/ml) (Roche Life Sciences) and 
DNase1 (0.02 mg/ml). Samples were then crushed through a 70 μm filter, washed with culture 
media, centrifuged and incubated on ice for 2 minutes in Gey’s solution. Lungs were then 
washed with RPMI and re-suspended in an appropriate amount of staining buffer. 
2.3.3 Small intestine lamina propria 
The dissection of the SI LP needed to occur within a short time frame to prevent cell death. It 
was dissected from below the stomach to above the caecum and then placed in Hank’s 
Balanced Salt Solution (HBSS, Sigma-Aldrich) containing 2% FCS. Within the solution, 
dissection forceps and scissors were used to remove the fat and PP before longitudinal cutting 
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of the SI, washing out the contents. The SI was cut into small pieces, roughly 2 cm 
longitudinally, and placed in a falcon tube containing HBSS and shaken vigorously. The SI was 
removed from the solution by being filtered through nitex mesh. The SI underwent a sequence 
of incubations with various medias; it was placed in a specific media, shaken vigorously for 20 
seconds, agitated at 37°C for 15/20 minutes, removed from the current media via being 
filtered, resuspended in HBSS and vigorously shaken for 20 seconds before final filtering and 
then resuspension and incubation in another media. This process was carried out with the first 
specific media being HBSS 2 mM EDTA (20 minutes), which was repeated twice and the second 
media being pre-warmed culture media containing 1 mg/mL collagenase VIII (Sigma-Aldrich) 
(15 minutes). After digestion the SI was filtered twice through 100 μm and 70 μm cell strainers 
before being centrifuged and re-suspended in an appropriate amount of staining buffer. 
2.3.4 Ear skin 
The ear was removed, cutting along the hairline of the ear, placed in a 1.5 mL eppendorf and 
cut into small sections. Samples were incubated at 37°C for 30 minutes in 1 mL of Dulbecco’s 
Modified Eagle Medium (DMEM) containing Liberase TM (6.25 mg/mL) and DNase1 (0.25 
mg/mL), whist being agitated in a thermomixer (Eppendorf). The tissue was filtered and 
washed, with DMEM, allowing the digested skin cells within the supernatant to be collected. 
The digestion and washing process was repeated two more times with the remaining 
undigested ear. Following the third incubation, using a 2 mL syringe plunger, the remaining 
undigested ear skin was crushed through the filter and washed with DMEM. Samples were 
centrifuged and re-suspended in an appropriate amount of staining buffer. 
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2.3.5 Blood 
1-2 mLs of blood was harvested, via cardiac puncture, in an eppendorf containing 300 µL of 
EDTA, to prevent clotting. Samples were then centrifuged (5 minutes, 2,000 rpm), supernatant 
removed, resuspended in in 500 µL of Gey’s solution and incubated on ice for 5 minutes. This 
was repeated two more times, before samples were resuspended in appropriate amount of 
staining buffer. 
2.3.6 Lymph node stromal digestion 
To specifically isolate stromal cells from LNs, instead of lymphocytes, a different digestion 
protocol to previous was used. LNs were removed, the fat and blood vessels removed, placed 
in a 1.5 mL eppendorf and cut into small pieces. Samples were resuspended in culture media 
with DNase1 (0.01 mg/mL) and Collagenase D (2.5 mg/mL) (Roche Life Sciences) and agitated 
at 37°C in a thermomixer. Every 5 minutes each sample was vigorously pipetted until it was 
fully digested (30-40 minutes) then EDTA (0.25 mM) was added to each sample. Samples were 
then filtered through a 70 µm cell strainer and resuspended in a desired amount of staining 
buffer. 
2.4 MAGNETIC-ACTIVATED CELL SORTING 
2.4.1 CD45+ enrichment 
Single cell suspensions were incubated with anti-CD45 MicroBeads (MACS) diluted in staining 
buffer for 40 minutes on ice. Samples were then directly run through pre-washed (with 
staining buffer) LS columns (MACS) and the negative fraction of CD45
-
 cells collected (Table 
2.6). Staining buffer was forced through the LS column with a syringe plunger eluting the 
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positive fraction of CD45
+
 cells. The desired fraction was washed and re-suspended in an 
appropriate amount of staining buffer. 
2.4.2 ILC enrichment 
Single cell suspensions were incubated with anti B220, CD3 and CD5 antibodies conjugated to 
APC, diluted in staining buffer for 30 minutes on ice (Table 2.7). Samples were washed twice 
with staining buffer and resuspended in anti-APC MicroBeads (MACS) diluted in staining buffer 
for 15 minutes (Table 2.6). Samples were washed again and run through LD columns (MACS) 
pre-washed with staining buffer. The negative fraction was collected, and staining buffer was 
used to elute the positive fraction, using a syringe plunger. 
Table 2.6. Microbeads used in cell separation 
MicroBeads Dilution Manufacture 
anti-CD45  1:60 MACS Miltenyi Biotec 
anti-APC 1:5 MACS Miltenyi Biotec 
 
2.5 FLOW CYTOMETRY 
2.5.1 Extracellular staining 
Cells were prepared for flow cytometry following the same protocol as Mackley et al and 
Dutton et al (216, 243). Antibodies used for flow cytometric analysis are shown in Table 2.7. 
All staining was conducted in a 96-well plate (Thermo Scientific) with cells being suspended in 
100 µL of antibody diluted in staining buffer, unless stated otherwise. The proportion of 
sample stained varied depending on the size of the tissue (Table 2.8). All tissues were initially 
stained with an APC-eFluor780 viability dye (1:1000, eBioscience), diluted in DPBS for 20 
minutes on ice. Following each incubation, 100µL of staining buffer was added to each sample 
prior to centrifugation (1,500 rpm, 2 minutes). Samples were then washed with 200 µl of 
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staining buffer twice before continuing with the subsequent staining step. All extracellular 
staining occurred in the dark at 4°C for 30 minutes, unless stated otherwise. Samples which 
extracellular staining panel included anti-CCR7 were incubated at 37°C for 30 minutes. 
Staining for lineage markers was either conducted using the same fluorochrome for all 
markers, or individual fluorochromes for seperate markers.  
Stains consisting of a primary and biotinylated antibody required a further 30 minute 
incubation step before incubation with secondary antibody, shown in Table 2.9. The 
secondary antibody for example, fluorochrome-conjugated streptavidin (SA), shown in Table 
2.10 was then incubated for a further 30 minutes. Samples which included the S1P receptor 1 
(S1PR1) primary antibody required the initial staining with the primary S1PR1 antibody 
followed by anti-Rat IgG1k biotin. A rat serum block was then applied for 15 minutes at 4°C to 
prevent any unspecific binding (Table 2.11). 
2.5.2 Intracellular staining 
Post extracellular staining, cells were permeabilised using the Foxp3 TF staining buffer kit 
(Foxp3 kit, BD Biosciences), following manufacture instructions. Each sample was 
resuspended in 100 μL of Foxp3 fixation/permeabilisation buffer (1:3 concentrate:diluent) and 
incubated for 30 minutes, 4°C. Post-permeabilisation all samples were washed with 200 µL 
Permeabilisation buffer (1:10 10x Permeabilisation buffer:dH2O) (BD Biosciences) and stained 
in 100 µL of intracellular staining antibody diluted in Permeabilisation buffer at room 
temperature for 45 minutes. Samples were then washed twice with Permeabilisation buffer 
and twice with staining buffer, before being filtered through 50 µm CellTrics filters (Sysmex) 
into fluorescence-activated cell sorting (FACS) tubes in 300 μL of staining buffer.  
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2.5.3 Intracellular staining in Kaede mice 
Intracellular staining via the Foxp3 kit resulted in the loss of Kaede protein from the cytoplasm 
and therefore Kaede Red and Kaede Green cells were unable to be identified. However, the 
Kaede protein was not lost when cells were fixed with the BD Cytofix/Cytoperm kit (BD kit) 
and stained in the Foxp3 kit which was used to stain for the intracellular marker Ki-67. The TF 
T-bet, GATA-3 and RORgt were not efficiently identified upon using the BD kit. Kaede cells 
were only analysed for the intracellular marker Ki-67 using a combination of the BD kit and 
Foxp3 kit. Post extracellular staining, samples were resuspended in 100 µL of BD kit 
Fixation/Permeablisation solution and incubated for 1 hour at 4°C. Samples were then washed 
with Foxp3 kit Permeabilisation buffer twice before being resuspended in antibody diluted in 
100 µL of Foxp3 kit Permeabilisation buffer for 45 minutes room temperature. Samples were 
then washed twice with Permeabilisation buffer and twice with staining buffer, before being 
filtered through 50 µm CellTrics filters (Sysmex) into fluorescence-activated cell sorting (FACS) 
tubes in 300 μL of staining buffer. 
2.5.4 Flow cytometry analysis 
Samples were run on the BD LSRFortessaTM X-20 (BD Biosciences), the data collected using 
BD FACSDiva Software (BD Biosciences) and analysed using Flow Jo software (Treestar). 10,000 
counting beads (Spherotech) were added to the samples prior to being run on the 
LSRFortessaTM X-20 to enable the total number of cells per sample to be calculated. Upon 
running the sample and analysing the data, the number of beads (x bead count) and the 
number of cells (y cell count) run in one sample were used to calculate the total cell number 















FITC (1:300) RA3-6B2 eBioscience 
PECy7 (1:200) RA3-6B2 eBioscience 
APC (1:200) RA3-6B2 BioLegend 
CCR6 (CD196) BV605 (1:100) 29-2L17 BioLegend 
CCR7 PE (1:100) 4B12 eBioscience 
CD38 
FITC (1:100) 145-2C11 eBioscience 
AF700 (1:100) eBio500A2 eBioscience 
PECy7 (1:200) 145-2C11 eBioscience 
APC (1:100) 145-2C11 eBioscience 
BV650 (1:100) 145-2C11 BD Horizon 
BV605 (1:100) 17A2 BioLegend 
CD4 BV785 (1:100) RM4-5 BioLegend 
CD5 
FITC (1:100) 53-7.3 eBioscience 
APC (1:100) 53-7.3 eBioscience 
PECy7 (1:200) 53-7.3 eBioscience 
CD8 BV711 (1:200) 53-6.7 BioLegend 
CD11b 
FITC (1:300) M1/70 eBioscience 
PECy7 (1:200) M1/70 eBioscience 
CD11c 
FITC (1:300) N418 eBioscience 
BV785 (1:200) N418 BioLegend 
PECy7 (1:200) N418 eBioscience 
CD19 
PECy7 (1:200) eBio1D3 eBioscience 
FITC (1:200) eBio1D3 eBioscience 
CD25 
BV650 (1:200) PC61 BioLegend 
AF700 (1:50) PC61 eBioscience 
CD31 APC (1:400) eBio390/390 eBioscience 
CD45 BV785 (1:100) 30-F11 BioLegend 
CD45.2 
eFluor450 (1:200) 104 eBioscience 








PECy7 (1:200) DX5 eBioscience 
AF700 (1:200) DX5 eBioscience 
FITC (1:200) DX5 eBioscience 
CD62L 
BV711 (1:100) MEL/14 BioLegend 
PECy7 (1:500) MEL/14 eBioscience 
APC (1:1500) MEL/14 eBioscience 
CD69 BV711 (1:100) H1.2F3 eBioscience 
CD103 PECy7 (1:200) 2E7 BioLegend 
CD123 FITC (1:500) 5B11 eBioscience 
CD207 (Langerin) APC (1:100) 4C7 BioLegend 
c-kit BV711 (1:100) H57-597 eBioscience 
EOMES PECy7 (1:50) Dan11mag eBioscience 
F4/80 
PECy7 (1:200) BM8 eBioscience 
FITC (1:200) BM8 eBioscience 
FcεRI 
PECy7 (1:200) MAR-1 eBioscience 
FITC (1:200) MAR-1 eBioscience 
GATA-3 PerCP710 (1:75) TWAJ eBioscience 
gp38 PECy7 (1:1000) 8.1.1 BioLegend 
Gr-1 
PECy7 (1:2000) RB6-8C5 eBioscience 
FITC (1:2000) RB6-8C5 eBioscience 
ICOS 
APC (1:200) C398.4A BioLegend 
PeCy7 (1:200) C398.4A BioLegend 
IL-7Rα (CD127) BV421 (1:50) A7R34 BioLegend 
Ki-67 
PECy7 (1:400) SolA15 eBioscience 
AF700 (1:50) SolA15 eBioscience 
KLRG1 
BV605 (1:200) 2F1 BioLegend 
APC (1:200) 2F1 eBioscience 
MHCII (I-A/I-E) 
BV510 (1:500) M5/114.15.2 BioLegend 
AF700 (1:100) M5/114.15.2 eBioscience 
NK1.1 
PECy7 (1:200) PK136 eBioscience 
BV650 (1:100) PK136 BD Horizon 
NKp46 (CD335) 
BV711 (1:50) 29A1.4 BioLegend 
PeCy7 (1:100) 29A1.4 eBioscience 
RORγt PE (1:100) AFKJS-9 eBioscience 
ST2 (IL-33Rα) PE (1:50) DIH9 BioLegend 







PE-Cy7 (1:50) eBio4B10 eBioscience 
TCRβ AF700 (1:100) H57-597 BioLegend 
TCR"ẟ APC (1:100) GL3 BioLegend 
BV711 (1:200) GL3 BD Horizon 
TCR V"1.1 BV421 (1:100) 2.11 BD Horizon 
TCR V"2 (V"4) PECy7 (1:200) UC3-10A6 eBioscience 
TCR V"3 (V"5) APC (1:200) 536 BioLegend 
TER-119 
PECy7 (1:200) TER-119 eBioscience 
FITC (1:100) TER-119 eBioscience 
AF700 (1:200) TER-119 BioLegend 
 
Table 2.8. Minimal proportions of tissues stained 
Total counts were performed with count beads, therefore a known proportion of the cellular 
suspension was used during flow cytometric analysis, which was then used to calculate the 
total numbers.  
Tissue Minimum proportion stained 
mesenteric LN  1/3 
Small Intestine  1/5 
Lung  1/8 
auricular LN  1/2 
Ear  1/2 
brachial LN  1/2 

















 MRG2a-83 Mouse Rat  BioLegend 
KLRG1 Biotin 
(1:100) 
 2F1 Syrian 
Hamster 
Mouse eBioscience  
S1PR1 Purified 
(1:10) 
713412 Rat Mouse R&D Systems 
 
Table 2.10. Fluorochrome-conjugated streptavidin 
Streptavidin Manufacture 
SA-PECy7 (1:500) eBioscience 
 
Table 2.11. Blocking serums used in flow cytometry 
Serum Diluted in  Concentration  
Rat Staining Buffer 10% 
 
2.6 IMMUNOFLUORESCENCE MICROSCOPY 
2.6.1 Preparation of frozen tissue slides 
Human tissues were supplied by MedImmune and murine samples were collected in 
Birmingham. Murine LN sections were cleaned and snap frozen on optimal cutting 
temperature (OCT) to aid sectioning. The SI LP was collected, the fat removed in HBSS 2% FCS 
and the lumen flushed with staining buffer before being tightly curled and snap frozen. Tissues 
were stored at -80°C until they were ready for sectioning. Samples were cut into 6 µm thick 
sections using the cryostat and positioned onto a 4-spotted glass slide (LNs) or clear glass slide 
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(SI LP). The slides were air dried before being fixed in acetone at 4°C for 20 minutes and then 
left to dry overnight. Dry tissue sections were stored at -20°C until use. 
2.6.2 Immunofluorescence staining of tissue 
Immunofluorescent staining requires a series of steps in which the tissue undergoes multiple 
incubations with specific serums and antibodies. All incubations occurred at room 
temperature in a humidified chamber and after each incubation the tissue was washed, a 
process in which excess antibody solution was removed from the slides before the tissue was 
suspended in PBS for 10 minutes. PBS/1% Bovine Serum Albumin (BSA) (Table 2.4) was used 
as a diluent for the antibodies and serums that were used during this process (Table 2.12-
2.14). 
Slides mounted with tissue were removed from storage and left to air dry for 20 minutes 
before being hydrated in PBS for 10 minutes. Initially the avidin/biotin block kit (Vector 
Laboratories) was used, according to manufacturer instructions, to block non-specific binding 
to biotin receptors or avidin binding sites. Following a 2 minute wash, a series of incubations 
were conducted, after each incubation containing an antibody mix the slides were washed, as 
described above, however, after incubation with a serum the serum was aspirated off of the 
slide with a pipette, not washed and the following solution applied to the tissue. 
A horse serum block was initially applied for 15 minutes, blocking non-specific protein binding 
sites, aspirated and then followed by the application of appropriate primary antibodies, which 
were incubated for 40 minutes (Table 2.12). The subsequent incubations with additional 
antibodies occurred for 30 minutes.  
To provide a signal strong enough to be effectively detected, multiple amplification steps were 
required for the identification of TFs. Initially the purified primary RORgt and GATA-3 
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antibodies were applied, followed by the secondary antibody donkey anti-rat-IgG FITC, which 
bound to the purified primary TF antibodies, due to the primary antibodies being raised within 
a rat. To further amplify the signal additional tertiary and quaternary antibodies were applied 
including rabbit anti-FITC AF488 and donkey anti-rabbit-IgG AF488, respectively (Table 2.13). 
To prevent any unspecific binding of tertiary and quaternary antibodies to the primary 
antibodies a rat serum block was applied and incubated for 15 minutes after secondary 
antibody incubation. 
Prior to secondary, tertiary and quaternary incubations the antibodies used were cross-
absorbed for 30 minutes with 10% human or mouse serum, depending on whether human or 
murine samples were being used. SA antibodies were used to detect biotinylated primary 
antibodies.  
Following this, samples were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) for 30 
seconds, then washed in fresh PBS 3 times. Prolong gold mounting media (Life Technologies) 
was applied to semi-dried slides to preserve the tissue sections. A cover slip was gently 
lowered onto the slide, avoiding bubbles and left to semi-dry before the coverslip was sealed 
with clear nail varnish. Post overnight drying in the dark at room temperature, slides were 
stored at 4°C until analysis. 
2.6.3 Analysis of immunofluorescence stained tissue 
Stained tissue samples were analysed using the Zeiss 780 Zen microscope (Zeiss). Automatic 
stitching via the Zen software (Zeiss) was used on tile-scanned images. The location of IL-7Ra+ 









Clone Host Anti- Manufacture 
CD3 AF594 (1:25) UCHT1 Rat Human eBioscience 
CD3 Biotin (1:25) UCHT1 Mouse IgG1 Human BioLegend 
CD3 Biotin (1:100) eBio500A2 
Syrian 
Hamster Mouse eBioscience 
CD161 AF647 (1:25) HP-3G10 Mouse IgG1 Human BioLegend 




(MHCII) AF647 (1:25) LN3 Mouse IgG2 Human BioLegend 




Mouse Rat BioLegend 
IL-7Rα 
(CD127) ef660 (1:25) A7R34 Rat Mouse eBioscience 
IL-7Rα 
(CD127) Biotin (1:25) eBioRDR5 Mouse Human eBioscience 
IL-7Rα 
(CD127) AF647 (1:25) A019D5 Mouse IgG1 Human BioLegend 















Affinity Pure Donkey 
α Rat IgG (H+L)  
FITC (1:150) 712-095-153 
Jackson  
Immunoresearch 
Rabbit IgG fraction α 
fluorescein/Oregon 
Green® 
AF488 (1:200) A-11090 
Molecular  
Probes 
Donkey α Rabbit IgG 
(H+L) 
AF488 (1:200) A-21206 
Molecular  
Probes 
SA AF555 (1:500) S-21381 
Molecular  
Probes 
2.7 PHOTOCONVERTIBLE KAEDE MICE 
2.7.1 Photoconvertible Kaede mice 
Photoconvertible Kaede mice ubiquitously express a gene, cloned from stony coral, which 
encodes a green fluorescent protein (GFP) called Kaede (53, 259). A tripeptide, His-Try-Gly, is 
what acts as the green chromophore within the Kaede protein and when exposed to 
ultraviolet (UV) light, ranging between 350 – 400 nm, is converted to Kaede red (53, 259, 260). 
The UV light induces a peptide cleavage and formation of a double bond within the Kaede 
chromophore (53, 260). The proteins excitation and emission wavelengths changes so it is 
now perceived as red, this photoconversion does not affect the reproduction, growth or 
migration of cells (53). The Kaede Green and Kaede Red fluorescence can be detected using 
flow cytometry, which does not induce photoconversion (53, 259). During cell proliferation, 
the photoconverted Kaede Red protein is diluted out and replaced with newly synthesised 
Kaede Green protein, however in lymphocytes the photoconverted Kaede Red protein has a 
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long biological half-life (53). Therefore, these mice can be used to track the migration of cells 
in vivo. 
2.7.2 Violet light conversion of the brachial lymph node 
Mice were administered with a subcutaneous injection of buprenorphine (Tamgesic, Animal 
Care UK) 1 hour prior to the administration of anaesthetic, gaseous isoflurane (Zoetis), with 
oxygen as a carrier fluid. The brachial LN (bLN) was exposed to UV light 365 nm light using a 
light emitting diode (LED), via a small incision in the arm, for 3 and a half minutes before single 
interrupted sutures were used to close the incision. Mice were subcutaneously injected with 
500 µL of pre-warmed saline solution and allowed to recover.  
2.7.3 Violet light conversion of the ear 
Mice were anesthetised with gaseous isoflurane and the ear exposed to UV 405 nm light using 
a light amplification by stimulated emission of radiation (LASER), which is a more intense beam 
of light. The LASER light source was used instead of the LED light source due to LED light being 
insufficient in photoconversion of the ear. To prevent damage the violet light exposure was 
applied in a swaying movement and given in doses; 1 x 20 seconds and 2 x 10 seconds with 10 
second intervals. Black card was used to shield the rest of the body from UV light, preventing 
unspecific UV exposure. The mice recovered from anaesthetic and were culled a maximum of 
72 hours after UV light conversion. 
2.7.4 Violet light conversion of the head 
Mice were anesthetised with gaseous isoflurane, the forehead shaved and then exposed to 
UV 405 nm light. To prevent damage the violet light exposure was applied in a swaying 
movement for 2 minutes. Black card was used to shield both ears preventing their violet light 
 56	
exposure, allowing for the assessment of cellular migration into the ear. The mice recovered 
from anaesthetic and were culled a maximum of 72 hours after violet light conversion. 
2.8 EAR INFLAMMATION MODELS  
2.8.1 Calcipotriol topical application to the ear 
Calcipotriol (MC903), a vitamin D3 analogue (Tocris), was used to induce AD-like inflammation 
on the ears of mice. MC903 was dissolved in absolute ethanol (VWR Chemicals) to achieve a 
final concentration of 200 µM. 20 µL (4 nmol) of MC903 or 20 µL of absolute ethanol, termed 
the vehicle control (VC), 10 µL on the dorsal and 10 µL on the ventral ear, was then applied to 
the ear. This was repeated on consecutive days for varying time periods reaching a maximum 
of 5 days.  
2.8.2 Aldara topical application to the ear 
Aldara (Imiquimod) 5% cream (Meda) was used to induce psoriasis-like inflammation on the 
ears of mice. 30 mg of Aldara 5% cream was applied, 15 mg to the dorsal and 15 mg to the 
ventral segment of the ear and repeated on consecutive days for varying time periods 
reaching a maximum of 5 days. 
2.9 FTY720 MOUSE MODELS 
2.9.1 FTY720 administration 
Mice were intraperitoneally injected (i.p) with 200 µL of FTY720 (1 mg/mL) (Sigma) dissolved 
in H20 or with H20 as a vehicle control. FTY720 was prepared in sterile conditions and filtered 
through a 0.2 µm filter prior to injection. Injections were repeated on consecutive days up to 
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6 days in conjunction with other procedures. FTY720 is an S1PR inhibitor and prevents the 
egress of cells from tissue in an S1P dependent manner (261). 
2.9.2 FTY720 in combination with previous models 
FTY720 was administered in combination with the bLN violet light conversion surgery protocol 
and the MC903 model. Administration started one day prior to the start of the protocols and 
injections were given every consecutive day during the procedure.  
2.10 ETHICAL APPROVAL 
All human tissue samples (whole FFPE tissue blocks or TMA’s) used in this study were sourced 
from donors whom provided full informed consent for the use of their samples in research. 
All samples were sourced through various commercial human biological samples vendors and 
this study performed under the MedImmune Research Tissue Bank Ethical Review REC 
reference 16/EE/0334 as approved by the East of England NRES committee. 
2.11  STATISTICAL ANALYSIS 
Data was collected using Flow Jo software (Treestar) and was statistically analysed using the 
computer program GraphPad Prism 7. When comparing two sets of data statistical 
significance was tested using an unpaired Mann Whitney t-test. Upon comparing more than 
two sets of data a Kruskal-Wallis one-way ANOVA with post hoc Dunn’s test was performed. 
For each of these test * = <0.05, ** p = < 0.01 and *** p =<0.005. Where a p value is not 
indicated, no statistical difference is observed. Due to the nature of the data the percentage 
of Kaede Green cells cannot be statistically compared to Kaede Red cells within a population, 
therefore no statistics are conducted on these data. 
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Chapter 3.   CHARACTERISATION OF ILCs 
3.1 INTRODUCTION 
ILCs are a recently characterised subset of lymphoid cells belonging to the innate immune 
system, with the initial discovery of cNK cells in 1975 and LTi-like cells in 1997 (111, 117). 
These cells were later included within the ILC population upon the proposal of a uniformed 
nomenclature in 2013 (101).  
IL-7Ra and CD90, are common markers expressed on ILCs, used either in conjunction or 
interchangeably in the identification of ILCs (107, 108, 243, 262). ILCs lack the expression of 
certain lineage markers which are expressed by and used in the identification of myeloid cells, 
DCs, T cells and B cells and is therefore another distinct feature of ILCs (101, 107). Despite a 
proposed method of ILC identification, current publications differ on lineage markers used in 
their identification, ranging from markers identifying T cells, B cells, DCs and neutrophils to 
the inclusion of eosinophil, erythrocyte, monocyte and macrophage markers (108, 110, 221, 
243). Through the use of flow cytometry and whole mouse genome arrays, ILCs were divided 
into 3 well characterised groups, similar to effector Th cell subgroups (28, 101). Group 1 ILCs 
express T-bet and produce Th1 cytokines, group 2 ILCs which express GATA-3 secrete Th2 
cytokines and thirdly RORgt dependent group 3 ILCs, which produce Th17 cytokines (101, 221, 
263).  
Within the current literature the TF RORgt is frequently used to identify ILC3s in the SI, lung, 
skin and mLN, enabling consistent identification and characterisation between tissues (107, 
114, 162, 229, 243, 264). In comparison, many publications identify ILC2s based on the 
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expression of cell surface markers and cytokine production. ILC2s within the lung have been 
identified based on the expression of ST2, KLRG1, ICOS and CD25 along with the cytokines IL- 5 
and IL-13 (108, 164, 221, 265). A caveat in the identification of ILC2s via surface markers, is 
that expression may be expected to vary between different tissues, which could result in 
inefficient ILC2 identification. For example, Kim et al., use ST2, which was originally shown on 
ILC2s within the lung, to identify ILC2s within the skin, without supporting evidence that ILC2s 
within the skin express ST2 (25, 231, 265). Different research groups use a variety of methods 
to identify ILC2s within different tissues, making it difficult to compare ILC2 functions across 
publications. For example, KLRG1 has been used within the gut, compared to other studies 
which have used GATA-3 (181, 182). ST2 is mainly used within the lung and skin, however ICOS 
has been targeted to induce ILC2 depletion alongside RORa (164, 231, 265). As discussed 
previously, ILC2s are comprised of ST2
-
 iILC2s and ST2
+
 nILC2s, suggesting that previous 
publications using ST2 to identify ILC2s may have missed the identification of iILC2s within 
their analysis (108).   
Group 1 ILCs are identified by their expression of T-bet, production of IFN-g and co-expression 
of NK1.1 and NKp46 (135, 263). This group is comprised of ILC1s and cNK cells, the latter being 
well documented cytotoxic cells. cNK cells are distinct from ILC1s as they also express CD49b 
and EOMES which is required for their development (135, 263). cNK cells IL-7 independent 
and EOMES dependent maturation enables efficient separation of ILC1s and cNK cells (127, 
128, 156). However, compared to cNK cells ILC1s are a relatively new identified population 
suggesting that previous publications investigating the functions of cNK cells may not have 
excluded ILC1s from their analysis. Furthermore, cNK cells and ILC1s are not the only subgroup 
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of ILCs to express T-bet. As previously discussed, NCR
-
 ILC3s can upregulate T-bet expression 
becoming NCR
+
 ILC3s, contributing to the production of IFN-g (130, 141). This level of plasticity 
between ILC3s developing into ILC1s poses a problem in identifying the main sources of IFN-g 
in different infections, suggesting that the expression of multiple TFs may be needed to ensure 
accurate identification of ILC subgroups (27, 130, 185). 
Varying protocols are used to prepare different tissues, with specific enzymes, temperatures 
and incubation periods required to achieve efficient tissue digestion and preparation of single 
cell suspensions (216, 243, 254). Furthermore, digestion protocols used for the same tissue 
may vary across different labs, with different use of equipment, enzymes and concentrations 
(243, 254). This again introduces a level of variation across publications especially when the 
conditions in which tissues are digested may influence the level of expression of surface 
proteins. Liu et al., have demonstrated the importance of digestion protocols by showing that 
different incubation lengths, alongside different types of enzymes, dramatically changes the 
detectible level of CD62L on splenic CD4
+
 T cells (266). This further suggests that using surface 
markers alone may not be the most efficient means of identifying ILCs. 
Human ILCs are similar to murine ILCs and are defined as IL-7Ra+ Lineage- and sub grouped 
into ILC1s, ILC2s and ILC3s (267). Alongside IL-7Ra expression, CD161 is also expressed on 
human ILCs and is commonly used in their identification (267, 268). Several further markers, 
not used in mice, have also been well established in identifying different human ILC subsets. 
























) (267-269). ILCs have currently been located within multiple human 
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tissues with their main analysis being conducted within human blood and tonsils. Due to ILCs 
being a rare population in tissue analysed, such as human blood, their analysis is normally 
conducted through the use of surface markers. (267-269). 
3.1.1 Project Aims 
The inconsistency across publications in the identification methods used to analyse ILCs makes 
it difficult to compare subgroups across different tissues. This chapter aimed to identify and 
compare ILC subsets and their phenotype in a consistent manner across lymphoid and non-
lymphoid tissues. This was achieved using flow cytometry or confocal imaging with ILCs being 
identified based on their expression of IL-7Ra, due to the functional relevance of IL-7 signalling 
in ILC development and maintenance being well documented (101, 270). In comparison to 
CD90 in which the function in ILC biology is unknown. 
3.2 RESULTS 
The results within this chapter have been published by Dutton et al., in Wellcome Open 
Research in 2017; Characterisation of innate lymphoid cell populations at different sites in 
mice with defective T cell immunity (216). 
3.2.1 ILC populations are identified within lymphoid and non-lymphoid tissues 
ILCs reside in non-lymphoid and lymphoid tissues and are identified by the lack of expression 
of lineage markers; B220 (identifies B cells and plasmacytoid DCs), CD3e, CD5 (identifies T 
cells), CD11c and CD11b (identifies DCs and neutrophils) (112, 271). All helper ILCs express 
IL- 7Ra and lack intracellular CD3e (iCD3e), which is expressed by immature T cells (Figure 
3.1a-e) (243). The largest percentage of ILCs, as a proportion of Live CD45
+
 cells, which will 
here on be referred to as CD45
+
 cells, was located within the ear and SI LP, however, 
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numerically ILCs were most abundant in the lung and SI LP, partially due to tissue size (Figure 
3.2a). Within the LNs ILCs were numerically less abundant and proportionally much reduced, 
largely contributed to by the presence of a large naïve lymphocyte population (243).  
Due to the inconsistency within the current literature of phenotypic markers used to identify 
ILC subsets in different tissues and disease models, ILC subsets were analysed based on their 





), ILC2s (RORgt- GATA-3+ T-bet-) and ILC3s (RORgt+ GATA-3-), providing a 
consistent identification method and therefore comparison across all lymphoid and non-
lymphoid tissues. Out of these three subgroups ILC1s were dominant in the ear and auricular 
LN (auLN), ILC3s within the SI LP, mLN and auLN and ILC2s within the lung (Figure 3.2b). 
Categorising ILC subgroups based on TF expression lead to the identification of a putative 
fourth ILC population, triple negative (TrN) ILCs, so called because this population lacked 
expression of T-bet, GATA-3 and RORgt. TrN ILCs were detected in all tissues analysed but 
were most prevalent in the ear and lung. 
3.2.2 ILC3 subsets are not evenly distributed between assessed tissues 
The recent identification of ILC1s as a distinct group from cNK cells and the lack of lineage 
markers identified to clearly separate ILC1s from cNK cells and NCR
+
 ILC3s has meant that 
ILC1s phenotype and functions are less characterised within the literature compared to ILC2s 
and ILC3s (130, 135, 263, 272). Therefore, within this study characterisation and phenotyping 
of the ILC subsets was restricted to ILC2s and ILC3s, which were assessed and compared across 
the Ear, auLN, SI LP, lung and mLN. Within adult mice ILC3s can be divided into 3 subgroups  
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Figure 3.1. Characterisation of ILCs in lymphoid and non-lymphoid tissue 
Cells were isolated from ear, auLN, SI LP, lung and mLN from WT mice as described in methods. 
When identifying ILCs the lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs 
were gated negatively for iCD3e.  
Each data point represents 2 ears, 2 auLNs, 1 SI LP, 1 lung and 1 mLN from one mouse. Data 
pooled a minimum of 3 experiments. Values on flow cytometry plots represent percentages 
of ILC as a proportion of Live CD45
+ 
cells and ILC subsets as a proportion of total ILCs. 
a) Representative flow cytometry plots, previously gated on Live CD45+ cells, showing ILCs 
(Lineage
- 
IL-7R⍺+ iCD38-), ILC1s (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2 
(Lineage
- 
IL-7R⍺+ iCD38- GATA-3+ ROR"t- T-bet-), ILC3 (Lineage- IL-7R⍺+ iCD38- GATA-3- 
ROR"t+) and TrN ILCs (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-) within the ear. 
b) Representative flow cytometry plots, previously gated on Live CD45+ cells, showing ILCs, 
ILC1s, ILC2, ILC3 and TrN ILCs within the auLN. 
c) Representative flow cytometry plots, previously gated on Live CD45+ cells, showing ILCs, 
ILC1s, ILC2, ILC3 and TrN ILCs within the SI LP. 
d) Representative flow cytometry plots, previously gated on Live CD45+ cells, showing ILCs, 
ILC1s, ILC2, ILC3 and TrN ILCs within the Lung. 
e) Representative flow cytometry plots, previously gated on Live CD45+ cells, showing ILCs, 












































































































































































   
Figure 3.2. Quantification of ILCs in lymphoid and non-lymphoid tissue 
Cells were isolated from ear, auLN, SI LP, lung and mLN from WT mice as described in methods. 
When identifying ILCs the lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs 
were gated negatively for iCD3e.  
Each data point represents 2 ears, 2 auLNs, 1 SI LP, 1 lung and 1 mLN from one mouse. Data 
pooled a minimum of 3 experiments. Values on flow cytometry plots represent percentages, 
bars on scatter plots represents the median, which is also shown numerically. Statistical 
significance was tested using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s test: 
*p≤0.05, **p≤0.01, ***p≤0.001. 
a) Percentage, as a proportion of Live CD45+ (left), and number (right) of ILCs (Live CD45+ 
Lineage
- 
IL-7R⍺+ iCD38-) cells within the ear (n=6), auLN (n=10), SI (n=30), lung (n=13) and 
mLN (n=26). 
b) Pie charts showing the mean percentage of ILC1s (Live CD45+ Lineage- IL-7R⍺+ iCD38- GATA-
3
- 





IL-7R⍺+ iCD38- GATA-3- ROR"t+), TrN ILCs (Live CD45+ Lineage- IL-7R⍺+ 
iCD38- GATA-3- ROR"t- T-bet-) and ungated cells (Live CD45+ Lineage- IL-7R⍺+ iCD38-) as a 









































































 ILC3s, as discussed previously (130, 139). The ability to compare 
ILC3s consistently across different tissues shows that the ILC3 subsets are not evenly 
distributed between these analysed sites (Figure 3.3a-c). Within the SI LP all three ILC3 
populations were clearly identified, consistent with the requirement for LTi-like cells in 
promoting epithelial repair and maintenance, NCR
-
 ILC3s in providing regulatory signals to 
CD4
+
 T cells and NCR
+
 ILC3s function in the protection against extracellular pathogens (26, 162, 
168, 187). In comparison LTi-like cells are the clear dominant population within the assessed 
lymphoid tissues and are important in the regulation of adaptive responses and maintenance 
of LN structure (114, 243, 244). ILC3s are the smallest subgroup of ILCs within the ear and the 
lung, shown in Figure 3.2, however, this population clearly consists of NCR
-
 ILC3s and LTi-like 
cells in both tissues. Within the lung ILC3s play a role in the protection against extracellular 
bacterial infections and within the skin are important in wound repair (107, 229). Therefore, 
ILC3 subsets seem to be distributed according to their functional requirement in different 
tissues. 
3.2.3 ILC2s phenotype differs between assessed tissues 
The plethora of ILC2 surface makers associated with their phenotype has caused 
inconsistencies in ILC2 identification across the literature. Therefore, within these studies 
ILC2s were identified via the expression of GATA-3, which is required for their full maturation 
and function, to enable the assessment and comparison of common ILC2 surface markers 
across the  ear, SI LP, Lung and mLN (136). Lineage
+
 IL-7Ra- cells were used as a control as 
these mainly represent APCs, such as B cells, DCs and macrophages which have very low, if  
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Figure 3.3. Analysation of ILC3 subsets isolated from different tissues 
Cells were isolated from ear, auLN, SI LP, lung and mLN as described in methods. Lineage 





iCD38- IL-7R⍺+ GATA-3- RORgt+). ILC3s were identified using differential 
expression of CCR6 and NKp46. 
Each data point represents 2 ears, 2 auLNs, 1 SI LP, 1 lung and 1 mLN from one mouse. Data 
pooled from a minimum of 3 experiments. Values on flow cytometry plots represent 
percentages, bars on scatter plots represents the median, which is also shown numerically. 
Statistical significance was tested using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s 
test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing expression of CCR6 and NKp46 on ILC3s 
within the ear, auLN, SI LP, lung and mLN. 
b) Percentage of ILC3s expressing CCR6 and NKp46 within the ear (n=7), auLN (n=10), SI LP 
(n=28), lung (n=13) and mLN (n=26). 
c) Number of ILC3s expressing CCR6 and NKp46 within the ear (n=7), auLN (n=10), SI (n=28), 






























































































































any, expression of the key ILC2 phenotypic markers assessed within these studies (273). 
Markers commonly associated with ILC2 identification, in previous studies, include CD25, 
KLRG1 and the co-stimulatory molecule ICOS which are highly expressed on ILC2s with the SI 
LP, Lung and mLN (Figure 3.4a-b) (25, 108, 142, 274). In comparison ILC2s within the ear lacked 
CD25 and KLRG1 expression with variable levels of ICOS. CD25 and KLRG1 are both activation 
markers expressed on activated T cells, suggesting that within the ear ILC2s had a low 
activation status (275, 276). As previously discussed, ILC2s within the mLN express MHCII, 
although at lower levels compared to APC B cells, which enables their interactions with CD4
+
 
T cells (164). MHCII expression was also detected on lung ILC2s, although at a reduced 
frequency in comparison to mLN ILC2s (164). Consistent with this study, a proportion of ILC2s 
within the mLN express MHCII, with the frequency of expression being comparably lower than 
APCs. Lung ILC2s, on the other hand, alongside ear and SI LP ILC2s had negligible levels of 
MHCII. ST2 is one of the most common markers used in ILC2 identification across a variety of 
tissues including the ear skin, mLN and lung and is important in the activation of ILC2s via 
IL- 33 stimulation (164, 221, 231). Controversially, ST2 expression was only highly expressed 
within the lung and mLN, with lower levels detected in the ear and SI LP. This may suggest that 
ST2 cannot be uniformly used across different tissues in the identification of ILC2s, showing 
the importance of establishing the phenotype of ILC2s in a specific tissue, in which GATA-3 is 
a useful tool, to enable efficient and correct identification of ILC subsets. 
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Figure 3.4. Characterisation of ILC2s isolated from different tissues 
Cells were isolated from ear, SI LP, lung and mLN as described in methods. Lineage markers 




iCD38- IL-7R⍺+ GATA-3+) and their phenotype assessed.  
Each data point represents 2 ears, 1 SI LP, 1 lung and 1 mLN from one mouse. Data pooled 
from a minimum of 3 experiments. Within scatter plots the bar represents the median. 
Statistical significance was tested using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s 
test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Percentage of ILC2s expressing CD25, KLRG1, ICOS, MHCII and ST2 normalised to mode 
within the ear (n=5), SI LP (n=8), lung (n=6-8) and mLN (n=6). 
b) Representative histograms showing the expression of CD25, KLRG1, ICOS, MHCII and ST2 
on ILC2s or Lineage
+
 IL-7R⍺+ cells within the ear (green line), SI LP (blue line), lung ILC2s 
(orange line) and mLN (red line), using lung Lineage
+
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3.2.4 Lineage- IL-7Ra+ cells lacking classical ILC TF expression are a true ILC population 
Until recently, publications contained little information on the presence or function of ILCs 
lacking the three TFs, T-bet, GATA-3 and RORgt. A study by Wang et al., published in 2017, has 
identified a fourth subgroup of ILCs, termed ILCregs that lack T-bet, GATA-3 and RORgt 
expression (113). They have been termed regulatory due to their ability to supress intestinal 
inflammation through the production of IL-10 (113). To confirm that the TrN ILC population 
identified within these studies was a true ILC population and was not being contaminated by 
IL-7Ra+ non ILCs the current lineage channel was extended to include antibodies that 
recognise cells expressing CD19 (identifying B cells), Ter119 (identifying erythrocytes), Gr1 
(identifying macrophages, monocytes and eosinophils), CD123 (identifying DCs), F4/80 
(identifying macrophages and eosinophils), CD49b (identifying cNK cells) and FceRI (identifying 
basophils and mast cells) (112, 164, 271, 274, 277-282). TrN ILCs were analysed within the ear 
due to this tissue containing the largest proportion of this population. Even with the extended 
lineage channel, the TrN population still remained to be the largest subset of ILCs within the 
ear (~50%), suggesting that this population is not comprised of IL-7Ra+ non-ILCs (Figure 3.5a-
b). 
To provide further evidence that the TrN ILCs resembled ILCs, expression of Id2 using Id2 GFP 
mice was undertaken. Id2 is paramount in the development of all ILC populations, supressing 
the developmental pathway towards the T or B cell lineage (127, 136, 152, 153). Expression 
has been identified in mature cNK cells, all ILC3 subsets and ILC2s and not within mature T or 
B cells (127, 136). However, ILCs Id2 dependent development is not unique, with other 
lineages such as DCs expressing Id2 in their mature state (258). Using WT mice as a control for 
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Id2 GFP gating, it was observed that within Id2 GFP reporter mice ~90% of ILCs within the ear 
express Id2, although their expression was weaker than cNK cells, which are a known 
population to express Id2 (Figure 3.5c-d) (127). The extended lineage used to identify ILCs 
confirmed that other populations expressing Id2 were not included within this analysis. This 
further supports the hypothesis that the TrN ILCs were likely to be an ILC population that 
doesn’t fit within the existing nomenclature. 
3.2.5 ILC identification via TF is affected by digestion protocols 
The lack of common ILC2 markers expressed within the ear, raised the concern that the ear 
digestion protocol (EDP) was downregulating or cleaving surface proteins during the 
preparation of the ear. This has been shown within previous studies which report that 
different digestion protocols can result in the reduced ability to identify certain surface 
markers, affecting analysis (266). If IL-7Ra+ Lineage+ hematopoietic cells were losing the 
expression of their lineage markers this could lead to their identification as IL-7Ra+ Lineage- 
ILCs. This would contaminate the ILC population and result in incorrect identification of ILC 
populations, potentially included within the TrN ILC gate. To test this hypothesis the lung was 
prepared under the normal lung digestion protocol (LDP) and compared to preparation under 
the EDP. These two protocols were compared due to them sharing the same digestion 
enzymes, Liberase TM and DNase, but at different concentrations. Within the EDP the 
enzymes were used at a higher concentration than the LDP, roughly x150 and x13 higher, 
respectively, and incubated at 37°C for twice as long. Thus, the EDP is a much harsher 
digestion to that of the LDP, but there are similarities in the enzymes used. Notably, isolating  
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Figure 3.5. Evidence that Lineage- IL-7R⍺+ GATA-3- ROR"t- T-bet- cells are ILCs 
Cells were isolated from the ear and spleen of WT mice and Id2 GFP reporter mice as described 
in methods. When identifying ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, CD123, CD49b, F4/80 and FceRI.   
Each data point represents 2 ears and 1 spleen from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages of ILC as a proportion 
of Live CD45
+
 cells and ILC subsets as a proportion of total ILCs. Bars on scatter plots represents 
the median, which is also shown numerically.  
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ Lineage- IL-





 IL-7R⍺+ iCD38- GATA-3+ ROR"t- T-bet-), ILC3s (Live CD45+ Lineage- IL-
7R⍺+ iCD38- GATA-3- ROR"t+) and TrN ILCs (Live CD45+ Lineage- IL-7R⍺+ iCD38- GATA-3- 
ROR"t- T-bet-) in the ear with the extended lineage. ILCs were gated negatively for iCD3e 
(gating strategy not shown).  





 IL-7R⍺+ iCD38-), as a total proportion of ILCs in the ear (n=6)  





 IL-7R⍺+) expression of Id2 GFP in Id2 GFP reporter mice (top) and WT 
controls (bottom) within the ear. 







) expression of Id2 GFP in Id2 GFP reporter mice (top) and WT 

















































































NKp46 Id2 GFP 
c) d) 
b) Ear – Extended Lineage 
ILC 
ILC 








cells from the lung using the EDP rather than the LDP, resulted in a significant 2-fold increase 
in CD45
+
 hematopoietic cells, and 4-fold increase in ILCs, based on Lineage
-
 IL-7Ra+ gating, 
revealing that greater yields of cells could be isolated with harsher digestion of the lung tissue 
(Figure 3.6a-b). Even though numerically there were more ILCs within the EDP, the proportion 
of CD45
+
 cells and ILCs were comparable between digestions, suggesting that ILC gating was 
not being contaminated. To further ensure that Lineage
+
 cells were not becoming Lineage
-
, 
expression the lineage markers that are identified on IL-7Ra+ hematopoietic populations, 
CD3e, CD5, CD49b, F4/80 and FceRI were assessed on CD45+ cells within the lung. All markers 
were not downregulated under the EDP, proposing that IL-7Ra+ Lineage+ populations are not 
‘artificially’ becoming IL-7Ra+ Lineage- due to digestion (Figure 3.7a-b).  
Harsher digestion of the lung tissue with the EDP appeared to release a higher yield of ILCs. 
To look in more detail at the ILCs isolated through digestion of the lung under the LDP or the 
EDP, TF expression by ILCs was assessed. Considering an increase in total ILCs under the EDP, 
TrN ILCs and ILC3s were the only subsets to increase numerically, suggesting that the EDP may 
affect the identification of ILC1 and ILC2 subsets (Figure 3.8a-b). A potential mechanism for 
this is that harsher digestion conditions, may affect the expression of signature TFs used to 
identify the ILC subsets, potentially resulting in the ‘artificial’ identification of TrN ILCs. To 
explore this further, TF expression was assessed in CD45
+
 cells from the lung under LDP or 
EDP. The EDP caused a significant decrease in the expression of T-bet and GATA-3 but not 
RORgt on CD45+ cells within the lung (Figure 3.8c-d). This suggests that the TrN population 
may be comprised of ILC1s and ILC2s that have lost their expression of T-bet and GATA-3, 
respectively. Whilst some TrN ILCs may exist and are apparent in tissues that have had a much  
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Figure 3.6. Identification of the ILC population is unaffected by the ear digestion protocol 
Cells were isolated from the ear using the ear digestion protocol (EDP) and the lung using 
either the normal lung digestion protocol (LDP) as described in methods of WT mice. When 
identifying ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, 
CD123, CD49b, F4/80 and FceRI. ILCs were gated negatively for iCD3e (gating strategy not 
shown).  
Each data point represents 2 ears and 1 lung from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells and ILCs (Live CD45+ IL-7R⍺+ 
Lineage
-
) populations within the lung under LDP (top) and lung under EDP (bottom). 
b) Percentage (top) and number (bottom) of Live CD45+ cells (left) and ILCs (right) within the 









































































   
Figure 3.7. Expression of lineage markers used to identify ILCs was not decreased under the 
ear digestion protocol 
Cells were isolated from the ear of WT mice using the EDP and the lung using either the normal 
LDP or the EDP as described in methods.  
Each data point represents 2 ears and 1 lung from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells expression of CD3e, CD5, 
CD49b, F4/80 and FceRI within the ear – EDP (left), lung – LDP (middle) and lung – EDP 
(right).  
b) Percentage of Live CD45+ cells expressing CD3e, CD5, CD49b, F4/80 or FceRI within the 
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Figure 3.8. ILC transcription factor expression is reduced under the EDP 
Cells were isolated from the ear using the EDP and the lung using either the normal LDP or the 
EDP as described in methods in WT mice. When identifying ILCs lineage markers include; B220, 
CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, CD123, CD49b, F4/80 and FceRI. ILCs were gated 
negatively for iCD3e (gating strategy not shown).  
Each data point represents 2 ears and 1 lung from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. 
a) Representative flow cytometry plots, previously gated on ILCs, showing ILC1s (Live CD45+ 
Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2s (Live CD45+ Lineage- IL-7R⍺+ iCD38- 
GATA-3
+ 





IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-), as a proportion of total ILCs 
within the lung under LDP (top) and lung under EDP (bottom). 
b) Percentage (top) and number (bottom) of ILC subsets within the lung under LDP (n=6) and 
lung under EDP (n=6). 
c) Representative flow cytometry plots showing Live CD45+ cells expression of RORgt, T-bet, 
and GATA-3 by Live CD45
+
 cells within the ear – EDP (left), lung – LDP (middle) and lung – 
EDP (right).  
d) Percentage of Live CD45+ cells expressing RORgt, T-bet, or GATA-3 within the lung under 
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Lung – Ear Digestion Protocol (EDP) 
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milder digestion (see figure 3.2), these data argue that this population is at least in part an 
artefact of how the cells are isolated. 
3.2.6 Various surface markers are downregulated under a harsh digestion protocol 
Comparing the two digestion protocols and observing the effect of the harsher digestion on 
the expression of T-bet and GATA-3 raised the possibility that other markers previously 
analysed may also be affected. Therefore, the expression of the markers that were previously 
chosen as key to characterising ILC2 were compared between the LDP and the EDP. The 
expression of CD25 and KLRG1 was downregulated under the EDP, however ICOS, MHCII and 
ST2 were not (Figure 3.9a-b). This suggests that previous phenotyping of ILC2s within the ear 
may be skewed as ILC2s were identified to lack expression of CD25 and KLRG1 which may just 
be a result of the digestion. Expanding this analysis, markers required for identifying T cell and 
ILC3 populations (CD4 and CD8), cellular migration (CD62L, CD69) and, given the impact on TF 
expression, the proliferation marker Ki-67 were also tested (42, 49, 243, 283). The expression 
of CD62L, CD4 and CD8 were downregulated under the EDP whereas CD69 and Ki-67 
expression were not (Figure 3.9c-d). This suggests that certain surface proteins are cleaved or 
downregulated during the EDP, which should be taken into consideration upon 
characterisation of ILCs and other populations such as T cells. These observations are 
summarised within table 3.1. These results emphasise the importance of digestion protocols 
and how they can affect the phenotype of the cell upon analysis. To determine whether the 
LDP was more appropriate in isolating cells from the ear the ear was digested using the EDP 
and compared to the LDP (Figure 3.10a-b). The decrease in number of CD45
+
 cells and ILC 
along with ILC percentage suggests that the LDP is insufficient in obtaining a significant yield  
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Figure 3.9. Identification of various markers used to phenotype ILCs have decreased 
expression under the ear digestion protocol 
Cells were isolated from the ear using the EDP and the lung using either the normal LDP or the 
EDP as described in methods in WT mice.  
Each data point represents 2 ears and 1 lung from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells expression of CD25, ICOS, 
KLRG1, MHCII and ST2 within the lung – LDP (top) and lung – EDP (bottom).  
b) Percentage of Live CD45+ cells expressing CD25, ICOS, KLRG1, MHCII or ST2 within the lung 
under the LDP (n=5-6) or the EDP (n=5-6).  
c) Representative flow cytometry plots showing Live CD45+ cell expression of CD62L, CD69, 
CD4, CD8 and Ki-67 within the lung – LDP (top) and lung – EDP (bottom).  
d) Percentage of Live CD45+ cells expressing CD62L, CD69, CD4, CD8 or Ki-67 within the lung 
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Table 3.1. Summarising table of markers expression compared between the EDP and LDP 
A summarising table showing whether the marker expression on Live CD45
+
 cells within the 
lung were reduced when the lung underwent the EDP compared to the LDP. 
Expression decreased Expression not decreased 
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Figure 3.10. Poor ILC isolation from ear skin using milder enzymatic digestion 
Cells were isolated from the ear using the ear digestion protocol (EDP) or the lung digestion 
protocol (LDP) as described in methods in WT mice. When identifying ILCs lineage markers 
include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, CD123, CD49b, F4/80 and FceRI. 
ILCs were gated negatively for iCD3e (gating strategy not shown). 
Each data point represents 2 ears from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001.  
a) Representative flow cytometry plots showing Live CD45+ cells and ILCs within the ear 
under EDP (top) and ear under LDP (bottom). 
b) Percentage (top) and number (bottom) of Live CD45+ cells and ILCs within the ear under 








































































of ILCs from the ear. This indicates that in some cases a harsh digestion is needed to obtain a 
significant cell yield, however the caveats associated with this should be taken into 
consideration. 
3.2.7 ILCs are located within secondary lymphoid tissues within mouse and human 
Flow cytometry is a useful technique used to quantify ILC populations within tissues, however, 
it is unable to pinpoint the location of cells within the microenvironment. Immunofluorescent 
imaging enables the visualisation of ILCs, locating the areas in which they reside and 
potentially which cells they interact with. Building on recently published methods, the location 
of ILCs within tissues was assessed (243). The stromal network of the mLN provides and 
maintains a niche microenvironment, supporting cellular interactions and the successful 
activation of the adaptive immune response (49). Similar to previous reports ILC3s are located 
within the interfollicular areas positioned at the edge of the B cell zones and T cell follicles 
(Figure 3.11a) (243). Within the auLN, the microenvironment and organisation of T and B cells 
is comparable with the mLN, alongside the positioning of ILC3s (Figure 3.11b). This location is 
key for interactions between T cells and B cells, in the initial stages of the adaptive immune 
response, suggesting ILC3s may have a role in influencing either T or B cell development (243). 
To compare the location of ILC3s within lymphoid tissue to non-lymphoid tissues the SI LP was 
assessed (Figure 3.11c). Comparable to other reports ILC3s were identified within clusters 
termed CP located near the luminal wall (284).  
Having identified murine ILCs in lymphoid tissue and due to the cross reactivity of the 
antibodies used in the murine samples with human tissue, the location of human ILCs was  
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Figure 3.11. Identification of ILC3s in murine lymphoid and non-lymphoid tissues 
Representative immunofluorescent microscopy images of WT mouse mLN, auLN and SI LP. 
Sections were stained for RORgt, CD3e and IL-7Ra then counterstained with DAPI, to identify 
ILC3s. Tilescanned image is positioned on the left, the region of interest (ROI) is highlighted by 
a white dashed box and the 3 images on the right are zoomed in areas of the ROI. Larger 
images scale bar represents 100µm and smaller images represents 50µm. Information 
regarding the health of the patient, from which the sample was obtained, was not provided. 
a) Tilescanned image of mLN section (n=4). 
b) Tilescanned image of auLN section (n=3). 
c) Tilescanned image of SI LP section (n=3). 
DAPI RORγt CD3 IL-7Rα 
DAPI RORγt CD3 IL-7Rα 
DAPI RORγt CD3 IL-7Rα 
a) b) 
c) 
mouse mLN – ILC3s mouse auLN – ILC3s 
mouse SI LP – ILC3s 
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investigated to provide a basic description of their location and phenotype. Initially the 
location of ILCs was determined within human adult mLNs, to compare to the positioning 
within mice. ILC3s were located within the interfollicular areas of adult human mLNs, similar 
to murine models and previous publications (Figure 3.12a) (285-287). Within murine models, 
ILC2s have been located in a similar position to ILC3s in the interfollicular areas (243). This 
positioning within the mLN supports the function of ILC2s in interacting with T cells, directing 
the development of the adaptive immune response (164). In contrast to ILC3s, ILC2s within 
the human mLN were observed at a different location than their position within the murine 
model (Figure 3.12b). ILC2s were instead located within the B cell follicles, suggesting a 
potential difference between the function of murine ILC2s and human ILC2s.  
To further characterise human ILCs in situ the staining panel was developed to include a 5th 
colour, enabling the identification and then phenotyping of ILCs. The current literature on 
human ILCs within SLTs is mainly derived from the adult palatine tonsils (286). All three ILC 
subsets are located within the tonsil, however studies have focused on characterising ILC3s, 
with recent publications suggesting their involvement in regulating the proliferation and 
survival of innate B cells (268, 288-290). The palatine tonsil is histologically similar to the 
human and mouse mLN, containing B cell follicles surrounded by T cell areas and similar to 
the mLN, ILC3s were located within the T cell zone, situated between B cell follicles (Figure 
3.13a) (291, 292). A common phenotypic marker of ILCs within human tissue is CD161 which 
is expressed by ILC3s within the tonsil (268, 293). Upon the introduction of CD161 as a 5
th
 
colour within the staining panel it was clear that the majority of ILC3s expressed CD161 (Figure 
3.13b). MHCII expression on ILCs, as discussed previously, is important in the regulation of 
CD4
+
 T cells within the spleen and SI (114, 162, 163). ILCs within the tonsil have also been  
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Figure 3.12. Identification of ILC2s and ILC3s in adult human mLNs 
Representative immunofluorescent microscopy images of adult human mLN. Sections were 
counterstained with DAPI. Tilescanned image is positioned on the left, the ROI is highlighted 
by a white dashed box and the 3 images on the right are zoomed in areas of the ROI. Larger 
images scale bar represents 100µm and smaller images represents 50µm. Information 
regarding the health of the patient, from which the sample was obtained, was not provided. 
a) Tilescanned image of mLN section, stained for RORgt, CD3e and IL-7Ra (n=9), identifying 
ILC3s. 
b) Tilescanned image of mLN section stained for GATA-3, CD3e and ICOS (n=5), identifying 
ILC2s. 
DAPI RORγt CD3 IL-7Rα 
DAPI GATA-3 CD3 ICOS 
a) 
b) Human mLN – ILC2s 
Human mLN 
Human mLN – ILC3s 
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Figure 3.13. Phenotyping of ILC3s within human adult tonsil 
Representative immunofluorescent microscopy images of adult human tonsil. Sections were 
counterstained with DAPI. Information regarding the health of the patient, from which the 
sample was obtained, was not provided. 
a) Slide scanned image of whole tonsil section stained for expression of RORgt, CD3e and 
IL- 7Ra (left). An interfollicular area is highlighted by a white dashed box. Tilescanned 
showing human tonsil interfollicular area stained for expression of RORgt, CD3e and 
IL- 7Ra (middle). ROI is highlighted by a white dashed box, the smaller 3 images are 
zoomed in areas of the ROI. Larger image scale bar represents 100µm and smaller images 
represents 50 µm (n=4).  
b) Image showing human tonsil interfollicular area stained for expression of RORgt, CD3e, 
IL- 7Ra and CD161. ROI is highlighted by a white dashed box, the smaller 3 images are 
zoomed in areas of the ROI. Larger image scale bar represents 100µm and smaller images 
represents 50 µm (n=4). 
c) Image showing human tonsil interfollicular area stained for expression of RORgt, CD3e, 
IL- 7Ra and MHCII. ROI is highlighted by a white dashed box, the smaller 3 images are 
zoomed in areas of the ROI. Larger image scale bar represents 100µm and smaller images 
represents 50 µm (n=4). 
DAPI RORγt CD3 IL-7Rα MHCII DAPI RORγt CD3 IL-7Rα CD161 
DAPI RORγt CD3 IL-7Rα 
a) 
b) c) 
Human tonsil - ILC3s 
Human tonsil – ILC3s CD161 expression Human tonsil  – ILC3s MHCII expression 
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identified to express MHCII by flow cytometry, which can be visualised by immunofluorescent 
microscopy within this study (Figure 3.13c) (289, 293). 
Through a consistent characterisation method, ILCs were identified and compared between 
murine lymphoid and non-lymphoid tissues, with further analysis of the ILC2 population 
revealing that their phenotype differed between tissues. The importance of specific digestion 
protocols was emphasised within this chapter, with TFs and surface protein expression being 
affected by certain protocols, affecting the accuracy of their analysis. Finally, some initial data 
was provided comparing the location and phenotype of ILCs within murine and human SLTs. 
3.3 SUMMARY 
Within this chapter characterisation of the ILC populations in lymphoid and non-lymphoid 
tissues, through the utilisation of TF expression, enabled the simple and robust identification 
of ILC subsets. Such analysis facilitated the comparisons of ILC groups between different 
tissues. These data observed that ILC2s phenotype varies within different tissues alongside 
the identification of a potentially novel population of ILCs lacking TFs. Further analysis of this 
population demonstrated that the manner in which the tissue is digested can have substantial 
effects, both on ILC surface marker expression but also, unexpectedly, the detectability of TF 
expression. Finally, within this chapter ILC2s and ILC3s locations within SLTs were compared 
across murine and human mLNs, alongside human tonsil samples revealing that ILC3s were 
consistently located within the interfollicular area with ILC2s interestingly being identified 
within B cell follicles.  
Consistent characterisation of ILCs via TF expression enabled their comparison across the ear, 
auLN, SI LP, lung and mLN (25, 108, 243). ILC3 subsets were observed to be dispersed in 
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different proportions within the tissues assessed and RORgt staining was important in the 





. Furthermore, the phenotype of ILC2s between the different tissues was observed not 
to be consistent. The main contradicting observation from these studies was the lack of ST2 
on ILC2s within the ear, which has previously been used to identify ILC2s within this tissue 
(112). As previously discussed ST2
-
 iILC2s reside within the SI LP and proliferate upon IL-25 
stimulation, and due to the lack of ST2 expression within the ear, it is possible that these cells 
also reside here (108, 254). However, iILC2s also express high levels of KLRG1, which is 
identified within the SI LP, but not the ear (108). Further analysis of IL-25R may identify 
whether ILC2s within the ear are similar to iILC2s being more responsive to IL-25 rather that 
IL-33 (108). The variation in the levels of ILC2 markers detected on ILCs within these different 
tissues emphasises that surface markers are not as accurate in identifying subgroups 
compared to staining for TFs or using TF-reporter mice.  
Analysis of ILC subsets through the use of TFs revealed the presence of a novel population of 
TrN ILCs. Extending the lineage markers used to identify ILCs, in accordance with other 
publications, confirmed that the ILC gating strategy was not contaminated by other 
hematopoietic cells (221). Furthermore, ~90% of the ILC population express Id2 within the 
ear, as TrN ILCs comprise of over half of total ILCs within the ear this indicates that TrN ILCs 
express Id2. It was also clear that lineage markers expressed by IL-7Ra+ Lineage+ cells were 
not downregulated under the EDP, indicating that TrN ILCs were not a contamination of non-
ILCs due to the digestion protocol, suggesting that TrN ILCs are a true ILC population. Further 
characterisation of these cells would be useful to further confirm their ILC phenotype, such as 
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CD90 expression. Currently within the literature little is published on the function and 
characterisation of ILCs which lack expression of T-bet, GATA-3 and RORgt apart from recent 
publication which has seemingly identified a group of TrN ILCs which also lack Foxp3 
expression, called ILCregs (113). ILCregs as well as requiring Id2 for their development also 
depended on the expression of DNA-binding protein inhibitor 3 (Id3) (113). These cells are 
described to reside mainly within the SI and abrogate intestinal inflammation via IL-10 
production (113). TrN ILCs may belong within the ILCreg population with further analysis of 
the TrN ILCs phenotype, including IL-10 production and Id3 expression, being required to 
confirm this (113). Although the TrN ILCs share similarities with the ILCregs, the localisation of 
these two populations are not comparable. ILCregs are abundant in the SI, and scarce within 
the lung, unlike TrN ILCs which along with the ear skin are most abundant within the lung 
(113). This suggests that ILCregs may contribute to a proportion of the identified TrN ILCs, 
however, it is unlikely that the entire population can be attributed to by ILCregs.  
It is further possible that the TrN population may also consist of ILC precursors, for example 
the CHILP population (Lineage
-
 IL-7Ra+ a4b7+ CD25- Id2+ GATA-3-) (27, 98). ILC progenitors 
(Lineage
-
 IL-7Ra+ a4b7+) are a rare population mainly studied within the foetal liver, foetal gut 
and adult BM with little being reported on their presence in adult tissue (155, 294). However, 
similar to ILCregs, given that ILC precursors are a rare population in adult tissue, it is unlikely 
that they contribute largely to the TrN ILCs.  
The importance in digestion protocols used for certain tissue preparations was elaborated 
upon the down regulation of T-bet and GATA-3 expression, under the EDP, diminishing the 
ability to identify ILC1s and ILC2s. This may result in ILC1s and ILC2s inclusion within the TrN 
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population gate, which may explain why it is such a large population in the ear. Therefore, 
although TrN ILCs are a true ILC population they may also contain ILC1 or ILC2 subgroups. The 
decrease of expression of a variety of surface markers on hematopoietic cells under the EDP, 
highlights the importance of digestion protocols on the analysis of surface markers used in the 
identification and characterisation of cellular populations.  
Interestingly TrN ILCs are most abundant within the lung and the ear with these tissues, 
compared to other tissue analysed, being the only digestion protocols that both include an 
enzymatic digestion involving Liberase TM enzyme. Previous reports have shown that certain 
enzymes can affect the expression of surface molecules, therefore, Liberase TM may be 
responsible for the loss of protein expression (266). However, the auLN and mLN undergo the 
same digestion protocol, which doesn’t require Liberase TM, and still contains TrN ILCs. The 
auLN in fact contains a larger proportion of TrN ILCs compared to the mLN, suggesting that 
the digestion protocol is not responsible for the entire TrN population, but that this TrN 
population still exists as true ILC subset, and is just altered by the digestion protocol. The LDP 
was unable to obtain a sufficient cell yield from the ear, and due to a more appropriate 
digestion protocol for the ear has not been established the EDP was continuously used when 
analysing ear skin. Through the assessment of different concentrations of Liberase TM and 
different incubation periods a more efficient EDP may be established, with a balance between 
obtaining an appropriate cell yield without affecting protein analysis.  
Comparisons between human and murine SLT microenvironments revealed the similarities 
and differences between ILC locations. Within the human mLN and tonsil and the murine LNs, 
ILC3s are situated within the interfollicular areas and expression of CD161 and MHCII can be 
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detected by immunofluorescent imaging in the tonsil. CD161 is not a marker specific for ILCs 
and is also identified on T cells (295). The initial identification of ILCs as CD3
-
 supports that the 
ILC3s identified are true ILCs, however a caveat of immunofluorescent microscopy is the lack 
of markers able to be used. This is a problem when assessing ILCs as a plethora of lineage 
markers are normally used in their identification. The location of ILC2s within murine and 
human mLNs differs, with human ILCs being located within the B cell follicle (243). This 
suggests that there may be differences between human and mouse ILC2s within the mLN. On 
the other hand, murine samples are taken from an animal where the immunological history is 
known and monitored. This is compared to human patients in which all immunological 
responses are not documented. A multitude of past infections may shape the 
microenvironment of human LNs and immune cell characteristics and functions. It is therefore 
interesting to observe that human ILC2s have the capability to enter B cell follicles and 
potentially interact with B cells, with IL-9 being an important cytokine in promoting B cell 
survival, which may also occur in murine samples (212). This identification method of ILC2s 
only involves ILCs being gated negatively for T cells and does not contain the extensive lineage 
marker pool used previously in flow cytometry analysis. This suggests, the identified ILCs may 
potentially be a different non-ILC IL-7Ra+ GATA-3+ ICOS+ CD3- population. Using phenotypic 
markers more commonly used in human staining, such as CRTH2 may be a more accurate 
method of detecting ILC2s (267-269). Within these studies the characterisation of ILCs was 
not continued further. This was mainly due to the unavailability of fresh tissue and the low 
impact factor of phenotyping ILCs in human tissue within the field.  
Overall these data are important in addressing the fundamental issues in the identification of 
ILCs within a range of lymphoid and non-lymphoid tissues. ILC2s do not consistently express 
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the same surface markers across different tissues, suggesting that TF staining is a more robust 
method of identification. Digestion protocols can, however, effect the identification of 
extracellular and intracellular proteins, used in the analysis of different populations. 
Therefore, understanding the effects of the digestion protocol is essential in the efficient 
analysis of cellular populations. ILCs were identified and phenotyped in human and murine 
SLT sections showing their location within the niche microenvironment of the mLN and tonsil. 
This initial characterisation of ILCs within human tissues, establishes a platform in which the 
position of ILCs across different tissues can be located and phenotyped.
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Chapter 4.   DETERMINING THE ROLE OF ICOS AND ICOSL 
INTERACTIONS IN ILC HOMEOSTASIS 
4.1 INTRODUCTION 
SLTs, such as LNs, provide a unique microenvironment which supports interactions between 
the innate and adaptive immune system paramount in the development of an effective 
immune response. Upon entry into the LN T cells crawl along fibroblastic reticular cells (FRCs), 
part of the stromal network, refining their movement to T cell zones and enabling their 
scanning of MHCII presented antigen on APCs, such and DCs, which are colocalised to the FRCs 
(50). Upon recognition of cognate antigen, via the TCR complex, naïve CD4
+
 T cells undergo a 
series of steps, involving co-stimulatory molecule interactions, leading to their full activation 
and development into a cytokine producing effector Th cell (54-57). These co-stimulatory 
interactions are essential for controlled activation of naïve CD4
+
 T cells and begins with CD28, 
which is upregulated on T cells upon TCR stimulation, interacting with CD80/CD86 enhancing 
T cell proliferation. CD28:CD80/CD86 interactions also leads to the upregulation of CTLA-4 and 
ICOS. CTLA-4 competes with CD28 for CD80/CD86, inhibiting and controlling T cell 
proliferation, whereas, ICOS:ICOSL interactions support T cell activation, survival and 
proliferation alongside OX40 and OX40L interactions (57, 60, 63, 64). 
ICOS is the third member of the CD28 superfamily, following CD28 and CTLA-4, and is 
upregulated on activated T cells upon CD28:CD80/CD86 interactions (296). Its ligand, ICOSL is 
located within a range of tissues, including lymphoid and non-lymphoid and its expression 
varies on different antigen presenting cells (297, 298). ICOSL is constitutively expressed on 
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naïve B cells, DCs, macrophages and splenocytes, however expression is induced by TNF-a and 
other inflammatory stimuli on fibroblasts and in non-lymphoid tissues (60, 61, 297, 299). 
Icos- /- mice have been previously used to understand the importance of ICOS:ICOSL 
interactions in T cell activation (62, 300). Under steady conditions T and B cell biology in Icos  - /- 
mice are comparable to WT mice, showing that ICOS is not required for the development of 
these populations (300). However, in vitro studies observed that ICOS was necessary for 
stimulated naïve T cells to efficiently proliferate and produce T effector cell cytokines such as 
IL-4, IFN-g and IL-10 (62, 296). This was supported in vivo by keyhole limpet hemocyanin (KLH) 
immunisations showing that ICOS:ICOSL interactions were paramount in the expansion of 
primed T cells within the LN and their ability to produce effector cytokines including IL-4, IL-5 
and IL-10 (57, 62, 301). ICOS:ICOSL interactions initiate a series of intracellular steps, including 
the recruitment of phosphatidylinositol 3-kinase (P13K) and subsequent activation of 
mitogen-activated protein (MAP) kinases which in turn regulates the cellular response (302). 
ICOS:ICOSL interactions are important in directing T cell differentiation, enhancing the 
development into Th2 and Tfh cells (302, 303). Studies originally explored the role of ICOS in 
the differentiation between Th1 and Th2 responses and suggested that signalling through 
ICOS:ICOSL interactions lead to the development and support of a Th2 response (57, 296). This 
was shown by blocking ICOS interactions in vitro, skewing Th effector development to favour 
Th1 cells (296). Furthermore, Coyle et al., have also shown that within a lung infection model 
ICOS is paramount in the activation of antigen-specific Th2 but not Th1 effector cells (57). Tfh 
cell development, maintenance and function was also shown to be dependent on ICOS as ICOS 
deficient mice had reduced numbers of Tfh cells and therefore impaired germinal centre 
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formation and class switching of IgA, IgE and IgG (57, 303). Furthermore, the migration of Tfh 
cells towards the B cell zone was reduced due to diminished expression of CXCR5 upon ICOSL 
blockade (304). Lack of ICOS:ICOSL interactions therefore resulted in the decreased ability of 
Tfh cells to communicate with B cells and the subsequent formation of normal germinal 
centres (304). The importance of ICOS:ICOSL interactions in the development of a normal B 
cell response was also shown upon immunisation with KLH, in which Icos -/- mice had a reduced 
production of KLH-specific IgG1 and IgG2, alongside a decrease in the number and size of 
germinal centres within the spleen (300). Similar to CD28 inhibition by CTLA-4, ICOS:ICOSL 
interactions are also regulated by a negative feed-back loop as transgenic mice that highly 
express ICOS on all T cells, showed that overstimulation resulted in reduced expression of 
ICOSL (305). Together, these studies determine a role for ICOS:ICOSL interactions in the 
proliferation, survival and maturation of effector Th2 and Tfh cells and the efficient induction 
of the B cell response.  
ILC2s have previously been shown to express ICOS within the lung, supported by data in 
Chapter 3, and also within the SI LP and mLN (25, 216, 221). The original focus of this PhD was 
to explore the role of co-stimulatory molecules within ILC biology and their cross-talk with the 
adaptive immune system, focusing principally on ICOS:ICOSL interactions. However, studies 
by Maazi et al., and Paclik et al., published in 2015, showed that ILC2s were dependent upon 
ICOS:ICOSL interactions for their homeostatic and inflammatory functions within the lung 
(262, 306). The data presented within this Chapter were collected in 2014-2015, before these 
publications, and focuses on the role of ICOS:ICOSL interactions in the development and 
maintenance of ILCs under steady state conditions. 
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4.1.1 Project Aims 
Within T cell biology ICOS:ICOSL interactions are important in the differentiation of Th2 cells, 
Tfh cells and the development of an effective B cell response. However, the role of ICOS on 
ILCs is still unclear. Due to the expression of ICOS on ILC2s and ILC3s, the aim of this chapter 
was to explore the impact in the deficiency of ICOS:ICOSL interactions on ILC2 and ILC3 
populations in the different tissues assessed in Chapter 3 (25, 216, 221). 
4.2 RESULTS  
The data within this chapter have been recently published by Dutton et al., in Wellcome Open 
Research in 2017 (216). 
4.2.1 ILC populations are not perturbed in the absence of ICOSL expression 
Co-stimulatory molecules are paramount in the activation of T cells upon recognition of 
cognate antigen providing proliferation and survival signals enabling naïve cells to mature into 
functional T helper cells (55-57). ICOS:ICOSL interactions aid cell proliferation, cytokine 
production alongside Th2 and Tfh cell differentiation (57, 62). ICOS is expressed on ILC2s, 
within the lung, mLN and SI LP, as shown in Chapter 3, and on a subset of ILC3s within the SI 
LP (216, 221). However, the role of ICOS:ICOSL interactions in ILCs biology is unknown. (216, 
221). 
To investigate the role of ICOS:ICOSL interactions in normal ILC biology under steady state 
conditions, ILC populations isolated from Icosl -/- mice were compared to those isolated from 
WT mice. Due to previous data showing high expression of ICOS on ILC2s within the SI LP, mLN 
and lung, the composition of ILC subsets was explored in detail within these tissues. Within 
the SI LP, WT and Icosl-/- mice had comparable percentages and numbers of CD45+ 
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hematopoietic cells and ILCs (Figure 4.1a-c). Interestingly, there was a modest, but significant 
decrease in the percentage of ILC2s and an increase in the percentage of ILC3s, suggesting 
that the two ILC subgroups known to express ICOS were perturbed in the absence of 
ICOS:ICOSL interactions. However, the total number of all ILC subsets, including ILC2s and 
ILC3s, was comparable between mice (Figure 4.1a-c). Within the mLN only an increase in 
percentage of CD45
+
 cells was detected in Icosl -/- mice (Figure 4.2a-c). This increase may be 
determined by alterations in the amount of cell death induced as part of the cell digestion 
protocol. All other populations were comparable between WT and Icosl -/- mice. Within the 
lung the percentage of ILCs was decreased within Icosl-/- mice which may be a result of 
alterations in the number of other (non-ILC) immune cells within the lung, due to there being 
no change in ILC number observed. All other populations were comparable between the WT 
and Icosl -/- mice apart from an increase in the percentage of ILC1s in Icosl -/- mice (Figure 4.3a-
c). Within these results modest differences in proportions of ILCs was observed between WT 
and Icosl -/- mice, however, these differences were not observed within the enumeration of 
ILCs. It would be assumed that changes in numbers would support differences between the 
two mice, indicating a clear role for ICOS:ICOSL interactions in ILC biology. Therefore, these 
data suggest that under steady state ICOSL expression is not required for the development 
and maintenance of ILC populations. 
4.2.2 Minimal impact of ICOS:ICOSL on the phenotype of ILC2s 
Currently ICOS or ICOSL expression has not been identified on ILC1s, therefore, this study will 
focus on the homeostasis of ILC2s and ILC3s in the absence of ICOS:ICOSL interactions. 
 96	
  
Figure 4.1. Minimal impact on ILC populations in the SI LP of Icosl-/- mice 
Tissues from WT mice were compared to Icosl-/- mice. Cells were isolated from SI LP as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs were 
gated negatively for iCD3e (gating not shown).  
Each data point represents 1 SI LP from one mouse. Data pooled from 7 experiments. Values 
on flow cytometry plots represent percentages, ILCs as a proportion of Live CD45
+
 cells and 
ILC subsets as a proportion of total ILCs. Bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ IL-7Ra+ 
Lineage
-
) and ILC1s (Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2 (Lineage- IL-7R⍺+ 
iCD38- GATA-3+ ROR"t- T-bet-), ILC3 (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t+) and TrN ILCs 
(Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-) within the WT SI LP or Icosl-/- SI LP. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets compared between the WT SI LP (n=13) 
and Icosl -/- SI LP (n=11). 
c) Number of Live CD45+ cells, ILCs and ILC subsets compared between the WT SI LP (n=13) 
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Figure 4.2. No impact on ILC populations within the mLN of Icosl-/- mice 
Tissues from WT mice were compared to Icosl-/- mice. Cells were isolated from mLN as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs were 
gated negatively for iCD3e (gating not shown).  
Each data point represents 1 mLN from one mouse. Data pooled from 5 experiments. Values 
on flow cytometry plots represent percentages, ILCs as a proportion of Live CD45
+
 cells and 
ILC subsets as a proportion of total ILCs. Bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ IL-7Ra+ 
Lineage
-
) and ILC1s (Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2 (Lineage- IL-7R⍺+ 
iCD38- GATA-3+ ROR"t- T-bet-), ILC3 (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t+) and TrN ILCs 
(Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-) within the WT mLN or Icosl-/- mLN. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets compared between the WT mLN (n=7) 
and Icosl-/- mLN (n=7). 
c) Number of Live CD45+ cells, ILCs and ILC subsets compared between the WT mLN (n=7) 



































































































































WT    Icosl-/- WT    Icosl-/- WT   Icosl-/- WT   Icosl-/- WT   Icosl-/- WT   Icosl-/- 
WT    Icosl-/- WT    Icosl-/- WT   Icosl-/- WT   Icosl-/- WT   Icosl-/- WT   Icosl-/- 
 98	
  
Figure 4.3. Minimal impact on ILC populations in the lungs of mice lacking ICOSL expression 
Tissues from WT mice were compared to Icosl-/- mice. Cells were isolated from the lung as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs were 
gated negatively for iCD3e (gating not shown).  
Each data point represents 1 lung from one mouse. Data pooled from 7 experiments. Values 
on flow cytometry plots represent percentages, ILCs as a proportion of Live CD45
+
 cells and 
ILC subsets as a proportion of total ILCs. Bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ IL-7Ra+ 
Lineage
-
) and ILC1s (Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2 (Lineage- IL-7R⍺+ 
iCD38- GATA-3+ ROR"t- T-bet-), ILC3 (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t+) and TrN ILCs 
(Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-)within the WT lung or Icosl -/- lung. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets compared between the WT lung (n=13) 
and Icosl -/- lung (n=11). 
c) Number of Live CD45+ cells, ILCs and ILC subsets compared between the WT lung (n=13) 
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Although numerically ILC2s were comparable in Icosl -/- and WT mice, their phenotype and 
therefore function may have been altered. In Chapter 3, ILC2s within the SI LP, mLN and lung 
were shown to all express high levels of CD25, ICOS and KLRG1. MHCII was refined to ILC2s 
within the mLN and ST2 to the mLN and lung. ICOS:ICOSL interactions have been associated 
with an increase in T cell activation, increased CD25 expression, downregulation of ICOSL and 
skewing of T effector cell differentiation towards the Th2 fate (296, 301, 305). Therefore, to 
determine whether the lack of ICOS:ICOSL interactions effects the expression of CD25, ICOS, 
ST2, the activation marker KLRG1, as well as MHCII, ILC2s were analysed in detail within WT 
and Icosl -/- mice (108, 275). ILC2s were assessed within the SI LP, mLN and lung, using Lineage+ 
IL-7Ra- cells for a gating strategy control. Within the SI LP an increase in percentage of ILC2s 
expressing CD25 and ICOS was observed (Figure 4.4a-c). ICOS expression may be increased 
potentially due to the absence of ligand and therefore reduced binding and internalisation. 
An increase in percentage of MHCII and ST2 expression was observed within Icosl -/- mice, 
however, a decrease in the percentage of KLRG1
+
 ILC2s (Figure 4.4a-c) (305). Although these 
differences were significant, they were very modest in nature making it difficult to 
convincingly conclude much about the biological relevance of such data. Importantly, no 










 ILC2s was observed 
between WT and Icosl -/- mice, further suggesting that slight changes in the proportions of cells 
expressing a given marker may not be biologically relevant (Figure 4.4d). Within the mLN the 
percentage and number of ILC2s expressing each marker was comparable between WT and 
Icosl -/- mice, suggesting that the ILC2 phenotype was not perturbed in the absence of ICOSL 
(Figure 4.5a-d). ILC2s within the lung were similar to that in the mLN with the percentages and 
numbers being comparable between the two mice, apart from an increase in the percentage 
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Figure 4.4. Minimal impact on ILC2 phenotype in the absence of ICOSL in the SI LP 
Tissues from WT mice were compared to Icosl -/- mice. Cells were isolated from SI LP as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC2s 




 IL-7Ra+ iCD3e- GATA-3+. 
Each data point represents 1 SI LP from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots of CD25, ICOS, KLRG1, MHCII and ST2 expression on 
ILC2s in the WT SI LP and Icosl -/- SI LP. 
b) Representative histograms, normalised to mode, showing the expression of CD25, ICOS, 
KLRG1, MHCII and ST2 by ILC2s or Lineage
+
 IL-7Ra- cells within the WT SI LP, which were 
used to help identify gating methods. 
c) Percentage of ILC2s expressing CD25, ICOS, KLRG1, MHCII and ST2 within WT SI LP (n= 8) 
and Icosl -/- SI LP (n=6). 
d) Number of ILC2s expressing CD25, ICOS, KLRG1, MHCII and ST2 within WT SI LP (n= 8) and 






ICOS KLRG1 MHCII 
84.9 3.2 97.3 
WT SI LP 
a) 
97.1 
CD25 ICOS KLRG1 MHCII 
95.9 5.2 92.8 











CD25 ICOS KLRG1 MHCII 































































































































WT    Icosl-/- WT    Icosl-/- WT    Icosl-/- WT    Icosl-/- WT    Icosl-/- 
WT    Icosl-/- WT    Icosl-/- WT    Icosl-/- WT    Icosl-/- WT    Icosl-/- 
 101	
  
Figure 4.5. No impact on ILC2 phenotype in the absence of ICOSL in the mLN 
Tissues from WT mice were compared to Icosl -/- mice. Cells were isolated from mLN as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC2s 




 IL-7Ra+ iCD3e- GATA-3+. 
Each data point represents 1 mLN from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots of CD25, ICOS, KLRG1, MHCII and ST2 expression on 
ILC2s in the WT mLN and Icosl -/- mLN. 
b) Representative histograms, normalised to mode, showing the expression of CD25, ICOS, 
KLRG1, MHCII and ST2 by ILC2s or Lineage
+
 IL-7Ra- cells within the WT mLN, which were 
used to help identify gating methods. 
c) Percentage of ILC2s expressing CD25, ICOS, KLRG1, MHCII and ST2 within WT mLN (n= 6-
7) and Icosl -/- mLN (n=4-5). 
d) Number of ILC2s expressing CD25, ICOS, KLRG1, MHCII and ST2 within WT mLN (n= 6-7) 
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 of ILC2s expressing CD25 (Figure 4.6a-d). Together these data suggest that the phenotype of 
ILC2 in terms of expression of the molecules CD25, ICOS, KLRG1, MHCII and ST2
 
was not greatly 
affected by the absence of ICOSL interactions.  
4.2.3 Minimal impact on ILC3 subgroups in the absence of ICOSL 
ILC3s within the SI LP, similar to ILC2s, also express ICOS (216, 296). Although the total number 
of ILC3s are unchanged in Icosl -/- mice compared to WT mice, the individual ILC3 subgroups 
have not been assessed. ILC3s are subdivided into 3 groups based on their expression of 

















). To determine whether specific subsets of ILC3s are altered in the absence of 
ICOS:ICOSL interactions the three subgroups were analysed within the SI LP, mLN and lung of 
WT and Icosl -/- mice. Within the SI LP and the mLN the percentage and number of NCR+, LTi-
like and NCR
-
 ILC3s was comparable between WT and Icosl -/- mice (Figure 4.7 & 4.8). ILC3s are 
the smallest subgroup of ILCs within the lung and although NCR
-
 and LTi-like ILC3s were 
comparable between WT and Icosl -/- mice, there was a significant increase in the number of 
NCR
+
 ILC3s within Icosl -/- mice (Figure 4.9a-b). This may suggest that ICOS:ICOSL interactions 
supress the development of NCR
-
 ILC3s into NCR
+
 ILC3s, however, due to such small numbers 
of ILC3s within the lung, and NCR
+
 cells making up under 10% of lung ILC3s, this is also 
potentially due to sample variability. Combined, these data provide further evidence that ILC2 
and ILC3 populations are fairly normal in the absence of ICOSL, arguing that ICOS:ICOSL 
interactions are not critical for normal homeostasis of ILCs. 
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Figure 4.6. Minimal impact on ILC2 phenotype within the lung of Icosl-/- mice 
Tissues from WT mice were compared to Icosl -/- mice. Cells were isolated from lung as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC2s 




 IL-7Ra+ iCD3e- GATA-3+. 
Each data point represents 1 lung from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots of CD25, ICOS, KLRG1, MHCII and ST2 expression on 
ILC2s in the WT lung and Icosl -/- lung. 
b) Representative histograms, normalised to mode, showing the expression of CD25, ICOS, 
KLRG1, MHCII and ST2 by ILC2s or Lineage
+
 IL-7Ra- cells within the WT lung, which were 
used to help identify gating methods. 
c) Percentage of ILC2s expressing CD25, ICOS, KLRG1, MHCII and ST2 within WT lung (n= 6-
8) and Icosl -/- lung (n=4-6). 
d) Number of ILC2s expressing CD25, ICOS, KLRG1, MHCII and ST2 within WT lung (n= 6-8) 
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Figure 4.7. ILC3 subsets are not perturbed in the absence of ICOSL in the SI LP 
Tissues from WT mice were compared to Icosl-/- mice. Cells were isolated from SI LP as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC3s 




 IL-7Ra+ iCD3e- GATA-3- RORgt+. 
Each data point represents 1 SI LP from one mouse. Data pooled from 7 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing expression of CCR6 and NKp46 on ILC3s 
within the WT SI LP compared to the Icosl -/- SI LP. 
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Figure 4.8. ILC3 subsets are not perturbed in the mLN of Icosl-/- mice 
Tissues from WT mice were compared to Icosl -/- mice. Cells were isolated from the mLN as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC3s 




 IL-7Ra+ iCD3e- GATA-3- RORgt+. 
Each data point represents 1 mLN from one mouse. Data pooled from 5 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing expression of CCR6 and NKp46 on ILC3s 
within the WT mLN compared to the Icosl -/- mLN. 
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Figure 4.9. Minimal impact on ILC3 subsets in ICOSL deficient lungs 
Tissues from WT mice were compared to Icosl -/- mice. Cells were isolated from the lung as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC3s 




 IL-7Ra+ iCD3e- GATA-3- RORgt+. 
Each data point represents 1 lung from one mouse. Data pooled from 7 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001.  
a) Representative flow cytometry plots showing expression of CCR6 and NKp46 on ILC3s 
within the WT lung compared to the Icosl -/- lung. 
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4.2.4 Perturbations of ILC3 subgroups in the absence ICOS  
Publications studying the role of ICOS have previously analysed ICOS:ICOSL interactions in Icos 
-/-
 mice or ICOS-transgenic mice, where ICOS is expressed on all T cells, instead of focusing on 
Icosl -/- mice (62, 300, 305). Therefore, to further confirm that ICOS:ICOSL interactions were 
not required for normal ILC biology, ILCs within WT and Icos-/- mice were assessed in the SI LP 
and the mLN. The composition of CD45
+
 cells, ILCs and ILC subsets within the SI LP was similar 
to observed in the Icosl -/- SI LP. Modest but significant differences were observed within the 
percentages of ILC2s and ILC3s, however, the total numbers of these cells were not different 
(Figure 4.10a-c). Similarly, ILC3 subgroups were comparable between WT and Icos -/- mice 
(Figure 4.11a-b). Within the mLN the percentage of ILC1s and ILC2s was modestly but 
significantly increased within Icos -/- mice, however, again this was not reflected in the total 
numbers (Figure 4.12a-c). Within the Icos -/- mice there was a significant decrease in the 
number of ILC3s, which was not observed within the Icosl -/- mice and the decrease in ILC3 was 
observed within the two dominant ILC3 subgroups within the mLN, the LTi-like and the NCR
-
 
ILC3 cell fraction (Figure 4.13a-b). This may suggest different requirements of ILC3s for ICOS 
over ICOSL.   
In summary, the data provided here, assessing ILC populations in both Icosl-/- and Icos -/- mice, 
has revealed no substantial differences in ILC number or phenotype within the lung and SI 
LP,with only occasional modest differences, mostly in the proportions of different ILC subsets. 
Consequently, the data strongly support the contention that the normal homeostasis of ILC2 
and ILC3 populations in mucosal tissues do not require ICOS:ICOSL interactions. Interestingly 
a requirement for ICOS over ICOSL in the establishment of a normal ILC3 population was 
required within the mLN, suggesting difference between Icos-/- and Icosl-/- mice. 
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Figure 4.10. Normal ILC populations in the SI LP of Icos-/- mice 
Tissues from WT mice were compared to Icos-/- mice. Cells were isolated from the SI LP as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs were 
gated negatively for iCD3e (gating not shown).  
Each data point represents 1 SI LP from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, ILCs as a proportion of Live CD45
+
 cells and 
ILC subsets as a proportion of total ILCs. Bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ IL-7Ra+ 
Lineage
-
) and ILC1s (Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2 (Lineage- IL-7R⍺+ 
iCD38- GATA-3+ ROR"t- T-bet-), ILC3 (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t+) and TrN ILCs 
(Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-) within the WT SI LP or Icos -/- SI LP. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets compared between the WT SI LP (n=10) 
and Icos -/- SI LP (n=10). 
c) Number of Live CD45+ cells, ILCs and ILC subsets compared between the WT SI LP (n=10) 
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Figure 4.11. ILC3 subsets are not perturbed in the SI LP of Icos-/- mice 
Tissues from WT mice were compared to Icos -/- mice. Cells were isolated from the SI LP as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC3s 




 IL-7Ra+ iCD3e- GATA-3- RORgt+. 
Each data point represents 1 SI LP from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing expression of CCR6 and NKp46 on ILC3s 
within the WT SI LP compared to the Icos -/- SI LP. 
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Figure 4.12. Reduced numbers of ILC3s in the mLN of Icos-/- mice 
Tissues from WT mice were compared to Icos -/- mice. Cells were isolated from the mLN as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILCs were 
gated negatively for iCD3e (gating not shown).  
Each data point represents 1 mLN from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, ILCs as a proportion of Live CD45
+
 cells and 
ILC subsets as a proportion of total ILCs. Bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ IL-7Ra+ 
Lineage
-
) and ILC1s (Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet+), ILC2 (Lineage- IL-7R⍺+ 
iCD38- GATA-3+ ROR"t- T-bet-), ILC3 (Lineage- IL-7R⍺+ iCD38- GATA-3- ROR"t+) and TrN ILCs 
(Lineage
- 
IL-7R⍺+ iCD38- GATA-3- ROR"t- T-bet-) within the WT mLN or Icos -/- mLN. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets compared between the WT mLN (n=10) 
and Icos -/- mLN (n=10). 
c) Number of Live CD45+ cells, ILCs and ILC subsets compared between the WT mLN (n=10) 
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Figure 4.13. Reduced numbers of all ILC3 populations in the mLN of Icos-/- mice 
Tissues from WT mice were compared to Icos -/- mice. Cells were isolated from the mLN as 
described in methods. Lineage markers include; B220, CD11c, CD11b, CD3 and CD5. ILC3s 




 IL-7Ra+ iCD3e- GATA-3- RORgt+. 
Each data point represents 1 mLN from one mouse. Data pooled from 4 experiments. Values 
on flow cytometry plots represent percentages, bars on scatter plots represents the median, 
which is also shown numerically. Statistical significance was tested using an unpaired, non-
parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
a) Representative flow cytometry plots showing expression of CCR6 and NKp46 on ILC3s 
within the WT mLN compared to the Icos -/- mLN. 
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4.3 SUMMARY 
In the absence of studies exploring the role of ICOS in ILC biology, ILCs were assessed in both 
mucosal and lymphoid tissues of Icosl -/- and Icos -/- mice to determine whether ICOS:ICOSL 
interactions were required in the development and maintenance of ILCs under steady state 
conditions. This investigation showed that within the SI LP, lung and mLN of Icosl -/- mice, 
although the proportion of ILCs varied compared to WT mice, upon enumeration no 
differences were observed. Changes in ILC numbers would clearly support a role of ICOS:ICOSL 
interactions in the development or maintenance of ILCs. Therefore, upon the observation that 
no ILC subset was numerically altered in Icosl -/- mice compared to WT mice there seemed to 
be little requirement for ICOS:ICOSL interactions under steady state conditions within the 
tissues analysed. It was then explored whether the phenotype of ILC2s or ILC3s was perturbed. 
For ILC2s this involved looking at the expression of known surface markers commonly used in 
the identification of ILC2s, as described in Chapter 3, and for ILC3s, where there are several 
subsets, it was explored whether the importance of ICOS:ICOSL interactions were subset 










 ILC2s was comparable 
between WT and Icosl -/- mice, alongside the number of NCR+, LTi-like and NCR- ILC3s within 
the SI LP, mLN and lung. This suggests that lacking ICOSL has minimal impact on the phenotype 
and subgroups of ILC2s and ILC3s, respectively. Similarly, within the Icos -/- SI LP the number 
of ILCs was comparable to WT mice. Although the comparison of WT and Icosl -/- mice 
suggested no defect in ILC homeostasis within the mLN, upon comparing WT to Icos -/- mice, a 
decrease in LTi-like and NCR
-
 ILC3s, was observed. These data indicate that ICOS:ICOSL 
interactions are not required for the development and maintenance of ILCs within the lung 
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and SI LP. Within the mLN, the differences in ILC3s requirement for ICOS over ICOSL suggests 
other ligands or receptors may be involved in these interactions.  
ILC biology seems to be unaffected in the absence of ICOSL within the SI LP, mLN and lung 
within naive mice. This suggests that, similar to T cells, ILCs do not require ICOS:ICOSL 
interactions in their development and homeostasis (300). Whilst these data were being 
collected two studies were published on ILC2s requirement for ICOS:ICOSL interactions by 
Maazi et al., and Paclik et al., (262, 306). Paclik et al., identified ILC2s based on their expression 
of GATA-3 and demonstrated that under steady state at least a 50% reduction in the number 
of ILC2s within the lung and SI LP of Icos -/- and Icosl -/- mice was observed (306). Results 
published by Paclik et al., are not comparable to the results obtained within this Chapter. Due 
to similarities within the gating strategies and a clear decrease being observed within Paclik 
et al., data it may be suggested that the differences observed, compared to this investigation, 
reflect variations in the animal facilities used to breed and house mice. An increase in the 
understanding of gut microbiota has bought to attention its effect on the health and immune 
system of the animal (307, 308). Microbiota are known to vary between animal facilities due 
to different husbandry related factors and may in turn have an impact on the analysis of 
immune cell populations (307). For example, C57BL/6 mice from different external suppliers 
had different abilities of the APC subsets to induce Tregs vs Th17 cells (307, 309). This may 
suggest why results within this investigation compared to Paclik et al., do not show similar 
effects on the ILC2 population in the absence of ICOS:ICOSL interactions. 
T cells dependency on ICOS:ICOSL interactions for efficient activation is only observed under 
immunological challenge, for example in KLH immunised mice (62). Therefore, the role of 
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ICOS:ICOSL interactions in the function of ILCs upon activation was planned to be further 
assessed under inflammatory conditions via intra nasal administration of IL-33, however, 
these experiments were conducted in the two papers discussed previously (262, 306). Maazi 
et al., and Paclik et al., both showed that under IL-33 driven airway hyperactivity ICOS:ICOSL 
interactions were important in the survival, proliferation and IL-13 production of ILC2s within 
the lung, with the absence of these interactions resulting in a reduced expansion of ILC2s and 
a reduction in inflammation (262, 306). Maazi et al., further discovered that ILC2s also express 
ICOSL and suggests that ILC2s are able to communicate with each other via ICOS:ICOSL 
interactions, promoting their survival and function through the STAT5 signalling pathway 
(262).  
Within the SI LP and lung total numbers of ILC3s were comparable between WT mice and mice 
lacking ICOS:ICOSL interactions, suggesting that these interactions play a redundant role in 
their development and maintenance under steady state conditions. These data were 
supported by Paclik et al., who also demonstrate that ILC3s were comparable between WT, 
Icos -/- and Icosl -/- mice within these tissues (306). However, Paclik et al., did not explore the 
role of ICOS:ICOSL interactions in lymphatic tissues, in which these studies determined a 
different requirement for ICOS compared to ICOSL on ILC3 subset numbers within the mLN. 
Currently within the literature it is believed that ICOS and ICOSL only interact with one 
another, however, these results showing differences between Icos -/- and Icosl -/- mice may be 
explained by a potential binding of ICOS, or ICOSL to another ligand or receptor. It would be 
interesting to determine whether this is specific to the mLN of whether ILC populations in 
other SLTs also exhibit a dependence on ICOS or ICOSL. 
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In summary, a lack of substantial differences between genetically depleted mice compared to 
WT mice suggests it is unlikely that ICOS:ICOSL interactions play a critical role in normal ILC 
homeostasis. Studies could be extended to test under inflammatory conditions, however, with 
the reports already published the value of such further work was questionably. The lack of 
substantial effects indicates that the ICOS:ICOSL pathway was not key, therefore, these 
studies were focused towards exploring other aspects of ILC biology, focusing on the 





Chapter 5.   DETERMINING THE MIGRATORY PROPERTIES OF ILCS 
WITHIN PERIPHERAL LNS 
5.1 INTRODUCTION 
The movement of lymphocytes and myeloid cells around the body is regulated by chemokines 
and integrins (49). These interactions control the directional migration or retention of 
populations within lymphoid or non-lymphoid tissues and is therefore, an essential feature of 
the immune system and fundamental for cell function. The cellular composition and structure 
of SLTs, including LNs, provides a niche microenvironment for naïve T cells and B cells to survey 
for antigen presented via MHCII on APCs (49, 310). Upon encountering cognate antigen T cells 
are activated through the TCR and develop into Th cells, which are important in the 
development of an effective immune response (310). Therefore, it is important to understand 
the mechanisms of leukocyte entry into the LN, via high endothelial venules (HEVs) or 
lymphatic vessels, and egress. The migratory properties of naïve lymphocytes within the 
immune system are well studied within the literature, however other populations, such as 
ILCs, migratory abilities are not clear. 
5.1.1 Lymphocyte entry into the LNs via HEVs 
Under homeostatic conditions naïve T and B cells migrate from primary lymphoid tissue into 
the blood, with naïve T cells searching for cognate antigen on APCs including DCs in SLTs (48). 
Entry into LNs occurs via HEVs, which are small blood vessels protruding into the LN and are 
paramount in the high input of naïve T cells and B cells from the blood (49, 311). Lymphocytes 
enter the LN, through HEVs, via a ‘tethering, rolling, sticking and transmigration’ mechanism 
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(49, 312). Within the blood, lymphocytes express CD62L which initiates tethering to the 
luminal wall of high endothelial cells (HECs). CD62L binds to a 6-sulpho sialyl-Lewis X motif on 
the type 1 transmembrane protein, sialomucin, which is expressed on the luminal facing side 
of HECs (49, 312-314). These interactions cause the cells to ‘roll’ along the luminal surface of 
HEVs before entry into the LN, in which CD62L is downregulated and only upregulated upon 
exit into the blood (49, 312, 315). To enable lymphocyte transmigration through HEVs the cells 
have to arrest and ‘stick’ to the luminal wall which occurs via chemokine activation of integrins 
on lymphocytes (316). CCL21, which is highly expressed by HEVs and in the T cell zone of LNs 
by FRCs, activates lymphocytes via its receptor CCR7, which is expressed on naïve lymphocytes 
and a subgroup of DCs (316, 317). CCL21 cell stimulation causes the upregulation and 
activation of integrin lymphocyte function-associated antigen 1 (LFA-1), which adheres to 
ICAM-1 expressed on the luminal side of HECs (316-318). This adhesion is efficient to arrest 
the ‘rolling’ phase of the cell, causing ‘sticking’ and eventually transmigration across the HEVs 
into the LN (318). This mechanism reflects the entry of lymphocytes into peripheral LNs, 
however, interactions between the integrin a4b7, on lymphocytes and mucosal addressin cell 
adhesion molecule 1 (MADCAM1) on HEVs, is required for the entry of lymphocytes into gut 
associated lymphoid tissue, such as the mLN (319-321) Mice deficient in CCL21 and CCL19, 
which also binds CCR7, (plt/plt mice) exhibited reduced LFA-1 mediated T cell adhesion to the 
HEVs, which was restored upon CCL21 but not CCL19 intracutaneous injections (316). 
Furthermore, Ccr7-/- mice and Cd62l-/- mice exhibit a decrease in lymphocytes within the LNs 
and within Ccr7-/- mice an increase in lymphocytes within the blood is observed (255, 313). 
These data support the importance of lymphocytes within the blood expressing CD62L and 
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CCR7 to enable their entry into the LN. Entry from the blood via HEVs into the LN is the main 
mechanism for T cells, including naïve, memory and Tregs, naïve B cells and cNK cells (49, 116).  
5.1.2 Lymphocyte migration into the LV via the lymphatics system 
The entry of lymphocytes into the LN also occurs via the lymphatics and is the main 
mechanism of entry for DCs (49). Lymph consists of immune cells and tissue-derived antigens 
and enters into the LN via afferent lymphatic vessels at the subcapsular sinus (35). Upon entry 
into the LN the lymph percolates from the subcapsular sinus through the medullary sinuses 
and the cortical sinuses before exiting via the efferent lymphatic vessel (35). DCs and T cells 
are both able to enter the LN parenchyma in a CCR7 dependent manner during this period, 
DCs through the base of the subcapsular sinus and T cells via the cortical or medullary sinuses 
(35).  
Upon entry into the LN, via HEVs or the afferent lymphatic vessel, naïve T cells investigate the 
LN for cognate antigen presentation by DCs (310). If this encounter does not occur T cells are 
able to leave through the efferent lymphatic vessel (310). From the efferent lymph 
lymphocytes enter the thoracic duct and can then re-enter the blood to recirculate around 
the body (322). Efficient egress of lymphocytes requires the expression of the G protein-
coupled, S1P receptor (322-325). There are 5 subgroups of S1P receptors with T cells and B 
cells expressing S1PR1
 
and S1PR4  and cNK cells expressing S1PR5 (324-326). S1P is generated 
in vivo by sphingosine kinase 1 and 2 and is highly concentrated in the blood and lymph (322, 
323). Through the use of sphingosine kinase 1 and 2 conditional knock outs, Pappu et al., and 
Pham et al., showed erythrocytes to be the major source of S1P in the blood and lymphatic 
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endothelial cells in the lymph (322, 323). The migration of innate and adaptive immune cells 
into the LN via either the blood or afferent lymphatic vessel is summarised within Figure 5.1. 
5.1.3 Lymphocyte egress from LNs occurs in an S1P dependent manner 
S1PR:S1P interactions are paramount in the egress of lymphocytes from the LN parenchyma 
via cortical and medullary sinuses, where they are transported into the lymph and then into 
blood, both of which have high concentrations of S1P (261, 322, 323, 327). The 
immunosuppressant drug FTY720 is an S1P receptor agonist, with lowest affinity to S1PR2 and 
S1PR5, and upon binding causes its downregulation (254, 261). Mandala et al., showed that 
administration of FTY720 prevents the egress of lymphocytes from SLTs, resulting in 
peripheral blood lymphopenia and a decrease in lymphocytes within the thoracic duct (261, 
325). Furthermore, lymphocytes were found clustered within T cell and B cell zones, with the 
medullary and cortical sinuses containing very few lymphocytes (261). S1P degradation by S1P 
lyase is paramount in creating a low extracellular concentration of S1P in SLTs (328). This 
enables the maintenance of an S1P concentration gradient between the LN and the blood and 
lymph, promoting efficient egress of lymphocytes (49, 328). Inhibition of S1P lyase 
consequently results in the sequestration of lymphocytes within SLT, shown by Schwab et al., 
(328). Upon the entry of lymphocytes into the lymph and blood, high extracellular 
concentrations of S1P results in the internalisation of S1PR1 (329). This eventually enables the 
re-entry of lymphocytes into the LN in a CCR7:CCL21 dependent manner (329). However, once 
back in the LN, where there are low levels of S1P, S1PR1 is upregulated to overcome 
CCR7:CCL21 interactions, allowing lymphocyte egress (329). This enables the recirculation of 
T cells through SLTs (35, 53, 330). T cells can either migrate directly from a primary LN to a 
secondary LN without entering the blood, shown by Braun et al., by injecting T cells into the  
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Figure 5.1. Lymphocyte entry into the LN 
Diagram of a LN which provides a niche microenvironment in which innate and adaptive 
immune cells are concentrated, facilitating their interactions. Cells are able to migrate into 
the LN via the blood, or the lymphatics. The main method of entry for DCs is through the 
afferent lymphatic vessel in which they migrate through the subcapsular sinus in a CCR7 
dependent manner. T cells are also able to enter through the afferent lymphatic vessel, 
however, they migrate into the medullary sinus before migrating into the T cell zone in a CCR7 
dependent mechanism. Ingress through the blood is the main route of entry into the LN for 
naïve T cells. Entry requires cells within the blood to undergo a ‘tethering, rolling, sticking and 
transmigration’ mechanism along the luminal wall of the HEV, in which CCR7 and CD62L 
expression is required. Naïve T cells express CD62L, which binds to sialomucin on the surface 
of the HECs required for cells to ‘roll’ along HEVs. CCR7 and CCL21, which are at high 
concentrations within the T cell zone, interactions increases the expression of integrins on T 
cells and subsequently the ‘sticking phase’ which eventually results in transmigration across 
the HEVs into the LN. Upon exit all hematopoietic cells egress via the efferent lymphatic vessel. 
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afferent lymphatic vessel of the popliteal LN and locating them within the iliac LN, which is 
downstream of the popliteal LN (35). T cells are also able  to migrate to contralateral LNs 
through the blood shown by Tomura et al., who uses photoconvertible Kaede mice to show 
the migration of lymphocytes from the inguinal LN (iLN) through to blood into other peripheral 
LNs, which was dramatically reduced under FTY720 treatment (35, 53, 330, 331).  
5.1.4 Retention of lymphocytes within the LN 
During particular immune responses lymphocyte egress from the LN is blocked in an IFN-a/b 
dependent manner (332). T cell and B cell activation through the IFN-a/b receptor strongly 
induces the expression of the activation marker CD69, a C-type lectin receptor (332, 333). A 
role for CD69 in regulating the migration of lymphocytes was suggested when overexpression 
of CD69 resulted in a decrease in the egress of single positive thymocytes from the thymus 
(333, 334). Furthermore, the adoptive transfer of WT and Cd69-/- lymphocytes into WT 
ploy(I:C), synthetic RNA which activates an immune response, treated hosts, by Shiow et al., 
revealed that WT lymphocytes were unable to efficiently egress from the LN into lymph 
compared to Cd69-/- cells which were (332). CD69 inhibits the egress of cells via forming cross-
interactions with S1PR1, in turn resulting in its downregulation and inhibition of function (332, 
335). 
5.1.5 Models used to track migration in vivo 
Cellular migration has been tracked using methods such as two-photon microscopy, parabiotic 
models and injections of labelled cells or fluorescent substrates (35, 50, 249). These methods, 
however, all have their limitations and inhibit the observation of cellular movement in a 
homeostatic environment. Within recent years, the development of fluorescent proteins has 
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enhanced the ability to assess in vivo cell migration (336). Phototransformable fluorescent 
proteins change structure and therefore emission spectra permanently upon photoconversion 
with unique wavelengths of light (336). One of the first discovered Phototrasformable 
fluorescent proteins was the Kaede protein, a GFP fluorescent protein, which has been used 
to design photoconvertible fluorescence protein Kaede transgenic mice (53, 336). These 
Kaede mice were designed by Tomura et al., and ubiquitously express the Kaede protein, 
cloned from stony coral, within the cytoplasm of all cells (53, 259). After synthesis the protein 
emits bright green fluorescence, however, when exposed to UV or violet light, between the 
wavelengths of 350-410 nm, it is converted to emit a bright red fluorescence (259, 260). 






 acts as the green 
chromophore and upon photoconversion, peptide cleavage occurs near the green 
chromophore, resulting in a change in the emission wavelength and excitation of the protein 
(260). The Kaede protein is now perceived as Kaede Red instead of Kaede Green and can be 
detected using fluorescence microscopes and flow cytometry (53, 260). The Kaede Red 
protein has a long biological half-life in lymphocytes in vivo, however, due to the location of 
the Kaede protein in the cytoplasm, after conversion of Kaede Green to Kaede Red, the Kaede 
Red protein can become diluted upon several cell divisions, so tracking of cells is limited to 
small time frames (53, 260). Kaede mice have previously been used to track the migration of 
T cells and B cells within peripheral LNs, the migration of DCs from skin to draining LN, 
retention of antigen-specific memory CD4
+
 T cells and ILC migration from gut to mLN (53, 92, 243, 
247).  
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5.1.6 Migratory properties of ILCs 
Through studies using parabiotic models, helper ILCs were established as tissue-resident, 
being replenished through local progenitor populations with minimal contribution of 
migratory mature ILCs (248, 249). cNK cells, on the other hand, are a well-known migratory 
population being able to enter LNs from the blood, with similar properties to cytotoxic CD8
+
 T 
cells (115-117). A limitation of the parabiotic models is the inability to assess migration 
through the lymphatics or the migration of cells within one mouse. Furthermore, ILC migration 
was not assessed in peripheral LN tissues, with the studies by Gasteiger et al., focusing on 
assessing ILC migration within the spleen and mLN (249). Evidence that ILCs move from the 
intestine to the mLN has been published, however, this involved substantial in vivo 
manipulation that may generate artefacts (243). Other studies propose the migration of ILCs 
from LN to tissues, however, these lacked any direct evidence of unmanipulated in vivo 
migration (226, 252). Huang et al., on the other hand has directly shown that iILC2s are able 
to respond to IL-25 stimulation within the gut and clearly disseminate to other tissues 
including the lung and mLN (254). Gasteiger et al., have also reported the presence of ILC1 
within the blood and their ability to equilibrate between the blood of parabiotic mice, but not 
to be able to enter the assessed tissue.   
5.1.7 Project Aims 
ILC migration between lymphoid and non-lymphoid tissue is still unclear, therefore the aim of 
this investigation was to use transgenic photoconvertible mice to directly assess the in vivo 
migration of ILCs within the peripheral LNs. Using a previously established Kaede bLN model, 
in which leukocyte migration could be observed, the hypothesis that ILCs were not solely a 
tissue-resident population within peripheral LNs was assessed. 
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5.2 RESULTS 
5.2.1 ILCs consist of migratory and tissue-resident populations within the bLN 
LNs provide a niche microenvironment for the interactions between innate and adaptive cells 
important in the activation of the adaptive immune system and therefore in the induction of 
an effective immune response (49). Under homeostatic conditions T cells, B cells, DCs and cNK 
cells, enter LNs through HEVs and/or afferent lymphatic vessels (49, 53, 337). Through the use 
of photoconvertible Kaede mice Tomura et al., have shown the rapid migratory kinetics of T 
cells, B cells and DCs in the iLN over 24 hours, demonstrating that photoconvertible mice are 
a unique model, enabling the direct visualisation of lymphocytes migratory patterns (53). Due 
to the migratory properties of ILCs currently being unclear between non-lymphoid and 
lymphoid tissues, Kaede mice were used to assess the migratory kinetics of ILCs in the 
peripheral bLN (53, 92). Marriott et al., previously established a Kaede model to track the 
migration of antigen-specific CD4
+
 memory T cells from the bLN (92). The bLN was 
photoconverted, labelling all of the cells within the LN from Kaede Green to Kaede Red. This 
enabled the assessment of the bLN at various time points post photoconversion, with Kaede 
Red cells remaining in the LN being termed ‘resident’ and new Kaede Green cells termed 
‘migratory’. This model also enabled the tracking of Kaede Red cells out of the bLN into other 
tissues (92). Using these methods, the bLN was fully converted from Kaede Green to Kaede 
Red and the Kaede expression assessed 0 hours and 72 hours post photoconversion (Figure 
5.2a-d) (92). The median percentage of cells expressing Kaede Red within the bLN was 99.7% 
at 0 hours, suggesting that the bLN was successfully photoconverted. Due to the nature of the 
data statistical significance could not be assessed between the percentage of Kaede Green 
and Kaede Red expressing cells within a population. Migration was observed 72 hours post 
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photoconversion due to it being anticipated that ILCs would be less migratory than naïve 
lymphocytes therefore leaving sufficient time to detect potential migration. Furthermore, 
Tomura et al., identifies Kaede Red expression in HeLa cells up to 72 hours post 
photoconversion and Marriott et al., shows the retention of Kaede Red antigen-specific CD4
+
 
T cells in the bLN 120 hours post photoconversion, suggesting that this time scale was 
appropriate to assess migration without the potential issues of loss of Kaede Red signal (53, 
92). After 72 hours >90% of the CD45
+
 cells, in the bLN, were Kaede Green, suggesting that 
cells within the bLN undergo dynamic changes over 3 days (Figure 5.2c-d) (53). The 
composition of the CD45
+
 Kaede Green ‘migratory’ population was mainly comprised of ab T 
cells, which although not directly phenotyped, were believed to mainly consist of naïve T cells 
which are highly migratory, trafficking through the blood and LNs spending up to 12 hours 
searching for cognate antigen within LNs (Figure 5.2e-f) (53). Smaller populations of gd T cells, 
ILCs and LCs also contributed to the Kaede Green population. ILC migration was compared to 
the migratory properties of T cells and LCs due these populations having different trafficking 
routes, blood vs lymph, and representing known migratory adaptive and innate populations, 
therefore a sensible comparison to ILCs for which the migratory properties are unknown (53, 
247, 337, 338). Similar proportions of ab, gd T cells, ILCs and LCs were found within the Kaede 
Red ‘residentiary’ population as the Kaede Green (Figure 5.2g-h). These data indicate that the 
ILC population, within the bLN, changes over time and whilst some ILCs are likely tissue-
resident, migratory ILC populations exist. 
LNs have a highly complex and organised structure composed of stromal cells. They provide a 
mesh network for movement of lymphocytes, alongside the production of cytokines to aid  
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Figure 5.2. Tracking dynamic changes in immune cell composition of a peripheral LN 
Violet light photoconversion of the bLN and cell isolation conducted as described in methods.  
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median. Samples were statistically tested using Kruskal-Wallis one-way ANOVA 
with post hoc Dunn’s test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs lineage 
markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Representative flow cytometry plots showing Kaede Green (KG) and Kaede Red (KR) 
expression of the bLN with no violet light photoconversion (left) and violet light 
photoconversion (right) 0 hours post photoconversion.  
b) Percentage of Live CD45+ cells that express Kaede Green or Kaede Red in the bLN 0 hours 
post photoconversion (n=8). 
c) Representative flow cytometry plot showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells within the bLN 72 hours post photoconversion. 
d) Percentage of Live CD45+ cells that express Kaede Green or Kaede Red in the bLN 72 hours 
post photoconversion (n=10).  
e) Representative flow cytometry plots of Live CD45+ Kaede Green cells, identifying ab T cells 







) in the bLN 72 hours post photoconversion. The percentages 
represent that population as a proportion of Live CD45
+
 Kaede Green cells. 
f) Percentage of Kaede Green Live CD45+ cells that are ab T cells (n=7), dg T cells (n=7), ILCs 
(n=10) or LCs (n=5). 
g) Representative flow cytometry plots of Live CD45+ Kaede Red cells, identifying ab T cells, 
dg T cells, ILCs and LCs in the bLN 72 hours post photoconversion. The percentages 
represent that population as a proportion of Live CD45
+
 Kaede Red cells. 
h) Percentage of Kaede Red Live CD45+ cells that are ab T cells (n=7), dg T cells (n=7), ILCs 
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 directional migration (49, 50). To contrast the highly migratory populations within an 
anticipated resident population, testing that the model works in identifying Kaede Red cells 
as tissue-resident, Kaede expression was analysed within the bLN stromal cells, 72 hours post 
photoconversion (Figure 5.3a-f) (50, 339). Few CD45
-
 stromal cells expressed Kaede Green, 
with a median of 4.1% Kaede Green stromal cells, similar to its sub populations; blood 
endothelial cells (BECs), FRCs and lymphatic endothelial cells (LECs) (Figure 5.3b-f). These data 
indicate that tissue-resident stromal cells maintain their Kaede Red expression over 72 hours, 
supporting the ability of the Kaede model to discriminate between resident and migratory 
populations. 
5.2.2 Migration into the bLN is dependent on CCR7 
Upon the identification of a new Kaede Green ILC population within the bLN, suggesting that 
ILCs migrate into the tissue rather than remaining in the LN as purely resident cells, the 
mechanism behind their entry was investigated. CCR7 is paramount in the recruitment of 
lymphocytes into LNs, with Ccr7-/- mice having significantly reduced numbers of T cells, B cells 
and DCs in the mLN and peripheral LNs (243, 255). Furthermore, CCR7 was shown to be 
directly involved in the migration of LTi-like ILC3s from the intestine to the mLN (243). To 
further explore this Ccr7-/- Kaede mice were made and compared to WT Kaede mice and the 
migration of lymphocytes, including ILCs assessed. Compared to WT Kaede, all populations, 
including ILCs were substantially decreased in number within Ccr7-/- Kaede mice, suggesting a 
dependency on CCR7 for ILC homeostasis (Figure 5.4a). Upon analysing the proportion of 
Kaede Green vs Kaede Red in all populations within WT Kaede, it was clear that T cells and LCs 
contain a high percentage of Kaede Green cells, consistent with these populations being highly 
migratory. In comparison ILCs have a more equal ratio of Kaede Green and Kaede Red  
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Figure 5.3. Stromal populations within the bLN remain Kaede Red 72 hours after 
photoconversion 
Violet light photoconversion of the bLN of WT Kaede mice and cell isolation of the stromal 
population were conducted as described in methods.  
All data shown are 72 hours post photoconversion. Each data point represents 1 bLN from one 
mouse. Data pooled from a minimum of 2 experiments. Values on flow cytometry plots 
represent percentages, bars on scatter plots represents the median.  
a) Representative flow cytometry plots showing the gating mechanism used to identify 





b) Representative flow cytometry plot showing Kaede Green and Kaede Red expression of 
stromal cells. 
c) Percentage of Kaede Green and Kaede Red stromal cells (n=7), 72 hours post 
photoconversion. 


























e) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
BECs, FRCs and LECs 72 hours post photoconversion. 
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expression suggesting that although they contain a proportion of migratory cells, there is still 
the presence of a clear resident population (Figure 5.4b-c). To assess whether migration was 
perturbed in the absence of CCR7, Kaede expression of each population was assessed in Ccr7- /- 
Kaede mice and the Kaede Green cells were enumerated to determine if ILC migration 
specifically into the LN was dependent on CCR7 expression (Figure 5.4b-d). All populations 
observed a decreased in Kaede Green cells entering into the bLN within the 72 hour assessed 
period, indicating that ILC migration into the peripheral LN is dependent on CCR7 (Figure 5.4d) 
(243, 255, 337). gd T cells share similarities with ILCs, given that they are lymphocytes but are 
considered more of an innate population than ab T cells, with a less diverse TCR and ability to 
provide a quick source of cytokine upon activation (338, 340, 341). Within the skin they are 
subdivided into three populations, dendritic epidermal T cells (DETCs) which express Vg5, 
dermal Vg4+ and dermal Vg4- T cells. DETCs are a tissue-resident population with dermal Vg4+ 
T cells possessing the ability to migrate into draining LNs upon skin inflammation (338, 341). 
Considering that gd T cells were the second largest population of cells entering the bLN, their 
subsets were further assessed within the Kaede model. Vg1 T cells were also assessed as these 
mainly reside within lymphatic tissues (338, 342). All subtypes of gd T cells were decreased in 
number in Ccr7-/- mice (Figure 5.5a). Upon analysis of Kaede expression Vg1 and Vg4 T cells 
had a high >80% Kaede Green expression, suggesting that they were highly migratory 
populations, consistent with previous publications studying the migratory properties of Vg4+ 
T cell (338). Although Vg5 T cells are a skin-resident population, the presence of Kaede Green 
Vg5 T cells suggests that a small proportion of these cells are able to migrate into the LN (341). 
Within the Ccr7-/- Kaede mice, Vg1 and Vg4 gd T cell population had a larger percentage of 
Kaede Green expressing cells to Kaede Red, similar to WT Kaede mice, however due to the  
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Figure 5.4. Migration of ILCs is CCR7 dependent 
Tissues from WT Kaede mice were compared to Ccr7-/- Kaede mice. Violet light 
photoconversion of the bLN and cell isolation were conducted as described in methods. All 
data shown are 72 hours post photoconversion.  
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and F4/80.  
a) Total numbers of ab T cells (Live CD45+ CD3e+ TCRb+ TCRgd-), gd T cells (Live CD45+ CD3e+ 
TCRb- TCRgd+), ILCs (Live CD45+ Lineage- IL-7Ra+) and LCs (Live CD45+ MHCII+ CD11c+ 
CD207
+
) in WT Kaede (n=5-7) and Ccr7-/- Kaede (n=7-8) mice. 
b) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
ab T cells, dg T cells, ILCs and LCs in the bLN of WT Kaede (top) and Ccr7-/- Kaede (bottom) 
mice.  
c) Percentage of Kaede Green and Kaede Red expression by ab T cells, gd T cells, ILCs and LCs 
in WT Kaede (n=5-10) and Ccr7-/- Kaede (n=7-8) mice. 
d) Number of Kaede Green ab T cells, gd T cells, ILCs and LCs in WT Kaede (n=5-7) and Ccr7-/- 
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reduced numbers of Vg5 T cells, their Kaede expression was extremely varied between 
samples (Figure 5.5b-c). All subsets observed decreased numbers of Kaede Green cells 
entering the bLN within 72 hours in Ccr7-/- mice compared to the WT Kaede mice (Figure 5.5d). 
These data are consistent with published migratory properties of dermal Vg4+ T cells but also 
suggest a migratory population of Vg1 T cells alongside a small Vg5 population, that all migrate 
into the bLN in a CCR7 dependent manner (338).  
5.2.3 Photoconversion does not result in the accumulation of cells within the bLN 
The photoconversion approach required a small incision to be made in the skin to expose the 
bLN. Since new Kaede Green ILCs moving into the tissue were detected it was a concern that 
the skin damage caused in this procedure resulted in the recruitment and accumulation of 
cells in the skin draining bLN. To assess the effect of surgery on the bLN, control mice, which 
had no surgical procedure, were compared to mice which underwent the violet light surgical 
procedure and were left to recover for 72 hours (Figure 5.6a). Upon comparison there was no 
difference in CD45
+
 cells, ILCs or ILC subsets, apart from an increase in number of TrN cells, 
within the bLN (Figure 5.6b). This suggests that the surgical procedure does not cause an 
increase and accumulation of cells within the bLN. Repeating this experiment in Kaede mice, 
showed that the increase in number of Kaede Green ILCs in the violet light mouse is 
accompanied by a loss of Kaede Red ILCs (Figure 5.6c-d). These data suggest that the ingress 
of ILCs is balanced by the loss of Kaede Red ILCs, either through egress or death.  
5.2.4 ILCs egress from the bLN in an S1P dependent manner 
For efficient egress from the LN, lymphocytes require the expression of S1PR and high levels 
of S1P in the blood and lymph (261, 322, 323). T cell and B cells express S1PR1 and S1PR4 and  
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Figure 5.5. CCR7 dependent trafficking of gd T cell subsets 
Tissues from WT Kaede mice were compared to Ccr7-/- Kaede mice. Violet light 
photoconversion of the bLN and cell isolation were conducted as described in methods. All 
data shown are 72 hours post photoconversion.  
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001.  
a) Total numbers of "ẟ T cells V"1, "ẟ T cells V"4 and "ẟ T cells V"5s in WT Kaede (n=7) and 
Ccr7-/- Kaede (n=8) mice. 
b) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
dg T cell subsets, "ẟ T cells V"1 (Live CD45+ CD3e+ TCR "ẟ+ V"1+), "ẟ T cells V"4 (Live CD45+ 
CD3e+ TCR "ẟ+ V"4+) "ẟ T cells V"5 (Live CD45+ CD3e+ TCR "ẟ+ V"5+) in WT Kaede (top) and 
Ccr7-/- Kaede (bottom) mice. 
c) Percentage of Kaede Green and Kaede Red expression by "ẟ T cells V"1, "ẟ T cells V"4 and 
"ẟ T cells V"5s in WT Kaede (n=7) and Ccr7-/- Kaede (n=8) mice. 
d) Number of Kaede Green "ẟ T cells V"1, "ẟ T cells V"4 and "ẟ T cells V"5s in WT Kaede 
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Figure 5.6. Photoconversion does not result in the accumulation of ILCs within the LN 
Mice either underwent photoconversion surgery (violet light) or did not (control), as described 
in methods. All data shown are 72 hours post photoconversion. Cell isolation of the bLN was 
conducted as described in methods.  
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 3 
experiments. Values on flow cytometry plots represent percentages, ILCs as a proportion of 
Live CD45
+
 cells and ILC subsets as a proportion of total ILCs. Bars on scatter plots represents 
the median, which is also shown numerically. Statistical significance was tested using an 
unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. 
When gating on ILCs in WT Kaede mice lineage markers include; B220, CD11c, CD11b, CD3, 
CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. In non Kaede mice, the additional lineage 
marker CD123 was used and ILCs were gated on negatively for iCD3e. 
a) Representative flow cytometry plots of WT mice showing Live CD45+ cells, ILCs (Live CD45+ 
Lineage
-





 IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- 
IL-7Ra+ iCD3e- RORgt+) and TrN cells (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- T-
bet
-
) in control (top) and violet light (bottom) mice. 
b) Percentage (top) and number (bottom) of WT mice Live CD45+, ILCs and ILC subsets in 
control (n=6) and violet light (n=7) mice. 
c) Representative flow cytometry plots showing WT Kaede mice Kaede Green and Kaede Red 
expression in ILCs in control (left) and violet light (right) mice. 
d) Number of WT Kaede mice Kaede Green and Kaede Red ILCs in control (n=6) and violet 
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ILCs have recently been shown to express S1PR1, S1PR4 and S1PR5, however, the majority of 
literature focuses on the role of S1PR1 in lymphocyte egress (254, 261). To determine whether 
ILCs had the capability to egress from the bLN in a similar manner to lymphocytes, their 
expression of S1PR1 was assessed. S1PR1 expression was observed on all ILC subgroups, with 
the highest expression on ILC3s (Figure 5.7a-b). This suggests that ILCs might exit the LN 
utilising S1PR1 in a similar manner to T cells. 
To formally test the hypothesis that ILC egress in an S1PR dependent manner FTY720, an S1PR 
agonist, which has previously been used in multiple studies to show the importance of 
S1PR:S1P interactions in the egress of lymphocytes from SLTs, was utilised (53, 261, 343). 
FTY720, however, does not efficiently block all S1PRs, including S1PR2 and S1PR5 and has 
therefore been mainly used to assess the S1PR1 and S1PR4 dependent migration of 
lymphocytes (254, 344). Tomura et al., administered FTY720 to Kaede mice and observed an 
increase in Kaede Red cells within the iLN 24 hours post photoconversion, showing that 
lymphocytes that normally egress via S1P mechanisms were sequestered in the LN (53). 
Therefore, within these studies, Kaede mice were injected with FTY720 one day prior to bLN 
photoconversion and everyday throughout the protocol. Blocking the S1PR-mediated egress 
of cells resulted in no difference in the number of CD45
+
 hematopoietic cells or T cells, 
however an increase in the number of ILCs, within the bLN was observed (Figure 5.8a-b). Naïve 
T cells recirculate through the blood entering and exiting LNs in search of cognate antigen and 
blocking their egress from LNs halts this recirculation suggesting why comparable numbers of 
T cells in control and FTY720 mice was observed (53). This is evident when assessing Kaede 
Green and Kaede Red expression, with an accumulation of Kaede Red T cells observed within 
the bLN of FTY720 mice, represented by a statistical decrease in number of Kaede Green T  
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Figure 5.7. ILCs express S1PR1 in the peripheral LN 
Cell isolation of the bLN from WT mice was conducted as stated in the methods. ILCs identified 
and their expression of S1PR1 analysed. 
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Representative flow cytometry plots showing the expression of S1PR1 on ILC1s (Live CD45+ 
Lineage
-
 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet+), ILC2s (Live CD45+ Lineage- IL-7Ra+ iCD3e- 





 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) in the bLN, compared to an 
isotype control.  
b) Percentage (left) and total number (right) of ILC subsets expressing S1PR1 in the bLN. Due 
to the range of numbers within the data it is presented on a logarithmic scale where values 
equal to 0 are represented as 1.  
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cells and increase in number of Kaede Red within the FTY720 treated mice (Figure 5.8c-e). 
Similar to T cells, blocking S1P-dependent egress of cells from the LN resulted in an increased 
number of Kaede Red ILCs, suggesting that under normal conditions ILCs egress from the 
tissue in an S1P dependent manner (Figure 5.8f-h). Interestingly there was no difference in 
the number of Kaede Green ILCs entering the bLN. Since FTY720 doesn’t efficiently block all 
S1PR, it is possible that some ILCs still egress from other tissues, dependent on either S1PR2 
or S1PR5, which in turn could explain normal numbers of Kaede Green ILC being able to enter 
the LN from circulation. Furthermore, the reduction in number and percentage of Kaede Red 
T cells in the contralateral LNs is consistent with a block in T cell recirculation (Figure 5.8i-j). 
Sequestration of ILCs within the bLN upon FTY720 administration indicates that ILCs, under 
homeostatic conditions, are able to leave the bLN within the 72 hour period assessed. Upon 
leaving the LN, naïve T cells recirculate through lymphoid tissue in the search for antigen. To 
determine whether ILCs recirculate through contralateral LNs, the bLN was photoconverted 
and 72 hours later, the presence of Kaede Red ILCs within a pool of contralateral LNs including 
the mLN, auLN, iLN, cervical LN (cLN), axillary LN (axLN), bLN was assessed. The cell suspension 
from the contralateral LNs was depleted of B cells and T cells through magnetic-activated cell 
sorting (MACS)-enrichment for B220, CD3 and CD5, to try to increase the proportion of ILCs, 
helping to track rare Kaede Red cells. Kaede Red T cells were identified in contralateral LNs 
and supporting their CCR7-dependent migration were reduced in Ccr7-/- Kaede mice (Figure 
5.9a-b) (53). In the depleted cell fraction a small proportion of Kaede Red ILCs were detected, 
including within Ccr7-/- Kaede mice, consistent with ILCs being a recirculatory population 
(Figure 5.9c-d). The low numbers of Kaede Red ILCs that could be detected may represent the  
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Figure 5.8. Inhibition of S1P mediated egress directly results in the accumulation of ILCs 
WT Kaede mice were administered i.p injections of 1 mg/mL FTY720 in H2O (FTY720) (n=7) or 
H2O (control) (n=4) one day prior to surgery and then every day after surgery as described in 
methods. All data shown are 72 hours post photoconversion. Cell isolation from bLN, mLN, 
iLN, auLN, axLN and cLN were conducted as discussed in methods.  
Each data point represents 1 bLN or 1 pool of contralateral LNs from one mouse. Data pooled 
from a minimum of 2 experiments. Values on flow cytometry plots represent percentages, 
bars on scatter plots represents the median, which is also shown numerically. Statistical 
significance was tested using an unpaired, non-parametric, Mann-Whitney two tailed T test: 
*p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, 
CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Representative flow cytometry plots showing Live CD45+ cells, T cells (Live CD45+ CD3e+) 




 IL-7Ra+) in control (top) and FTY720 (bottom) mice.  
b) Number of Live CD45+ cells, T cells and ILCs in control and FTY720 mice.  
c) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
T cells in control (left) and FTY720 (right) mice.  
d) Percentage of Kaede Green and Kaede Red T cells in control and FTY720 mice. 
e) Number of Kaede Green (left) and Kaede Red (right) T cells in control and FTY720 mice.  
f) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
ILCs in control (left) and FTY720 (right) mice.  
g) Percentage of Kaede Green and Kaede Red ILCs in control and FTY720 mice. 
h) Number of Kaede Green (left) and Kaede Red (right) ILCs in control and FTY720 mice.  
i) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
T cells in contralateral LNs in control (left) and FTY720 (right) mice.  
j) Percentage (right) and number (left) of Kaede Red T cells in contralateral LNs of control 





















































































































































































































Figure 5.9. ILCs recirculate into contralateral LNs 
A pool of contralateral LNs from WT Kaede mice were compared to Ccr7-/- Kaede mice. Violet 
light photoconversion of the bLN and cell isolation of contralateral LNs were conducted as 
stated in methods. All data shown are 72 hours post photoconversion.  
Each data point represents 1 bLN or 1 pool of contralateral LNs (mLN, iLN, auLN, axLN and 
cLN) from one mouse. Data pooled from a minimum of 2 experiments. Values on flow 
cytometry plots represent percentages, bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs lineage 
markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Representative flow cytometry plots of T cells (Live CD45+ Lineage+ IL-7Ra+) (left) and their 
expression of Kaede Green and Kaede Red (right) in B220, CD3 and CD5 enriched fraction 
of contralateral LNs of WT Kaede (top) and Ccr7-/- Kaede (bottom) mice.  
b) Percentage of Kaede Red T cells in contralateral LNs of WT Kaede (n=14) and Ccr7-/- Kaede 
(n=8) mice.  
c) Representative flow cytometry plots of ILCs (Live CD45+ Lineage- IL-7Ra+) (left) and their 
expression of Kaede Green and Kaede Red (right) in B220, CD3 and CD5 depleted fraction 
of contralateral LNs of WT Kaede (top) and Ccr7-/- Kaede (bottom) mice. 
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challenges of trying to track very small populations in vivo and potentially ILC may leave LNs 
and go to other locations that were not assessed. These data do suggest that at least some 
ILCs leave the peripheral LNs and then recirculate back through these tissues. 
In addition to the role of CCR7 and S1P, the molecules CD62L and CD69 play critical roles in 
the movement of lymphocytes into and out of LNs (312, 315, 332, 334). CD62L is paramount 
in the mechanistic entry of lymphocytes into the LN from the blood, enabling cells to ‘tether’ 
and ‘roll’ along the HEVs before transmigrating into the LN parenchyma where it is 
downregulated immediately (49, 312, 315). CD69, on the other hand, is involved in the 
retention of activated lymphocytes in the LN via downregulating S1PR1 (332, 335). To further 
investigate the mechanisms controlling ILC migration into and out of LNs, CD62L and CD69 
expression was assessed. Migratory Kaede Green ILCs express higher levels of CD62L 
compared to resident Kaede Red which is consistent with these cells migrating in from the 
blood (Figure 5.10a-b). In comparison, CD69 levels are increased on Kaede Red resident ILCs 
compared to Kaede Green (Figure 5.10c-d). This differential expression of CD69 is consistent 
with the cells staying within the LN and not egressing. These data further support that Kaede 
Green ILCs are migratory and Kaede Red ILCs are a resident population.  
5.2.5 ILC1s are the most migratory subset of ILCs within the bLN 
In some situations, there is evidence that ILC subsets show differing abilities to migrate into 
or out of LNs. iILC2s are the dominant migratory population under IL-25 administration and 
Nippostrongylus brasiliensis infections, migrating through the lymph and blood into the lung, 




Figure 5.10. Kaede Green and Kaede Red ILCs express migratory and resident markers, 
respectively 
WT Kaede mice underwent photoconversion of the bLN as described in methods. All Kaede 
data was analysed 72 hours post photoconversion. Isolation of cells from the bLN were 
conducted as in shown in methods. 
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs lineage 
markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Representative flow cytometry plots of Kaede Green (left) and Kaede Red (right) ILCs (Live 
CD45
+
 IL-7R⍺+ Lineage-) expression of CD62L in the bLN.  
b) Percentage of Kaede Green and Kaede Red ILCs expressing CD62L (n=13). 
c) Representative flow cytometry plots of Kaede Green (left) and Kaede Red (right) ILCs 
expression of CD69 in the bLN.  
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mLN and Kim et al., have shown ILC1s and ILC3s migrating from the mLN to the gut and ILC2s 
from the BM to the gut, supporting that ILC subsets have different migratory kinetics (243, 
252). It is therefore important to determine whether these data within this study are 
explained by the partial migration of all subsets, or whether particular subsets in the LN are 
more migratory vs resident. Due to the Kaede protein being located within the cytoplasm, 
intracellular staining through cell permeablisation, via the Foxp3 BD kit or BD kit, was not 
efficient at labelling for TFs whilst maintaining optimal Kaede protein expression. This made it 
difficult to accurately identify ILC subsets through the use of TFs in Kaede mice. Consequently, 
a staining panel including TFs, alongside an array of ILC specific cell surface (CS) markers was 
used to determine a method to identify ILC subgroups solely on the use of CS markers. CS 


































) (Figure 5.11a). Upon comparing the 
percentage and number of ILC subsets identified by either TFs or CS markers, a decrease in 
ILC2s identified via the CS marker method was observed (Figure 5.11b). This suggests that 
although using CS markers enables the identification of ILC subsets, it is not as efficient as TFs, 
with some ILCs remaining unidentified. To further determine that CS identified ILCs were 
gated into the correct subgroup, their expression of T-bet, GATA-3 and RORgt was assessed. 






 (>70%) and ungated cells (>40%), 
express T-bet, GATA-3, RORgt, and no TFs, respectively (Figure 5.11c-d). However, this gating 
mechanism has not managed to identify all of the ILC subsets, with the ungated population 
being comprised of ~20% of T-bet+ ILC1s, GATA-3+ ILC2s, and RORgt+ ILC3s. This suggests that 
the CS marker gating mechanism is able to identify ILC1s, ILC2s and ILC3s, however, doesn’t  
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Figure 5.11. Identification of ILC subsets in the bLN using cell surface markers 
bLN from WT mice were isolated and ILCs identified using TF or cell surface (CS) markers (n=8), 
within the same staining panel. ILCs identified by CS markers are marked with 
cs
. 
Each data point represents 1 bLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Paired samples were statistically 
tested using an unpaired, non-parametric, Mann-Whitney two tailed T test, when comparing 
more than two sets of data statistical significance was tested using Kruskal-Wallis one-way 
ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs 
lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and 
F4/80. 
a) Representative flow cytometry plots showing gating mechanism to identify (Live CD45+ 
Lineage
-
 IL-7Ra+) ILC subsets using TFs (top) and CS proteins (bottom). TF gated ILC 
subsets; ILC1s (RORgt- GATA-3- T-bet+), ILC2s (RORgt- GATA-3+ T-bet-), ILC3s (GATA-3- 

























b) Percentage (left) and number (right) of ILC subsets identified by TF compared to CS 
proteins. 
c) Representative flow cytometry plots showing TF expression of RORgt, GATA-3 and T-bet 
by ILCs identified by CS markers, ILC1s
CS
 (top left), ILC2s
CS
 (bottom left), ILC3s
CS
 (top right) 
and ungated (bottom right). 
d) Percentage of ILC1sCS, ILC2sCS, ILC3sCS and ungated cells that express T-bet (left), GATA-3 
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include all of the individual subgroups within the bLN, with some ILC1s, ILC2s and ILC3s lying 
within the ungated population. To determine whether ILC subsets in the LN show equal 
abilities to enter and leave the LN, the subsets were identified with the surface markers 
described above and Kaede Green versus Kaede Red expression assessed 72 hours post 
photoconversion. (Figure 5.12a-d). Upon comparing the percentage of Kaede Green cells 
within each subset, ILC1s
cs
 had the highest proportion of Kaede Green expressing cells and 
were the only subset to have a greater proportion of Kaede Green cells than Kaede Red (Figure 
5.12c-e). This would suggest that ILC1s are more migratory than ILC2s and ILC3s which were 
more tissue-resident over the 72 hour time frame. It was a concern that the ILC1 population 
was being contaminated by cNK cells, which are known to efficiently enter and exit LNs (116, 
251, 326, 345). To determine that they were not included in this gating strategy, cNK cells 




 RORgt- EOMES+ within the lineage- IL-7Ra+ ILC population 
(Figure 5.12f-g). Due to the lineage dump channel containing CD49b, a phenotypic marker of 
cNK cells, cNK cells were a very small fraction of the ILC population, excluding them from this 
analysis, concluding that the identified ILC1s were comprised of helper ILC1s. 
cNK cells are able to recirculate through the blood and SLT, being able to be primed by DCs in 
LNs  (115-117, 346). To compare cNK cell recirculation to ILC1 recirculation, cNK cells Kaede 
expression was analysed within the bLN 72 hours post photoconversion. Within the lab it was 
confirmed that the cNK cells (NK1.1
+





 (Withers lab unpublished observations). The majority of cNK cells expressed 
Kaede Green ~90%, consistent with their ability to rapidly migrate through the LN (Figure 
5.13a-b)(116, 249). Furthermore, analysing the contralateral LNs for the expression of Kaede 
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Figure 5.12. The majority of ILC migration at 72 hours are ILC1s 
WT Kaede mice underwent violet light photoconversion as described in methods. All Kaede 
data shown are 72 hours post photoconversion. Isolation of cells from the bLN were 
conducted as in shown in methods. 
Each data point represents 1 bLN or from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median. Statistical significance was tested using Kruskal-Wallis one-way 
ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs in WT 
Kaede mice lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, 
F4/80, FceRI and F4/80. In non Kaede mice, the additional lineage marker CD123 was used and 
ILCs were gated on negatively for iCD3e. 







 IL-7Ra+ CD4- (NK1.1 NKp46)+), ILC2scs (Live CD45+ 
Lineage
-
 IL-7Ra+ CD4- (NK1.1 NKp46)- (KLRG1 CD25)+) and ILC3scs (Live CD45+ Lineage- 
IL- 7Ra+ CD4+). 
b) Percentage of ILC subsets identified using CS markers (n=7). 








d) Percentage of Kaede Green and Kaede Red expressing ILC1scs, ILC2scs and ILC3scs (n=7).  
e) Percentage of Kaede Green ILC1scs, ILC2scs and ILC3scs within the bLN 72 hours post 
photoconversion (n=7). 
f) Representative flow cytometry plots in WT mice showing ILC1s (Live CD45+ Lineage- 
IL- 7Ra+ RORgt- GATA-3- T-bet+ EOMES-), ILC2s (Live CD45+ Lineage- IL-7Ra+ RORgt- GATA- 3+ 
T-bet
-




 IL-7Ra+ RORgt+), NK cells (Live CD45+ Lineage- IL-7Ra+ 
RORgt- GATA-3- T-bet+ EOMES+) and TrN cells (Live CD45+ Lineage- IL-7Ra+ RORgt- GATA-3- 
T-bet
-
) in the bLN. 
g) Percentage of ILC1s, ILC2s, ILC3s, NK cells and TrN cells in the bLN (n=4). 

























































































































Red cNK cells supported their ability to recirculate through draining LNs (Figure 5.13c-d). Due 
to ILC1s being the main migratory population out of the three ILC subgroups, their ability to 
recirculate was also assessed and a small population of Kaede Red ILC1s was identified (Figure 
5.13c-d). Together, this suggests that ILC1s are similar to their closely related cNK cells and 
able to traffic into LNs from the blood via HEV and recirculate through LNs after their egress. 
This chapter has shown that ILCs traffic into and out of a peripheral LN and although in small 
numbers, recirculate to contralateral LNs within 72 hours. Furthermore, the data indicate that 
it is really the ILC1 subset that likely accounts for most of the migration observed when the 
total ILC population is assessed. Whilst ILC in human blood have been extensively 
characterised and studied, the ILC composition of murine blood is poorly understood, 
although Gasteiger et al described ILC1 being present in the circulation (249, 267). Therefore, 
to investigate whether ILC migrating into the LN may traffic direct from the circulation, ILC 
populations in murine blood were assessed (Figure 5.14a-b). The percentage of ILCs was 
assessed due to an inability to harvest the exact same volume of blood per mouse. With 
hindsight analysing a set volume of blood from each mouse would enable cells to be 
enumerated and compared across mice, however, due to ILCs being a rare population as much 
blood as possible was collected. Consistent with previous reports ILC1s were the most 
abundant subgroup of ILCs within the blood, alongside a few ILC2s (249, 347). Combining the 
blood of 3 mice, and enriching for CD45
+
 cells via MACS-enrichment, enabled a high yield of 
cells to be obtained and therefore ILC1s were identified via T-bet expression as the dominant 
ILC population within the blood (Figure 5.14c-d). For efficient egress out of the blood and into 
the LN duel expression of CD62L and CCR7 is required, therefore T-bet
+
 ILC1s were analysed  
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Figure 5.13. cNK cells are able to recirculate through draining LNs 
Kaede mice underwent violet light photoconversion as described in methods. The 
photoconverted bLN and a pool of contralateral LNs were analysed 72 hours post 
photoconversion. cNK cells and ILC1s were identified within Kaede mice. Cell isolation of the 
bLN and contralateral LNs were conducted as stated in methods. 
Each data point represents 1 bLN or 1 pool of contralateral LNs (mLN, iLN, auLN, axLN and 
cLN) from one mouse. Data pooled from a minimum of 2 experiments. Values on flow 
cytometry plots represent percentages, bars on scatter plots represents the median, which is 
also shown numerically. Statistical significance was tested using an unpaired, non-parametric, 
Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs lineage 
markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Representative flow cytometry plots of cNK cells (Live CD45+ CD3- TCRβ- NK1.1+ IL-7Ra- 
CD49b
+
) and their expression of Kaede Green and Kaede Red in the bLN. 
b) Percentage of Kaede Green and Kaede Red cNK cells (n=6).  
c) Representative flow cytometry plots of cNK cells and ILC1s (Live CD45+ CD3- TCRβ- NK1.1+ 
IL-7Ra+ CD49b-) Kaede Green and Kaede Red expression in contralateral LNs of Kaede 
mice.  
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for the expression of these two markers (49, 255, 315). It was observed that ILC1s contain a 




, suggesting that they possess the ability to enter LNs,  




 cells, suggesting that some ILC1s possess the ability to 
enter the LN and others do not (Figure 5.14 e-g). 
Within this chapter it was observed that ILCs were not solely comprised of a tissue-resident 
population, with a proportion of ILCs being able to migrate into peripheral LNs in a CCR7 
dependent manner. Furthermore, egress of ILCs from LNs in an S1PR dependent manner and 
ability to circulate through draining LNs was observed. ILC1s were discovered to be the 
dominant ILC migratory population, sharing similar abilities with cNK cells, located within the 
blood expressing surface proteins consistent with the requirement to enter LNs. 
5.3 SUMMARY 
With new publications within the literature, challenging the original consensus that ILCs were 
strictly a tissue-resident population, this chapter aimed to determine whether there is 
evidence that ILCs are able to move in an out of peripheral LNs. Complete photoconversion of 
all the cells within the bLN from Kaede Green to Kaede Red fluorescence has enabled the in 
vivo visualisation of cell migration both into and out of the bLN. This model led to the 
identification of a tissue-resident and CCR7 dependent migratory ILC population. 
Furthermore, the data provided clear evidence that ILCs normally egress from the LN in an 
S1P dependent manner and that they are able to recirculate through peripheral LNs. Within 
the blood ILC1s express a phenotype which suggests they are  able to enter LNs from the 
blood, therefore, it was concluded that migratory ILCs, which were mainly comprised of ILC1s, 
are able to recirculate through LNs in a similar manner to cNK cells. The findings within this  
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Figure 5.14. CCR7+ CD62L+ ILC1s are located within the blood 
Each data point represents blood collected from (a-b) one WT mouse (c-g) three WT mice. 
Data pooled from a minimum of 3 experiments. Values on flow cytometry plots represent 
percentages. Statistical significance was tested using an unpaired, non-parametric, Mann-
Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs lineage 
markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, CD123, Gr1, F4/80, FceRI and 
F4/80. 
a) Representative flow cytometry plots showing ILC1s (Live CD45+ Lineage- IL-7Ra+ (NK1.1 
NKp46)
+




 IL-7Ra+ (NK1.1 NKp46)- KLRG1+) and ILC2s within 
the blood.  
b) Percentage of ILC subsets in the blood (n=8). 





 IL-7Ra+ T-bet+) and T-bet- ILCs (Live CD45+ Lineage- IL-7Ra+ T-bet-).  
d) Percentage of T-bet expression by ILCs within the blood (n=4). 
e) Representative flow cytometry plots showing expression of CCR7 and CD62L on T-bet+ 
ILC1s.  
f) Representative histogram showing expression of CCR7, normalised to mode, of T cells 
isotype control (pink dashed line), T cells (orange line) and ILC1s (blue line) (n=3).   





















































































Chapter, using photoconvertible Kaede mice to further understand ILC migration within the 
peripheral LN is summarised in Figure 5.15. Furthermore, a suggested model of specific ILC 
subset migration is proposed in Figure 5.16. 
At the heart of this chapter is a photoconversion approach which has utilised a model of 
temporal labelling of all cells within a LN to interrogate migration into and out of the tissue. 
This model enables the visualisation of cell migration in vivo through photoconversion via 
violet light exposure, which does not affect the function of the cell (53). Within these studies 
the retention of Kaede Red expression within CD45
-
 stromal cells and the large influx of Kaede 
Green CD45
+
 T cells within the bLN provides strong evidence that this model can be used to 
distinguish between cells that are migratory and others that are tissue-resident. Upon the 
deletion of a key molecule integral in the migration of lymphocytes into the LNs, such as CCR7 
in the migration of T cells, the differences observed in Kaede Green ‘migratory’ cells entering 
the bLN is entirely consistent with the differences being migratory related. Similarly, blocking 
the S1P dependent egress of lymphocytes, via FTY720 administration, caused the 
accumulation of Kaede Red labelled cells providing strong evidence that under normal 
conditions these cells exit the tissue. Combined this evidence clearly argues that the temporal 
labelling of the LN is a robust means of assessing movement into and out of the LN and this 
approach demonstrates the ingress and egress of ILC from peripheral LNs. The main caveat of 
the Kaede model is the ability for proliferating Kaede Red cells to dilute out Kaede Red 
expression and replace it within Kaede Green. To combat this, analysis of migration was 
assessed a maximum of 72 hours post photoconversion as previously shown by Tomura et al., 
and Marriott et al., as discussed previously (53, 92). Furthermore, work within the lab has 
revealed a low Ki-67 expression by ILCs in the LN under steady state (Withers lab unpublished  
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Figure 5.15. Summary Diagram of ILC migration within bLN Kaede model 
All of the cells within the bLN can be photoconverted from Kaede Green to Kaede Red upon 
exposure to violet light. 72 hours post photoconversion a migratory population of Kaede 
Green ILCs was observed within the bLN, suggesting to have entered from the lymphatics or 
through HEVs, with this migration being dependent on CCR7. ILCs are present within the blood 
with duel expression of CD62L and CCR7, which are required for the migration of cells from 
the blood into the LN. Kaede Red resident ILCs are shown to express high levels of CD69, 
consistent with their retention in the LN. ILCs were shown to egress from the bLN in an S1P 
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Figure 5.16. Summary Diagram of proposed model of ILC subset migration 
ILC1s and cNK cells are able to travel through the blood, entering and exiting peripheral LNs 
in a manner dependent on CD62L and CCR7 expression for entry and S1PR expression for 
egress. ILC2s and ILC3s are a more resident population, remaining within peripheral LNs under 
steady state conditions.  
This diagram simplifies the migratory properties of ILC subsets, with the presence of a smaller 
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Within this model Kaede Red cells have been termed tissue-resident cells, however, these cells 
may not be permanently resident. Migration was only observed over a 72 hour period, 
therefore, Kaede Red expression is suggestive of a resident population, but does not take into 
account the potential for Kaede Red cells to leave the LN after the 72 hour time frame, 
identifying migratory cells that have much slower kinetics than assessed here. Longer time 
periods would need to be assessed to determine whether Kaede Red ILCs are a long-lasting 
resident population. Although the Kaede protein has a long half-life, observing migration 
beyond 72 hours is not ideal. Dendra mice are a new photoconvertible mouse model used to 
track the migration of cells (336, 348-350). Similar to Kaede mice the photoactivatable GFP 
Dendra2 is converted into a red fluorescence upon exposure to violet light (348, 349, 351). 
However, the Dendra2 protein is fused to histones, which are important in the structure and 
organisation of nucleosomes (348, 349). This increases protein stability allowing the tracking 
of converted cells over a longer period of time, with reports identifying populations remaining 
resident for up to 4 weeks (348-350). These mice would therefore be useful to test whether 
‘resident’ ILCs within the bLN remain over several weeks. From these results, a further 
hypothesis could be proposed that tissue-resident ILCs are permanently resident within the 
LN. 
These studies alongside showing the ability of ILCs to enter peripheral LNs have also provided 
evidence that ILCs are able to exit in an S1P dependent manner. Clear evidence supporting 
this conclusion  was shown via blocking S1P receptors resulting in the accumulation of ILCs 
within the bLN. S1PR1 was detected on a proportion of cells within the bLN, suggesting its 
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involvement in ILC egress, however, other reports have also shown iILC2s within the lung and 
mLN, under certain conditions, have inducible expression of S1PR1 and S1PR4, alongside mLN 
ILC2s expressing S1PR5 (254). Further analysis of differential receptor expression across the 
ILC subsets would be required to further explore the mechanism of ILC egress. FTY720 
selectively blocks S1PR1, S1PR3 and S1PR4, suggesting that if ILC egress also depends on 
S1PR5, this would not be inhibited within these experiments using FTY720 (254, 261, 345). It 
is therefore reasonable to assume that there may be tissues from which ILCs egress in an 
S1PR5 dependent manner, enabling them to reach the blood or lymph and still enter the LN. 
This may potentially  explain the Kaede Green ILC population observed migrating into the bLN 
of mice administered with FTY720. Supporting this, Huang et al., reports that under FTY720 
administration iILC2 migration was blocked from the intestine into the lung, where iILC2s only 
express S1PR1 and S1PR4, but only partially blocked migration to the mLN, where they 
additionally express S1PR5 (254). Furthermore, cNK cells egress from the LN in an S1PR5 
dependent manner which is also unable to be blocked via FTY720 administration (344). This 
suggests that the ILCs observed migrating into the bLN under FTY720 administration might 
migrate within an S1PR5 dependent mechanism and that additional blocking with a substance 
specific to S1PR5 may completely block ILC recirculation and therefore Kaede Green ILCs 
entering the bLN. Altogether this would suggest that ILC egress is partly dependent on S1PR1 
or S1PR4, due to FTY720 causing accumulation of ILCs within the LN and bLN ILCs expressing 
S1PR1, but may also be dependent on S1PR5, as suggested by other publications exploring ILC 
and cNK cell migration. 
ILC egress was accompanied by their recirculation into other LNs, evident by the detection of 
Kaede Red ILCs being identified within contralateral LNs. This identified population was 
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modest but significant and surprisingly, comparable to Ccr7-/- Kaede mice. This may suggest a 
redundancy in CCR7 for ILCs to recirculate into contralateral LNs, unlike T cells, contradicting 
data showing ILCs dependency on CCR7 to enter LNs. On the other hand, it is most likely due 
to a reduced ability in identifying a rare lymphocyte population and sample size, suggesting 
further work is needed to confidently conclude whether ILCs recirculate in a CCR7 
independent manner. ILCs are sparse within SLTs, comprising of roughly 1,000 cells within the 
bLN, therefore locating small numbers of Kaede Red ILCs in the contralateral LNs is 
unsurprising. The additional conversion of the iLN and axLN alongside the bLN would increase 
the number of converted ILCs, and therefore the number of Kaede Red ILCs able to be tracked 
within the contralateral LNs, increasing the chance of identifying a more substantial 
population of migratory ILCs. A further method to identify the location of where ILCs migrate 
to would be to assess the migration into ipsilateral LNs. The efferent lymphatic vessel of the 
bLN drains directly to the axLN, if ILCs are able to egress through the efferent lymphatic vessel 
in a similar manner to T cells then they may be able to directly drain into the secondary LN 
without entering the blood (35, 331). Previously when Marriott et al., established 
photoconversion of the bLN it was a concern that the axLN occasionally underwent partial 
photoconversion (92). This prevented the ability to analyse Kaede Red ILCs within the axLN as 
it could not be determined whether they had migrated from the bLN or were converted upon 
initial violet light exposure. With a refined labelling protocol, it is possible that this caveat 
could be removed and the migration of ILCs from a primary to a secondary LN assessed.  
The migration of ILCs into the bLN within the 72 hours was shown to be reduced within Ccr7- /- 
Kaede mice, suggesting that similar to T cells, ILCs depend on CCR7 for their entry into the LN 
(316).  However, these experiments do not specifically identify whether ILCs directly express 
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CCR7 and require CCR7:CCL21/CCL19 interactions or whether a separate cell type, which is 
required for ILC entry, is dependent on CCR7. Assessing the expression of CCR7 on ILCs within 
the bLN would help to determine  whether ILCs directly or indirectly require CCR7 for their 
ingress into the peripheral LNs. 
Initialy within this investigation the migration of ILC as a total population was assessed. To 
better understand whether all ILCs were equally migratory or had distinct migratory 
properties ILC subgroups migration needed to be assessed. However, due to the need to 
preserve Kaede expression, using a fixation and permeabilisation staining method to enable 
detection of TFs was an issue. The solution was a compromise, using surface markers to clearly 
identify some, but not all ILC subsets with some ILC1s, ILC2s and ILC3s falling within the 







meaning with this staining panel they are unable to be identified separately and therefore 
were included within the ungated cells. A more efficient staining panel was unable to be 
established, so the current panel was used to identify that ILC1s are the main subgroup of 
migratory ILCs. Within photoconvertible Dendra mice the Dendra2 protein is fused to histones 
and not present within the cytoplasm, suggesting that these cells may be able to undergo 
intracellular TF staining, therefore they may be useful in the accurate identification of ILC 
subsets through the use of T-bet, GATA-3 and RORgt (349). 
ILC1s were identified as the dominant population of ILCs migrating into the bLN and the source 
of ILC1s was investigated. They were located within the blood to have duel expression of 
CD62L and CCR7, in which a simple explanation of this data is that ILC1s move via HEVs into 
LNs, in a similar manner to cNK cells (49, 116). This is supported by their ability to recirculate 
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into other peripheral LNs. Upon entry into LNs CD62L is promptly downregulated which may 
explain why CD62L expression is low on Kaede Green ILCs within the bLN (~20%) (315). A 
further similarity between the closely related ILC1s and cNK cells is their ability to migrate into 
contralateral LNs. Kaede Red ILC2s and ILC3s were not individually analysed within the pool 
of contralateral LNs and therefore their ability to recirculate was not assessed. It would be 
interesting to determine whether ILC1s were the only helper ILC subset able to recirculate 
through LNs, which could be determined using the CS panel described earlier, however, due 
to a small number of recirculatory ILCs being identified, this could be problematic. 
These data identified within this chapter add to the understanding of the migratory properties 
of ILCs. The identification of a migratory ILC population entering the bLN is consistent with the 
identification of ILCs entering the mLN from the intestine (243, 252, 254). However, this 
investigation shows the ingress into peripheral LNs rather than the mLN. This migratory 
population was potentially not observed within the parabiotic mice used by Gasteiger et al., 
as they only assessed entry into the mLN and spleen lymphoid tissues and not the peripheral 
lymphoid tissues (249). Consistent with Gasteiger et al., and Huang et al., ILCs were identified 
within the blood, mainly ILC1s, with these data identifying the expression of CD62L and CCR7 
on ILC1s essential for their entry into LNs (249, 254). ILC2s were not observed to be abundant 
within the blood as shown by Huang et al., however this was only observed after i.p. injection 
of IL-25 or infection with Nippostrongylus brasiliensis (254). It would therefore be interesting 
to observe the migratory properties of ILCs under different inflammation models. 
Furthermore, ILC1s which are closely related to cNK cells seem to have a similar migratory 
ability to previously published reports on cNK cell migration (116). Currently within the 
literature ILC migration is mainly assessed from non-lymphoid tissue into draining LNs and 
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with ILC migration not being assessed within parabiotic mice, it is therefore suggested that 
they can migrate within the lymphatic system. This raises the question of whether the ILCs 
entering the peripheral LNs are originating from non-lymphoid tissue and draining through 
the lymph into the LN. 
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Chapter 6.   ASSESSING THE MECHANISMS OF ILC MIGRATION 
BETWEEN SKIN AND DRAINING PERIPHERAL LN 
6.1 INTRODUCTION 
Within Chapter 5 direct evidence was provided showing that ILCs, can recirculate through LNs. 
Thus, a clear pathway through which ILC1 migrate would appear to be from the blood into the 
LN. Another method of hematopoietic cell entry into the LN is via the afferent lymphatic vessel 
(49). Certain LNs exist within a sequence, with the primary LNs efferent lymphatics directly 
becoming the afferent lymphatics of the secondary, termed a chain of LNs (35). This chain 
allows the direct migration of cells from one LN to another, as discussed previously with T cells 
(35, 53). Hematopoietic cells are also able to enter the lymphatic system via lymphatic 
terminals in non-lymphoid tissue. This is the main route of DC entry, enabling the transport of 
antigen from tissue to draining LN, for example skin DCs to draining peripheral LNs (247). 
Activation and maturation of dermal DCs within skin leads to the downregulation of proteins 
associated within tissue residency such as E-cadherin and upregulation of chemokine 
receptors such as CCR7 allowing migration towards lymphatic terminals (352-354). CCR7 
expression is paramount in the migration of DCs into the draining lymphatics with Ccr7-/- DCs 
in WT hosts being able to migrate to the lymphatics terminals but unable to cross the 
endothelium into the lymph (353). Furthermore, CCL21, the ligand for CCR7, is located on LECs 
that are situated in the lymphatic terminals (353). Upregulation of S1PR1 expression on DCs is 
also suggested to be important in the efficient trafficking of DCs to draining LNs (355). 
Epidermal DCs, such as LC, are also able to exit the skin via lymphatic terminals after initial 
entry into the dermis in a CXCR4 dependent mechanism (356, 357). Within the lymphatics, 
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DCs initially use lamellipodia to actively migrate in the same directions as the lymphatic flow, 
before they freely drift towards the draining LN (353). A variety of models have previously 
been used to show that DCs are able to migrate under steady state conditions, from the skin 
to draining LNs, and that their migration increases under inflammatory conditions (53, 247, 
352, 353). 
Migration into the LN from non-lymphoid tissue is another route of entry for T cells, although 
their main route of entry is via HEV (49, 311, 338, 358). This migration is paramount in the 
immune surveillance of memory T cells, allowing them to recirculate through non-lymphoid 
and lymphoid tissues (35, 53, 358-360). Furthermore, the migration of gd T cells from skin to 
draining LN under inflammatory models has also been shown to ameliorate the CD8
+
 T cells 
response within the LN and to support DC function via production of TNF-a (338). Interestingly 
the mechanistic egress from the skin varies depending on the T cell population, with gd T cells 
egress being independent of CCR7 and CD4
+
 ab T cells migration being CCR7 dependent (338, 
361).  
6.1.1 Project Aims 
Although ILCs are located within non-lymphoid tissues and their draining LNs, their migration 
between these sites is currently still unclear, with the parabiotic models used to assess ILC 
tissue residency, unable to assess such movement. To directly address this question of ILC 
migration from tissue to draining LN, Kaede mice were used to assess migration from the ear 
to the draining auLN in comparison to T cells and LCs. The aim of these studies was to 
determine whether ILCs were able to migrate from non-lymphoid tissue to the draining LN 
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through the lymphatic system. The hypothesis that ILC migration from draining LN to auLN 
increasing under inflammatory conditions was also tested. 
6.2 RESULTS 
6.2.1 Minimal ILC migration to the auLN from the ear steady state 
To directly test the migration of ILC from tissue to draining LN the migration of ILCs from ear 
skin to the draining auLN was assessed. When using Kaede mice the efficient labelling of all 
cells in a defined area, such as the whole bLN, allows the tracking of cells into and out of that 
specific tissue. Therefore, the ear was selected as a specific area of skin to assess migration 
between skin and draining LN, since it was anticipated that that all cells within the ear could 
be photoconverted, rather than segments of back skin (53). Within this model ILC migration 
was compared to T cells and LCs. Egress from the blood is the main mechanism for naïve T 
cells to enter the LN (49). LCs, however, mainly enter through the afferent lymphatic vessel, 
originating from non-lymphoid tissue (49). Therefore, these two migratory populations, from 
the adaptive and innate sides of the immune system, respectively, were assessed to address 
whether ILCs can drain through the lymphatics in a similar manner.  
Photoconversion of the ear from Kaede Green to Kaede Red was conducted without 
photoconverting any cells within the auLN, establishing a simple model to track migration 
under steady state conditions (Figure 6.1a-b). Due to the composition of the skin, a different 
light source was used to photoconvert the ear with a wavelength of 405 nm. A caveat of this 
light source is the potential induction of damage upon exposure to violet light, which 
depending on light source and length of exposure can result in damage of the epithelium, 
detectable 2 hours post irradiation (362, 363). Strid et al., reported that upon damage elicited 
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by tape stripping, IL-13 mRNA production is rapidly increased within 2 hours by TCRgd+ DETCs 
(340, 364). Therefore, to determine whether the dose of violet light applied to the ear was 
sufficient to elicit damage assessed by IL-13 production, IL-13 GFP reporter mice were 
analysed 2 hours post exposure. The proportion and number of T cells producing IL-13 GFP 
was comparable between control and violet light exposed ears, suggesting that the 
photoconversion method employed did not result in damage that could be measured by IL-13 
release (Figure 6.1c-d). Therefore, this suggests that the establishment of this Kaede model 
enables the in vivo assessment of cell migration in mice under steady state conditions from 
the ear to draining auLN and into the ear. 
Migration from non-lymphoid tissue is a primary mechanism of entry for DCs into the LN. LCs 
are thought to be a subset of DCs that reside within the epidermis and upon activation they 
migrate into the dermis towards the lymphatic terminals where they transmigrate into the 
lymphatic vessel and move towards the draining LN (365, 366). Despite recent conflicting 
publications suggesting minimal migration of LCs from skin to draining LNs, LC and T cell, 
migration was studied in conjunction with ILCs, to compare ILC with migratory innate and 
adaptive immune cells (247, 367, 368). Initially the composition of the auLN was analysed 0, 
48 and 72 hours post ear photoconversion (Figure 6.2a). An increase in the proportion and 
number of Kaede Red CD45
+
 hematopoietic was observed between 0 and 48 hours which was 
maintained at 72 hours (Figure 6.2a-b). Albeit a small number of Kaede Red cells being 
detected, these results support previous publications that cells continuously, although at a 
low frequency, migrate from the ear to the draining LN under steady state conditions (53, 
247). To determine whether ILCs were amongst this migratory population, Kaede Red 
hematopoietic cells within the auLN were analysed in more detail 72 hours post  
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Figure 6.1. Photoconversion does not elicit gd T cell IL-13 production 
WT Kaede violet light photoconversion of the ear and cell isolation of the ear and auLN were 
conducted as described in methods.  
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001.  
a) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in the ear 0 hours after no violet light photoconversion (control) and violet 
light photoconversion (violet light). 
b) Percentage of Live CD45+ Kaede Red cells within the ear and auLN 0 hours after violet light 
photoconversion (n=12). 
c) Representative flow cytometry plots of IL-13 production in IL-13 GFP reporter mice by T 
cells (Live CD45
+
 CD3e+) within the ear after no violet light photoconversion (control) or 2 
hours post violet light photoconversion (violet light). 
d) Percentage (left) and number (right) of IL-13 GFP+ T cells within the ear in control (n=9) 
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photoconversion. The Kaede Red migratory population was mainly comprised of T cells, with 
a smaller proportion of LCs and very few ILCs (Figure 6.2c-d). Conversion of all cells within the 
ear also enabled the assessment of Kaede Green putative migratory populations into the ear 
from the periphery. The initial labelling of the ear was efficient with >95% of CD45
+
 cells within 
the ear expressing Kaede Red at 0 hours (Figure 6.2e). Although a small proportion of 
hematopoietic cells remained Kaede Green, the increase in proportion and number of Kaede 
Green cells over time was consistent with the movement of new cells into the ear after initial 
labelling (Figure 6.2e-f).  It was observed that at 72 hours this migratory population was 
comprised of T cells amongst a small population of LCs (Figure 6.2g-h). Interestingly ILCs, 
although a small proportion, were also identified within this Kaede Green migratory 
population. Together these data suggest there is minimal migration of ILCs from the ear to the 
auLN under steady state conditions, however, a small population of ILCs are potentially able 
to migrate into the ear.  
6.2.2 Atopic Dermatitis causes an increase in ear and auLN cellularity 
Since minimal migration of ILCs was detected at steady state it was hypothesised that ILC 
migration to the auLN would increase under inflammatory conditions, since the induction of 
skin inflammation via various skin irritants increases the migration of immune cells into the 
inflamed skin and the draining LN (247, 358, 359, 365). To this end, MC903 was applied to the 
ears establishing an AD model. This is an extensively used model characterised by an 
inappropriate type two immune response (112, 227, 369-371). MC903 is a vitamin D3 
analogue that binds to an intracellular vitamin D receptor in keratinocytes, inducing an 
increase in production of alarmins such as TSLP, IL-25 and IL-33 (112, 369, 372, 373). In turn, 
these alarmins drive a type two response resulting in accumulation of basophils, eosinophils,  
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Figure 6.2. Tracking migration of immune cells in the ear and draining auLN 
WT Kaede violet light photoconversion of the ear and cell isolation of the ear and auLN were 
conducted as described in methods. Immune cell migration was assessed 0, 48 and 72 hours 
post violet light photoconversion. 
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and CD49b. 
a) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in the auLN 0, 48 and 72 hours post photoconversion.  
b) Percentage (left) and number (right) of Live CD45+ Kaede Red cells in the auLN 0 (n=12), 
48 (n=12) and 72 hours (n=10) post photoconversion. 
c) Representative flow cytometry plots of Live CD45+ Kaede Red T cells (CD3e+) ILCs (Lineage- 
IL-7Ra+) and LCs (MHCII+ CD11c+ CD207+) in the auLN 72 hours post photoconversion. Each 
population is shown as a proportion of the Live CD45
+ 
Kaede Red population. 
d) Percentage Live CD45+ Kaede Red T cells (n=5), ILCs (n=12) and LCs (n=5) in the auLN.  
e) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+ 
cells in the ear 0, 48 and 72 hours post photoconversion.  
f) Percentage (left) and number (right) of Live CD45+ Kaede Green cells in the ear 0, (n=12), 
48 (n=11) and 72 hours (n=11) post photoconversion. 
g) Representative flow cytometry plots of Live CD45+ Kaede Green T cells ILCs and LCs in the 
ear 72 hours post photoconversion. Each population is shown as a proportion of the Live 
CD45
+
 Kaede Green population. 
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effector Th2 cells, DCs, mast cells and ILC2s in the dermal layer (112, 369). The increase in type 
2 cytokine production, such as IL-4 and IL-13, results in the downregulation of genes important 
in skin barrier function such as filaggrin, leading to further increased skin permeability to 
allergens (374, 375). To validate the model within the lab, the ear and auLN were analysed 
post application of ethanol VC or MC903 for 5 days. This time frame was chosen to study the 
initial innate response, whilst providing sufficient time to assess migration and reduce 
potential discomfort to the mice. Previous publications studying the effects of MC903 conduct 
analysis after 14-17 days of application, with reports of visual damage occurring after 5-7 days 
of application (112, 369, 370). It was therefore important to determine whether 5 days of 
application was sufficient to cause a measurable response. Visually, after 5 days, the VC and 
MC903 treated ears were comparable, with no lesion development (Figure 6.3a). However, 
ear thickness increased within the MC903 treated mice accompanied by an increase in the 
percentage and number of CD45
+
 hematopoietic cells (Figure 6.3b-d). Most importantly, the 
auLN substantially increased in size alongside a statistical increase in the number of CD45
+
 
hematopoietic cells (Figure 6.3e-g). Accumulation of basophils within the ear is a hallmark of 
MC903 induced AD development, therefore, basophils were assessed within the ear and auLN 
(231). Basophils were observed to increase in number within both tissues (Figure 6.3h-k). It is 
clear that the auLN has increase in cellularity, this may be due to all populations expanding 
proportionally, elucidating to why the percentage of basophils are comparable between VC 
and MC903 treated mice. Together these data show that 5 days of treatment elicits 
inflammation within the ears and a substantial response within the auLN. This suggests that 
this is an appropriate model to assess the migration of cells within an early innate response 
from the ear to the auLN. 
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Figure 6.3. Establishment of the MC903 atopic dermatitis model 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT mice on day 0 (D0) – day 4 (D4), ethanol was applied alone as a vehicle 
control (VC). WT mice were culled 72 hours post final dose on D5. Cells were isolated from the 
ears and auLN as described in methods.  
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. 
a) Representative photos of ears with VC or MC903 topical application. 
b) Thickness of VC (n=15) and MC903 (n=12) treated ears 24 hours after last topical 
application.  
c) Representative flow cytometry plots showing Live CD45+ cells within the VC (left) and 
MC903 (right) ears. 
d) Percentage (left) and number (right) of Live CD45+ cells in VC (n=7) and MC903 (n=11) ears. 
e) Representative photos of auLN of VC or MC903 treated mice. Ruler scale is 1 mm, per small 
division. 
f) Representative flow cytometry plots showing Live CD45+ cells within VC (left) and MC903 
(right) auLNs. 
g) Percentage (left) and number (right) of Live CD45+ cells VC (n=7) and MC903 (n=12) auLNs. 









 FceRI+) in the ear of VC (left) and MC903 (right) treated mice. 
i) Percentage (left) and number (right) of basophils within VC (n=7) and MC903 (n=12) ears.  
j) Representative flow cytometry plots of basophils in VC (left) and MC903 (right) auLNs. 
k) Percentage (left) and number (right) of basophils within VC (n=7) and MC903 (n=12) auLN.  
































































































































































ILC2s contribute to the type 2 response induced by MC903 in a manner independent of 
adaptive immunity (112). Studies depleting ILC2s within the MC903 model resulted in 
attenuation of AD inflammation (112, 231). Currently, there is debate within the literature as 
to whether ILC2s are recruited into the inflamed skin in an IL-33 and IL-25 dependent manner, 
or whether these cytokines are redundant and instead the ILC2 response is driven by TSLP, 
with the TSLP receptor being highly expressed on ILC2s (112, 227). Recruitment and 
proliferation of ILC2s is further contributed to by basophil derived IL-4 (231). To explore the 
ILC response within the MC903 model, total ILCs alongside ILC subsets were further analysed. 
Similar to basophils, there was no change in the percentage of total ILCs within the auLN 
(Figure 6.4a-b). However, over a 10-fold increase in number of ILCs was observed alongside 
an increase in all ILC subsets in MC903 treated mice (Figure 6.4c). The comparisons of ILC 
percentages may be skewed due to ILC2s and TrN ILCs undergoing a larger expansion 
numerically, compared to ILC1s and ILC3s (Figure 6.4b). This may suggest why the percentage 
of ILC3s was decreased within the MC903 model but an increase in number was observed. The 
significant increase in ILC numbers indicate that the MC903 model is an appropriate model for 
directly testing whether ILCs migrate from inflamed ear skin to the auLN. Although an increase 
in hematopoietic cells was observed within the MC903 treated ear, there was a decrease in 
proportion of ILCs and numbers were comparable to VC ears (Figure 6.5a-c). This proportional 
decrease likely reflects a large increase of another non-ILC population. An increase in 
proportion and number of ILC2s in the MC903 treated ear, consistent with other studies using 
the MC903 AD model, was counteracted by a decrease of TrN ILCs, which may explain why no 
change was observed in the total number of ILCs (112, 231). These data support the 
development of an ILC2 driven AD model. Following the large expansion of ILCs within the  
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Figure 6.4. An increase in all ILC subsets is observed within the auLN of atopic dermatitis 
mice 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT mice for D0-D4, ethanol was applied alone as a VC. WT mice were culled 
72 hours post final dose on D5. Cells were isolated from the auLN as described in methods.  
Each data point represents 1 auLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, CD123, F4/80, FceRI and CD49b. ILCs were gated on negatively for iCD3e 
(gating strategy not shown). 





 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet+), ILC2s (Live CD45+ Lineage- 
IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt+) 




 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) in the auLN of VC 
(top) and MC903 (bottom) treated mice. 
b) Percentage of ILCs and ILC subsets in the auLN of VC (n=7) and MC903 (n=11) treated mice. 































































































Figure 6.5. Atopic dermatitis elicits an increase in ILC2s within the ear 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT mice on D0-D4, ethanol was applied alone as a VC. WT mice were culled 
72 hours post final dose on D5. Cells were isolated from the ears as described in methods. 
Each data point represents 1 ear from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, CD123, F4/80, FceRI and CD49b. ILCs were gated on negatively for iCD3e 
(gating strategy not shown). 





 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet+), ILC2s (Live CD45+ Lineage- 
IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt+) 




 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) in the ears of VC 
(top) and MC903 (bottom) treated mice. 
b) Percentage of ILCs and ILC subsets in the ears of VC (n=7) and MC903 (n=11) treated mice. 





























































































auLN it was concluded that this model was suitable to assess ILC migration from the ear to 
draining auLN under MC903 driven inflammatory conditions. 
T cell accumulation within the ear is a hallmark of prolonged MC903 treatment (370). To 
determine whether 5 days of treatment was sufficient in eliciting T cell recruitment, ab T cells 
(CD3
+
 TCR gd-) and gd T cells (CD3- TCR gd+) were analysed within the auLN and ear of MC903 
treated mice. Although decreased proportions of T cells, as a whole population, and ab T cells 
were observed within the auLN of the MC903 model, there was an increase in numbers of all 
T cell populations (Figure 6.6a-c). Interestingly, although in number there was a much larger 
presence of Kaede Red ab T cells within the auLN, there was a larger proportional increase of 
gd T cells, potentially consistent with their early innate functions. Within the ears, although 
the proportion of total T cells was comparable between VC and MC903 mice, there was an 
overall increase in T cell number, which was contributed to solely by gd T cells (Figure 6.6d-f). 
Similar to the auLN this supports the analysis of the early innate phase of the immune 
response with effector ab Th cells not yet being recruited to the inflamed tissue. This indicates 
that 5 days of MC903 application is efficient to amount an inflammatory response within the 
ear and auLN and that the main subset of T cells migrating into the ear are gd T cells, consistent 
with an early innate response. 
LC are also paramount in the development of MC903 driven AD. LC depleted mice did not 
develop AD-like symptoms upon MC903 application and further studies show their 
importance in migration from the ear to the draining LN to prime naïve CD4
+
 T cells into 
effector Th2 cells, driving the type 2 response (366). Upon analysis of the LC population it was 
clear that within the auLN and the ear of MC903 treated mice there was an increase in the  
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Figure 6.6. Atopic dermatitis elicits an increase in gd T cells within the ear 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT mice on D0-D4, ethanol was applied alone as a VC. WT mice were culled 
72 hours post final dose on D5. Cells were isolated from the ear and auLN as described in 
methods.  
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. 
a) Representative flow cytometry plots showing T cells (Live CD45+ CD3e+), ab T cells (Live 
CD45
+
 CD3e+ TCRdg-) and dg T cells (Live CD45+ CD3e+ TCRdg+) in the auLN of VC (top) and 
MC903 (bottom) treated mice. 
b) Percentage of T cells, ab T cells and dg T cells in the auLN of VC (n=11) and MC903 (n=11) 
treated mice. 
c) Number of T cells, ab T cells and dg T cells in the auLN of VC (n=11) and MC903 (n=11) 
treated mice. 
d) Representative flow cytometry plots showing T cells (Live CD45+ iCD3e+), ab T cells (Live 
CD45
+
 CD3e+ TCRdg-) and dg T cells (Live CD45+ CD3e+ TCRdg+) in the ears of VC (top) and 
MC903 (bottom) treated mice. 
e) Percentage of T cells, ab T cells and dg T cells in the ears of VC (n=10) and MC903 (n=8) 
treated mice. 
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percentage and number of LCs compared to VC treated mice (Figure 6.7a-d). This suggests an 
increase in the recruitment of LCs in the skin and migration of LCs from skin to auLN, 
supporting previous studies (366).  
6.2.3 ILC migration is induced under an atopic dermatitis inflammation model 
MC903 application resulted in increased numbers of ILCs within the auLN. To test the 
hypothesis that this increase of ILCs reflected enhanced migration from inflamed skin, the 
MC903 and Kaede models were combined enabling cell migration to be assessed under an 
inflammatory condition. Migration was observed at two different time points through the 
course of the 5 day MC903 model. The early phase of the MC903 model was assessed by 
photoconverting the ear on day 0 (D0) and assessing migration on day 2 (D2), and the later 
phases by photoconverting the ear on D2 of the MC903 model and taking mice on day 5 (D5) 
(Figure 6.8a). A hallmark of MC903 AD inflammation is the thickening of the ear. To determine 
that ear thickening did not prevent the efficient photoconversion of all cells within the ear the 
percentage of Kaede Red cells was assessed immediately after photoconversion in Kaede mice 
treated with MC903 two days prior. Upon comparison to control mice, which were taken 0 
hours post photoconversion with no MC903 application, it was clear that the MC903 
treatment and potential thickening of the ear, did not affect the ability to fully photoconvert 
the ear from Kaede Green to Kaede Red (Figure 6.8b). This meant that the cells migrating into 
the ear as well as from the ear to the auLN could still be analysed. Analysis of the auLN at the 




 cells between D0-D2 and 
D2-D5 within the MC903 model (Figure 6.8c-e). This suggests that migration is increased upon 
MC903 application and is maintained through the initial 5 days. All subsets observed increased 
numbers of Kaede Red cells within the auLN 72 hours post photoconversion, consistent with  
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Figure 6.7. Increase in LCs within the auLN and ear of atopic dermatitis mice 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear on D0-D4, ethanol was applied alone as a VC. WT mice were culled 72 hours 
post final dose on D5. Cells were isolated from the ear and auLN as described in methods.  
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled from a minimum 
of 2 experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001.  
a) Representative flow cytometry plots showing LCs (Live CD45+ MHCII+ CD11c+ CD207+) in 
the auLN of VC (top) and MC903 (bottom) treated mice. 
b) Percentage (top) and number (bottom) of LCs in the auLN of VC (n=9) and MC903 (n=12) 
treated mice. 
c) Representative flow cytometry plots showing LCs (Live CD45+ MHCII+ CD11c+ CD207+) in 
the ear of VC (top) and MC903 (bottom) treated mice. 




















































































an increase in migration from the ear to the auLN, with LCs undergoing over a 40-fold increase 
(Figure 6.8f-g). This supports previous publications of LC migration increasing upon skin 
inflammation. Together these data show that under inflammatory conditions ILC migration 
into the auLN is increase, roughly 9-fold, alongside the increased migration of T cells and LCs.  
Within the MC903 model it is clear that the numerical increase in Kaede Red CD45
+
 cells within 
the auLN of MC903 treated mice does not solely contribute to the overall increase in 
hematopoietic cells observed in Figure 6.3g. This is also true for the ILC population. The 10-
fold increase within the auLN, is evidently not exclusively due to ILC migration from the ear, 
suggesting other mechanisms for ILC expansion within the auLN. It is therefore possible that 
local proliferation may drive ILC accumulation. To explore this, the expression of the 
proliferation marker Ki-67 was analysed in ILCs in the auLN of MC903 treated mice (283). 
Compared to VC, ILCs within the MC903 model have a substantially larger proportion 
expressing Ki-67, and this was seen across all ILC subsets (Figure 6.9a-c). This indicates that 
although the migration of ILCs from the ear contributes to the increase in ILC numbers within 
the auLN of MC903 treated mice, another contributing mechanism is the proliferation of ILCs.  
LN hypertrophy is a common indicator of activation of the immune system (376). The 
prevention of cellular egress from the LN results in accumulation of leukocytes, increasing the 
probability of naïve T cells finding cognate antigen on APCs. Egress impairment under 
immunological challenge is regulated by many mechanisms including the upregulation of 
CD69 and the activation of adrenergic nerves (332, 335, 377). With ILCs being able to egress 
from peripheral LNs and recirculate through contralateral LNs via the blood it possible that 
their expansion within the MC903 auLN occurs due to influx from other tissues, as well as from 
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Figure 6.8. ILC migration into the draining auLN increases upon MC903 induced 
inflammation 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT Kaede mice on either D0-D1 or D0-D4, ethanol was applied alone as a 
VC. Violet light photoconversion of the ear occurred on D0 or D2 and mice were either culled 
on D2 or D5. Cells were isolated from the auLN as described in methods.  
Each data point represents 1 auLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Paired samples were statistically 
tested using an unpaired, non-parametric, Mann-Whitney two tailed T test, when comparing 
more than two sets of data statistical significance was tested using Kruskal-Wallis one-way 
ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, ***p≤0.001. Gating on ILCs lineage 
markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and F4/80. 
a) Schematic representation of experimental design, assessing ILC migration in the MC903 
Kaede model from D0-D2 (top) and D2-D5 (bottom).  
b) Percentage of Kaede Red Live CD45+ cells 0 hours post photoconversion on untreated ears 
(control) (n=10) and D2 of MC903 treated ears (MC903) (n=10).  
c) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in VC and MC903 auLN at D0-D2 (left) and D2-D5 (right).  
d) Number of Live CD45+ Kaede Red cells in VC (n=6) and MC903 (n=7) auLN at D0-D2. 
e) Number of Live CD45+ Kaede Red cells in VC (n=8) and MC903 (n=8) auLN at D2-D5. 
f) Representative flow cytometry plots of Live CD45+ Kaede Red ab T cells (CD3e+ TCRgd-), gd 
T cells (CD3e+ TCRgd+), ILCs (Lineage- IL-7Ra+) and LCs (MHCII+ CD11c+ CD207+) in the auLN 
of VC (top) and MC903 (bottom) treated mice between D2-D5. Each population is shown 
as a proportion of the Live CD45
+
 Kaede Red population. 
g) Number of Live CD45+ Kaede Red ab T cells, gd T cells, ILCs and LCs in VC (n=8-11) and 
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Figure 6.9. Proliferation of ILCs within the auLN is a contributing factor to their expansion 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT mice on D0-D5, ethanol was applied alone as a VC. All mice were culled 
on D5, 72 hours post final dose. Cells were isolated from the auLN as described in methods.  
Each data point represents 1 auLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and F4/80. Non Kaede mice ILCs were gated on negatively for 
iCD3e (gating strategy not shown). 
a) Representative flow cytometry plots showing Ki-67 expression on ILCs (Live CD45+ Lineage- 
IL-7Ra+) in the auLN of VC (left) and MC903 (right) treated mice.  
b) Percentage of ILCs expressing Ki-67 in the auLN of VC (n=6) and MC903 (n=7) treated mice. 
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the ear skin. Within Chapter 5, ILCs egress from the LN was shown to be dependent on S1P 
and S1PR interactions and upon S1P receptor blockade, with FTY720, Kaede Red ILCs 
accumulated within the LN consistent with a decrease in their S1P dependent egress. 
However, not all ILC migration was blocked, with the maintenance of a Kaede Green ILC 
population migrating into the bLN within FTY720 treated mice. To determine whether this 
partial block of S1P dependent migration of ILCs affected the accumulation of ILCs within the 
MC903 auLN the administration of FTY720 was combined with the MC903 model. VC was 
applied to the ears of mice administered H2O control (VC, control) and compared to mice with 
MC903 application and H2O control (MC903, control) or FTY720 (MC903, FTY720) (Figure 
6.10a). Upon comparing these three models, it was observed that the MC903 model was 
induced efficiently, with MC903, control mice having an increased number of T cells, ILCs and 
all ILC subsets compared to VC, control mice (Figure 6.10b-d). Upon analysis of the T cell 
population it is clear that blocking egress of T cells severely inhibits the accumulation of T cells 
in the auLN of MC903 treated mice, so that the MC903, FTY720 mice were comparable to the 
VC, control mice. This suggests that the main mechanism of increase of number of T cells 
within the auLN is via cellular influx in an S1P dependent manner and not proliferation within 
this early innate phase. However, upon assessment of ILCs it was observed that the number 
of ILCs were comparable between MC903, control and MC903, FTY720 mice for number of 
ILCs, ILC1s ILC2s and TrN ILCs. This would suggest that blocking S1P dependent migration of 
ILCs does not affect the accumulation of ILCs within the auLN of MC903 treated mice 
suggesting their main mechanism for increased numbers is proliferation. However, this is 
different for ILC3s, in which there was a decrease in the number of ILC3s within the auLN of 
MC903, FTY720 mice which was comparable to VC, control mice. This indicates that ILC3s  
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Figure 6.10. Blocking ILC S1P dependent migration does not affect ILC expansion within the 
auLN 
WT mice were injected with either 1 mg/mL of FTY720 in H2O (FTY720) or H2O (control) i.p on 
D0-D5. On D2-D5 FTY720 injected WT mice received topical application of 4 nmol of MC903 
dissolved in absolute ethanol to the dorsal and ventral sides of the ear (MC903, FTY720) 
(n=12). Mice receiving H2O i.p injections received topical application of either MC903 (MC903, 
control) (n=12) or VC (VC, control) (n=10). Mice were culled on D6, 24 hours post final i.p and 
topical application. Cells were isolated from the auLN as described in methods.  
Each data point represents 1 auLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, ILCs are shown as a 
percentage of Live CD45
+
 cells and ILC subsets as a percentage of total ILCs. Bars on scatter 
plots represents the median, which is also shown numerically. Statistical significance was 
tested using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and F4/80. ILCs were gated on negatively for iCD3e (gating 
not shown). 
a) Schematic representation of experimental design, syringe represents FTY720/H20 
(control) i.p injections and the pipettes represent MC903/VC topical ear application. 





 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet+), ILC2s (Live CD45+ Lineage- 
IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt+), 




 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) and T cells (Live CD45+ 
CD3e+) in VC control, MC903 control and MC903 FTY720 mice. 
c) Number of T cells and ILCs in VC control, MC903 control and MC903 FTY720 mice. 
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potentially egress from tissues in an S1P dependent manner and migrate into the auLN, 
contributing to the accumulation of ILC3s in the MC903 treated mice. This eludes to individual 
ILC subsets having various different behaviouristic mechanisms. Overall, blocking S1P 
dependent egress of ILCs from tissues does not prevent the accumulation of ILCs within the 
auLN of MC903 treated mice, suggesting that proliferation is a key contributor to their 
expansion. However, there is a large range in the experimental data, limiting the conclusions 
made, suggesting further experimental approaches are required here. The mechanisms of ILC 
egress from lymphoid and non-lymphoid tissue has not been extensively reviewed, as 
discussed previously, with various S1PR needing to be further analysed, alongside FTY720 only 
partially blocking ILC migration.  
6.2.4 ILCs migrate into the ear in atopic dermatitis inflamed skin 
Immune cells are recruited to the MC903 inflamed ear, including T cells and DCs (370). T cells 
and DCs in the blood both express P-selectin glycoprotein ligand 1 which interacts with 
P- selectin and E-selectin, expressed on dermal venules (378, 379). These interactions are 
required for the egress of these cells out of dermal vessels and into inflamed skin (378, 379). 
To dynamically assess hematopoietic cell migration into the ear, Kaede Green CD45
+
 cells were 
analysed within the MC903 treated ears between D0-D2 and D2-D5 (Figure 6.11a-c). Kaede 
Green cells were observed within the ear at D2, however, numbers were comparable to VC 
treated mice. This suggests that the main recruitment of hematopoietic cells into the ear 
occurs between D2-D5 where an increase in Kaede Green CD45
+
 cells was observed. All 
populations observed an increase in number of Kaede Green cells within the ear 72 hours post 
photoconversion, suggesting an increase in migration into the ear, with again LCs having the 
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largest proportional increase, in comparison to other publications (Figure 6.11d-e). This 
suggests that alongside T cells and LCs, ILCs are recruited into the inflamed skin. 
A substantial increase in the Kaede Green CD45
+
 population was detected within the MC903 
ear, especially in comparison to the migratory Kaede Red population into the auLN, with the 
Kaede Green population making up over ~50% of CD45+ cells within the ear. As discussed, a 
caveat of the Kaede model is that rapid proliferation will cause dilution of the photoconverted 
Kaede Red protein such that the cells become Kaede Green again. Thus, a concern was that 
proliferation due to the MC903-induced inflammation was converting Kaede Red cells within 
the ear to Kaede Green and them being incorrectly defined as migratory cells. To explore the 
proliferation profile of ILCs within the MC903 model, the expression of Ki-67 was assessed on 
all ILCs within the ear. An increase in the percentage of Ki-67
+
 ILCs and all ILC subsets, except 
ILC3s, was observed consistent with enhanced ILC proliferation in the inflamed ear (Figure 
6.12a-c). To determine whether the identified Kaede Green ILCs within the ear have diluted 
out their Kaede Red expression due to proliferation, or whether they were a true migratory 
population, the expression of Ki-67 on specifically Kaede Green ILCs within the ear was 
assessed. Although there was an increase in the percentage of Kaede Green ILCs expressing 
Ki-67 in the MC903 ear compared to the VC, it was evident that the there was a clear 
population of Kaede Green ILCs within the MC903 ear that were Ki-67
-
 (Figure 6.12d-e). This 
suggests that although some tissue-resident Kaede Red ILCs are proliferating, potentially 
losing their Kaede Red expression and being identified as migratory Kaede Green ILCs, there 




Figure 6.11. Atopic dermatitis drives enhanced ILC recruitment to skin 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT Kaede mice on either D0-D1 or D0-D4, ethanol was applied alone as a 
VC. Violet light photoconversion of the ear occurred on D0 or D2 and mice were either culled 
on D2 or D5. Cells were isolated from the ear as described in methods.  
Each data point represents 1 ear from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Paired samples were statistically 
tested using an unpaired, non-parametric, Mann-Whitney two tailed T test, when comparing 
more than two sets of data statistical significance was tested using Kruskal-Wallis one-way 
ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, ***p≤0.001. When gating on ILCs 
lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, F4/80, FceRI and 
F4/80. 
a) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in VC and MC903 treated ears at D0-D2 (left) and D2-D5 (right) time points.  
b) Number of Live CD45+ Kaede Green cells in VC (n=6) and MC903 (n=7) treated ears at D0-
D2 time point. 
c) Number of Live CD45+ Kaede Green cells in VC (n=8) and MC903 (n=8) treated ears at D2-
D5 time point. 
d) Representative flow cytometry plots of Live CD45+ Kaede Green ab T cells (CD3e+ TCRgd-), 
gd T cells (CD3e+ TCRgd+), ILCs (Lineage- IL-7Ra+) and LCs (MHCII+ CD11c+ CD207+) in the 
auLN of VC (top) and MC903 (bottom) treated mice at D2-D5 time point. Each population 
is shown as a proportion of the Live CD45
+
 Kaede Green population. 
e) Number of Live CD45+ Kaede Green ab T cells, gd T cells, ILCs and LCs in VC (n=9-11) and 
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Figure 6.12. A true population of migratory ILCs enter the inflamed ear 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear on D0-D5, ethanol was applied alone as a VC. All mice were culled on D5, 72 
hours post final dose. Cells were isolated from the ear as described in methods.  
Each data point represents 1 ear from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and F4/80. Non Kaede mice ILCs were gated on negatively for 
iCD3e (gating strategy not shown). 
a) Representative flow cytometry plots showing Ki-67 expression on ILCs (Live CD45+ Lineage- 
IL-7Ra+ iCD3e-) in the ears of VC (left) and MC903 (right) treated mice.  
b) Percentage of ILCs expressing Ki-67 in the ears of VC (n=6) and MC903 (n=7) treated mice. 





 IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- IL-7Ra+ 
iCD3e- RORgt+) and TrN ILCs (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) 
expressing Ki-67 in the ears of VC (n=6-7) and MC903 (n=6-7) treated mice. 







 IL-7Ra+) in the ears of VC (left) and MC903 (right) treated mice. Ki-67- 
Kaede Green ILCs in the MC903 treated ear are highlighted in a black bold box. 
























































6.2.5 Cell migration into the ear from surrounding skin 
The data described in this chapter so far has revealed that T cells, ILCs and LCs migrate into 
the ear under MC903 induced inflammation. T cells and DCs are known to migrate into 
inflamed skin through the blood, however their primary origin is still unclear (380). Previous 
reports have shown ILCs to migrate from the draining LN to the ear, however, due to being 
unable to photoconvert the draining auLN, migration from the adjected skin was assessed, 
initially investigating migration from the opposite ear (226). The migration of T cells was 
assessed due to them being a larger and more easily identifiable migratory population 
compared to ILCs. The MC903 model was combined with the Kaede mice as before, however, 
the opposite ear to the MC903 treated ear was instead photoconverted (Figure 6.13a). This 
allowed for the tracking of cells from one uninflamed photoconverted ear to the MC903 
treated unphotoconverted ear. Upon analysis of the treated ear, very small  numbers of Kaede 
Red T cells were identified within the MC903 and VC treated ears (Figure 6.13b-d). It therefore, 
became apparent that migration of T cells from one ear to the other was minimal and likely 
not increased within inflammation. 
A potential limit of labelling the opposite ear was the small area of skin converted, and thus 
number of cells that were Kaede Red, making tracking such small migratory populations 
technically challenging over a larger distance. The area of skin between the two ears, termed 
head skin, is directly adjacent to the treated ear and therefore migration from this area was 
also assessed. MC903 treatment of Kaede mice occurred as normal but at D2 the head skin 
was shaved, photoconverted and the treated ear analysed at D5 (Figure 6.14a). Initially to 
confirm that the ear and auLN were not photoconverted during this process the ear and auLN 
were analysed at 0 hours post head photoconversion and Kaede expression assessed. All cells  
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Figure 6.13. Minimal migration of T cells occurs from the opposite ear into the inflamed ear 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the left ear (treated ear) of WT Kaede mice on D0-D4, ethanol was applied alone as a 
VC. Violet light photoconversion of the right ear (photoconverted ear) occurred on D2, and 
mice were culled on D5. Cells were isolated from the ear as described in methods.  
Each data point represents 1 ear from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001.  
a) Schematic representation of experimental design, pipette represents MC903/VC topical 
ear application, the purple light represents violet light photoconversion of the ear.  
b) Represented flow cytometry showing Kaede Green and Kaede Red expression of Live 
CD45
+
 cells and the percentage of Live CD45
+





 CD3e+) in the treated ears of VC (top) and MC903) treated mice. 
c) Percentage (left) and number (middle) of Live CD45+ Kaede Red cells in the treated ears of 
VC (n=6) and MC903 (n=6) mice. 























































































within the ear and auLN were Kaede Green, showing that they were not photoconverted 
within this process, allowing the migration of cells into the ear and auLN to be assessed (Figure 
6.14b-c). Upon analysis of the MC903 treated ear, it was observed that compared to the VC 
treated ear there was an increase in the number of Kaede Red CD45
+
 and T cells and that the 
majority of these T cells are gd T cells (Figure 6.14d-e). This suggests that cells are able to 
redistribute into the ear from adjacent skin, albeit in small numbers, with the main proportion 
of cells migrating from the skin to skin being gd T cells. To determine whether cells were 
migrating from the surrounding skin into the auLN, Kaede Red cells were analysed within the 
auLN of head skin photoconverted MC903 ear treated mice. Interestingly there was an 
increase in the number of Kaede Red CD45
+
 and T cells migrating from the head skin to the 
auLN. With a 37-fold increase in Kaede Red gd T cells and a 7-fold increase in ab T cells (Figure 
6.14f-g). This suggests that the increase in cells within the auLN of MC903 treated mice is also 
contributed to by the migration of cells from skin adjacent to the ear, potentially due to the 
spread of MC903 by the mouse via grooming.  
6.2.6 ILC migration is dependent on inflammatory conditions 
ILC migration from the ear to the auLN and into the ear from the periphery was recorded 
within the MC903 inflammatory model. To determine whether this migration was specific to 
the MC903 model, or whether another inflammatory model could induce ILC migration the 
Aldara driven psoriasis-like model was established. Aldara cream contains 5% IQM which upon 
topical application to the skin activates the immune system, via TLR7 and TLR8, driving an 
IL- 17/IL-23 response in a multi mechanistic manner (381, 382). Aldara driven psoriasis is 
defined by an increase in hematopoietic cell recruitment, such as T cells, DCs, macrophages  
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Figure 6.14. Migration from adjacent skin to inflamed ear is limited in atopic dermatitis 
model 
4 nmol of MC903 dissolved in absolute ethanol was topically applied to the dorsal and ventral 
sides of the ear of WT Kaede mice on D0-D4, ethanol was applied alone as a VC. Violet light 
photoconversion of the skin between the ears (head skin) occurred on D2, and mice were 
culled on D5. Cells were isolated from the ear and auLN as described in methods.  
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled 1 experiment. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, 
F4/80, FceRI and F4/80.  
a) Schematic representation of experimental design, pipette represents MC903/VC topical 
ear application, the purple light represents violet light photoconversion of the head skin.  
b) Represented flow cytometry showing Kaede Green and Kaede Red expression of Live 
CD45
+
 cells in the ear and auLN 0 hours post violet light conversion of the head skin.  
c) Percentage of Live CD45+ Kaede Green cells in the ear (n=6) and auLN (n=10) 0 hours post 
violet light conversion of the head skin. 
d) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells and the percentage of Live CD45
+





 CD3e+), ab T cells (Live CD45+ KR+ CD3e+ bTCR+ gdTCR-) and gd T cells (Live CD45+ 
KR
+
 CD3e+ bTCR- gdTCR+) within the ears of VC (top) and MC903 (bottom) mice.  
e) Number of Kaede Red Live CD45+, T cells, ab T cells and gd T cells in VC (n=6) and MC903 
(n=8) treated ears. 
f) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells and the percentage of Live CD45
+
 Kaede Red cells which are T cells, ab T 
cells and gd T cells within the auLN of VC (top) and MC903 (bottom) mice.  
g) Number of Kaede Red Live CD45+, T cells, ab T cells and gd T cells in VC (n=6) and MC903 
(n=8) treated auLN. 
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and neutrophils, into the inflamed skin alongside an increase in the proliferation of 
keratinocytes (381, 382). Upon application of Aldara, keratinocyte cell death is immediately 
triggered, resulting in the release of IL-1a, which in turn promotes keratinocyte proliferation 
as well as the recruitment of neutrophils (383, 384). Through the TLR7 and TLR8, IQM induces 
IL-23 production via dermal myeloid cells in turn stimulating gd T cells proliferation and 
production of IL-17 and IL-22 (232, 233, 383). These cytokines are important in driving this 
immune response due to mice deficient in IL-23, IL-22 or IL-17 receptor have a reduction in 
the development of Aldara driven psoriasis (381, 384). Amongst gd T cells production of IL-17 
and IL-22, ILC3s have also been observed to contribute to the production of these cytokines 
in psoriasis via IL-23 stimulation (233). Furthermore, LCs migration from the skin to draining 
LN, similar to the MC903 driven AD model, has also been recorded within the Aldara model 
(381, 383, 385). Similar to the AD model Aldara treatment increases the skin inflammation and 
migration into the LN, however, Aldara treatment drives a type-17 response with the 
involvement of IL-17 and IL-22 producing ILC3s, compared to the type-2 ILC2 driven MC903 
model (112, 231, 233, 381). To establish the psoriasis model, 15 mg of Aldara cream was 
topically applied to the dorsal and ventral side of the ear for 5 consecutive days (381). Due to 
not having access to Aldara cream without IQM the controls had nothing applied to their ears. 
Although a decrease was observed in ILC percentage, similar to the MC903 model, there was 
an increase in the number or CD45
+
 cells and ILCs within the auLN (Figure 6.15a-c). 
Interestingly, although ILC3s are involved in the contribution of IL-17 and IL-22 in the Aldara 
model it was observed that all the ILC subsets are increased in number within the Aldara 
treated auLN, apart from ILC3s (233). However, ILC3s were reported to be present within the 




Figure 6.15. Aldara induced psoriasis stimulates an inflammatory response within the auLN 
30 mg of Aldara cream was topically applied evenly to the dorsal and ventral sides of the ear 
on D0-D4, as a control no Aldara was applied (control). Mice were culled on D5, 24 hours post 
final dose. Cells were isolated from the auLN as described in methods.  
Each data point represents 1 auLN from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. ILCs were gated on negatively for iCD3e (gating strategy not shown). 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ Lineage- 





 IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- 
IL- 7Ra+ iCD3e- RORgt+) and TrN cells (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- 
T- bet
-
) in the auLNs of control (top) and Aldara (bottom) treated mice. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets in the auLNs of control (n=6) and Aldara 
(n=8) treated mice.  
c) Number (bottom) of Live CD45+ cells, ILCs and ILC subsets in the auLNs of control (n=6) 

































































































































 similar to the MC903 model, Aldara application elicits an increase in auLN cellularity 
suggesting migration from the ear to the auLN. 
Leukocyte recruitment, including ILC3s, into the inflamed skin is a hallmark of Aldara driven 
psoriasis (233, 381). Therefore, ILC subgroups were assessed within the ears of Aldara treated 
mice. Within the ear there was an increase in the percentage and number of CD45
+
 cells with 
the Aldara treated mice, accompanied by a decrease in ILC percentage but increase in ILC 
numbers (Figure 6.16a-c). Through analysis of the ILC subsets, it was clear that the TrN ILC 
population was the only subset to increase within the Aldara treated ear. This may actually 
reflect an increase in ILC2s or ILC1s that have down regulated their GATA-3 and T-bet 
expression due to cell preparation methods, as discussed previously. Interestingly there was 
no change between the control and Aldara treated mice in the number of ILC3s, with a 
decrease being observed within the ILC3 percentages. This may be due to previous studies 
examining ILC3 involvement in psoriasis being conducted in the back skin, rather than the ear, 
where ILC3s are more numerous (233). Due to the different composition of the back skin it is 
more likely it has more ILC3s, suggesting why the results may vary within the ear (229, 233).  
These data show that different locations of skin inflammation may result in a varied response. 
Although the Aldara model established did not seem to elicit an ILC3 driven response, an 
increase in ILCs was observed within the auLN and the ear, suggesting that the Aldara model 
is another inflammation model that can be used to assess migration. 
Previous publications assessing the role of ILC3s within the Aldara model studied the response 
within the back skin (233). However, due to the Kaede model being established to assess 
migration between the ear and the auLN, although the observed response within the ear was  
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Figure 6.16. Aldara induced psoriasis stimulates an inflammatory response within the ear 
30 mg of Aldara cream was topically applied evenly to the dorsal and ventral sides of the ear 
on D0-D4, as a control no Aldara was applied (control). Mice were culled on D5, 24 hours post 
final dose. Cells were isolated from the ears as described in methods.  
Each data point represents 1 ear from one mouse. Data pooled from a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. ILCs were gated on negatively for iCD3e (gating strategy not shown). 
a) Representative flow cytometry plots showing Live CD45+ cells, ILCs (Live CD45+ Lineage- 





 IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- 
IL- 7Ra+ iCD3e- RORgt+) and TrN cells (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- 
T- bet
-
) in the ears of control (top) and Aldara (bottom) treated mice. 
b) Percentage of Live CD45+ cells, ILCs and ILC subsets in the ears of control (n=6) and Aldara 
(n=8) treated mice. 
c) Number of Live CD45+ cells, ILCs and ILC subsets in the ears of control (n=6) and Aldara 

































































































































not as expected the migration of ILCs was still assessed between the ear and auLN. To 
determine whether all cells within the ear could be fully photoconverted from Kaede Green 
to Kaede Red during Aldara application, ears were photoconverted and analysed immediately 
after no application of Aldara or 2 days post Aldara application. Compared to control mice, it 
was observed that the 2 day Aldara treated ears had equivalent levels of photoconversion 
(Figure 6.17a-b). Therefore, the migration of cells within the Aldara model from the ear to 
auLN and into the ear could be assessed. To this end the Aldara model was combined with the 
Kaede mice and migration assessed from D2 to D5. Similar to the MC903 model, there was an 
increase in the number of Kaede Red CD45
+
 cells migrating from the ear to the auLN (Figure 
6.17c-d). However, minimal ILC migration was observed, with the Kaede Red ILCs being 
comparable between the control and Aldara mice (Figure 6.17e-f). This suggests that ILC 
migration from the ear to the auLN is dependent on the type of immune response. Within the 
ear a large increase in the number of Kaede Green CD45
+
 cells within Aldara treated mice 
compared to control mice was observed alongside an increase in the number of Kaede Green 
migratory ILCs (Figure 6.17g-j). These data further support the ability of ILCs to migrate into 
inflamed skin, as migration occurs in both the MC903 and the Aldara models. However, 
migration of ILCs from the ear to the draining auLN seem to be dependent on the specific 
immune response.  
6.2.7 ILC homeostasis is perturbed in Ccr6-/- mice 
To further elucidate the migratory abilities of ILCs, the mechanisms important in the retention 
or movement of such cells was investigated. Under inflammatory skin conditions, including 
AD and psoriasis, epidermal keratinocytes can increase their production of CCL20 resulting in 
the recruitment of CCR6 expressing cells to the skin, mainly memory and effector T cells  
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Figure 6.17. ILCs migrate into the inflamed skin of Aldara treated mice 
30 mg of Aldara cream was evenly topically applied to the dorsal and ventral sides of the ear 
on D0-D4, as a control no Aldara was applied (control). Violet light photoconversion of the ear 
occurred on D2 and mice were culled on D5, 24 hours post final dose. Cells were isolated from 
the ear and auLN as described in methods.  
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, 
***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, 
CD19, Ter119, Gr1, F4/80, FceRI and F4/80.  
a) Representative flow cytometry plots of Kaede Green and Kaede Red expression of Live 
CD45
+
 cells 0 hours post violet light photoconversion on untreated ears (control) (left) and 
D2 of Aldara treated ears (Aldara) (right). 
b) Percentage of Kaede Red Live CD45+ cells 0 hours post violet light photoconversion on 
untreated ears (control) (n=10) and D2 of MC903 treated ears (Aldara) (n=10).  
c) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in the control (left) and Aldara (right) auLN.  
d) Number of Live CD45+ Kaede Red cells in the control (n=6) and Aldara (n=9) auLN. 
e) Representative flow cytometry plots showing Kaede Red ILCs (Live CD45+ KR+ Lineage- 
IL- 7Ra+) in the control (left) and Aldara (right) auLN.  
f) Number of Kaede Red ILCs in the control (n=6) and Aldara (n=9) auLN. 
g) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in the control (left) and Aldara (right) ears.  
h) Number of Live CD45+ Kaede Green cells in the control (n=7) and Aldara (n=9) ears. 
i) Representative flow cytometry plots showing Kaede Green ILCs (Live CD45+ KG+ Lineage- 
IL-7Ra+) in the control (left) and Aldara (right) ears.  
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alongside immature DCs, including LC precursors (386-388). CCL20 is also expressed in the 
subcapsular sinus of the mLN and PP and is important in the localisation of DCs within the LN 
(389, 390). It was therefore hypothesised that ILC migration into the inflamed ear skin was 
dependent upon CCR6:CCL20 interactions. Notably, within the auLN and ear it was observed 
that a significant proportion of all ILC subsets expressed CCR6, in comparison to other tissues, 
such as the mLN where only ILC3s expressed CCR6 (Figure 6.18a-d). These data support the 
contention that ILCs migrate into the inflamed skin in a CCL20-dependent manner. 
To investigate the biological function of CCR6 on ILCs in vivo the ears and auLN of Ccr6-/- mice 
were compared to WT mice under steady state conditions. Within the auLN, albeit a decrease 
in the percentage of CD45+ cells, the number of CD45+ cells and ILCs was comparable between 
WT and Ccr6-/- mice (Figure 6.19a-c). Interestingly, a decrease in the percentage and number 
of ILC1s and ILC2s was observed, alongside an increase in TrN ILCs. This indicates that the 
homeostasis of ILCs might be dependent on CCR6 within the auLN. Within the ear, there was 
an increase in the percentage of CD45+ cells, however, the numbers were comparable 
between mice (Figure 6.20a-c). Furthermore, the proportion and number of ILCs and the 
individual subsets were comparable between WT and Ccr6-/- mice, with a modest increase in 
percentage of ILC2s within Ccr6-/- mice. These results interestingly suggest a dependency on 
CCR6 for normal ILC homeostasis in the auLN, however not within the ear.  
Comparisons between WT and Ccr6-/- mice suggested a role for CCR6 in the normal 
distribution of ILCs within the auLN, but not the ear. Interestingly, perturbations of ILC 
populations observed within the auLN might suggest a defect in the migration of ILCs from the 
ear to the draining LN, however it was already established that within these studies ILC  
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Figure 6.18. CCR6 is expressed on all ILC subsets within the ear and auLN 
Cells were isolated from the ear, auLN and mLN of WT and Ccr6-/- mice as described in 
methods. 
Each data point represents 1 ear, 1 auLN and 1 mLN from one mouse. Data pooled from a 
minimum of 2 experiments. Values on flow cytometry plots represent percentages, bars on 
scatter plots represents the median, which is also shown numerically. Statistical significance 
was tested using an unpaired, non-parametric, Mann-Whitney two tailed T test: *p≤0.05, 
**p≤0.01, ***p≤0.001. When gating on ILCs lineage markers include; B220, CD11c, CD11b, 
CD3, CD5, CD19, Ter119, CD123, Gr1, F4/80, FceRI and F4/80. ILCs were gated on negatively 
for iCD3e. 
a) Representative flow cytometry plots showing CCR6 expression on ILC1s (Live CD45+ 
Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet+), ILC2s (Live CD45+ Lineage- IL-7Ra+ iCD3e- 
RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt+) and TrN ILCs (Live 
CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) in the ear of WT mice and Ccr6-/- mice 
(far right) as a gating control. 
b) Representative flow cytometry plots showing CCR6 expression on ILC1s, ILC2s, ILC3s and 
TrN ILCs in the auLN of WT mice and Ccr6-/- mice (far right) as a gating control. 
c) Representative flow cytometry plots showing CCR6 expression on ILC1s, ILC2s, ILC3s and 
TrN ILCs in the mLN of WT mice. 
d) Percentage of CCR6+ ILC1s, ILC2s, ILC3s and TrN ILCs in the ear (n=7) (left), auLN (n=7) 
(middle) and mLN (n=8) (right). 
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Figure 6.19. ILC1s and ILC2s are deficient in auLN of Ccr6-/- mice 
Tissues from WT mice were compared to Ccr6-/- mice. Cells were isolated from the auLN as 
described in methods. 
Each data point represents 1 auLN from one mouse. Data pooled a minimum of 2 experiments. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, CD123, 
Gr1, F4/80, FceRI and F4/80. ILCs were gated on negatively for iCD3e (gating not shown). 
a) Representative flow cytometry plots showing Live CD45+ cells ILCs (Live CD45+ Lineage- 





 IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- 
IL- 7Ra+ iCD3e- RORgt+) and TrN cells (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- 
T- bet
-
) in the auLN of WT (top) and Ccr6-/- (bottom) mice.  
b) Percentage of Live CD45+ cells, ILCs and ILC subsets in the auLN of WT (n=11) and Ccr6-/- 
(n=12) mice.  
c) Number of Live CD45+ cells, ILCs and ILC subsets in the auLN of WT (n=11) and Ccr6-/- (n=12) 
mice. Due to the range of numbers within the data it is presented on a logarithmic scale 
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Figure 6.20. ILCs are unchanged within ears of Ccr6-/- mice 
Tissues from WT mice were compared to Ccr6-/- mice. Cells were isolated from the ear as 
described in methods. 
Each data point represents 1 ear from one mouse. Data pooled a minimum of 2 experiments. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, CD123, 
Gr1, F4/80, FceRI and F4/80. ILCs were gated on negatively for iCD3e (gating strategy not 
shown). 
a) Representative flow cytometry plots showing Live CD45+ cells ILCs (Live CD45+ Lineage- 





 IL-7Ra+ iCD3e- RORgt- GATA-3+ T-bet-), ILC3s (Live CD45+ Lineage- 
IL- 7Ra+ iCD3e- RORgt+) and TrN cells (Live CD45+ Lineage- IL-7Ra+ iCD3e- RORgt- GATA-3- 
T- bet
-
) in the ears of WT (top) and Ccr6-/- (bottom) mice.  
b) Percentage of Live CD45+ cells, ILCs and ILC subsets in the ears of WT (n=12) and Ccr6-/- 
(n=12) mice. 






































































































































WT   Ccr6-/- WT  Ccr6-/- WT  Ccr6-/- WT  Ccr6-/- WT  Ccr6-/- 
WT   Ccr6-/- WT  Ccr6-/- WT  Ccr6-/- WT  Ccr6-/- WT  Ccr6-/- 
WT   Ccr6-/- 
WT   Ccr6-/- 
 197	
migration from the ear to auLN under steady state conditions was minimal. Therefore, to 
determine whether this perturbation in ILCs was important in the development of MC903 AD-
like inflammation, the response to MC903 was compared between WT and Ccr6-/- mice. In 
accordance with previous results an increase in the thickening of the ear was observed 
between WT VC and MC903 treated ears (Figure 6.21a). A similar observation was seen within 
the Ccr6-/- VC and MC903 treated mice, with the WT VC and CCR6 VC alongside the WT MC903 
and Ccr6-/- MC903 mice being comparable (Figure 6.21a). Confirming the establishment of the 
MC903 model, an increase in CD45
+
 cell number within the auLN alongside number and 
percentage within the ear was observed between WT VC and MC903 treated mice (Figure 
6.21b-e). Within the auLN the Ccr6-/- VC and MC903 treated mice respond similarly to WT 
mice, with Ccr6-/- MC903 mice having an increased CD45+ population comparable with WT 
MC903 treated auLN (Figure 6.21b-c). This suggests that the Ccr6-/- auLN is able to amount an 
equivalent response to WT mice upon MC903 treatment. The ears of Ccr6-/- MC903 mice had 
a comparable number of CD45
+
 cells to CCR6 VC treated mice (Figure 6.21d-e). However, WT 
MC903 and Ccr6-/- MC903 mice were comparable, alongside WT VC and Ccr6-/- VC mice (Figure 
6.21d). This suggests that there are perturbations in the immune response within the ear of 
Ccr6-/- mice, which were not observed in naïve Ccr6-/- mice. However, it is difficult to make 
clear conclusions from these data. Due to the complex nature of making multiple comparisons 
simultaneously and the basic question focusing on the difference in immune responses 
between WT and Ccr6-/- mice the data presented hereafter compares WT MC903 mice and 
Ccr6-/- MC903 mice only in order to clearly emphasise the key findings.  
Upon MC903 induced inflammation, the cellularity of the auLN increases in a similar manner 
to WT mice. In comparison, the ear had a defect in cell expansion. Due to the reduced  
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Figure 6.21. Ccr6-/- mice are unable to elicit a comparable inflammatory response in the ear 
compared to WT mice 
Tissues from WT mice were compared to Ccr6-/- mice. 4 nmol of MC903 dissolved in absolute 
ethanol was topically applied to the dorsal and ventral sides of the ear on D0-D4 (WT MC903 
and Ccr6-/- MC903), ethanol was applied alone as a VC (WT VC, Ccr6-/- VC). Mice were culled 
on D5, 24 hours post final dose. Cells were isolated from the ear and auLN as described in 
methods. 
Each data point represents 1 ear and 1 auLN from one mouse. Data pooled a minimum of 2 
experiments. Values on flow cytometry plots represent percentages, bars on scatter plots 
represents the median, which is also shown numerically. Statistical significance was tested 
using Kruskal-Wallis one-way ANOVA with post hoc Dunn’s test: *p≤0.05, **p≤0.01, 
***p≤0.001.  
a) Thickness of the ears of WT VC (n=15), WT MC903 (n=12), Ccr6-/- VC (n=8) and Ccr6-/- 
MC903 (n=10) treated mice. 
b) Representative flow cytometry plots showing Live CD45+ cells in the auLN of WT (left) or 
Ccr6-/- (right) mice with VC or MC903 treatment. 
c) Percentage (left) and number (right) of Live CD45+ cells in the auLN of WT VC (n=7), WT 
MC903 (n=14), Ccr6-/- VC (n=8) and Ccr6-/- MC903 (n=10) treated mice. 
d) Representative flow cytometry plots showing Live CD45+ cells in the ear of WT (left) or 
Ccr6-/- (right) mice with VC or MC903 treatment. 
e) Percentage (left) and number (right) of Live CD45+ cells in the ears of WT VC (n=7), WT 
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cellularity of ILC1s and ILC2s within the naïve Ccr6-/- auLN, ILC subgroups were further assessed 
in the MC903 treated mice. Within the auLN, a decrease in the number of ILCs was observed 
in the Ccr6-/- MC903 treated mice. This was due to a decrease in ILC2s which was reflected in 
percentage and number (Figure 6.22a-c). This suggests that upon MC903 treatment the 
expansion of ILC2s within the auLN is limited. Focusing within the ear, albeit the percentages 
of ILCs being comparable between mice, there was a decrease in the number of ILCs within 
the Ccr6-/- treated ear, which is comprised of a decrease in ILC2s, ILC3s and TrN ILCs (Figure 
6.23a-c). ILC2s are important in the development of MC903 and as described previously, 
studies conducted by Kim et al., (2013) have shown that a depletion in ILC2s reduces AD in 
mice. Therefore, this reduction in ILC2 accumulation within the ear of Ccr6-/- MC903 treated 
suggests that CCR6 is potentially important in the recruitment of ILC2s and therefore the 
development of AD.  
6.2.8 ILCs migrate into the inflamed ear in a CCR6 dependent manner 
CCR6:CCL20 interactions are important in the recruitment of T cells and DCs into the ear under 
inflammatory conditions (386). Furthermore, CCR6 has been shown to be important in the 
localisation and migration of cells under inflammatory conditions into draining LNs (389, 390). 
Therefore, the reduction in ILCs within the ear and auLN observed within Ccr6-/- MC903 
treated mice, compared to WT MC903 treated mice may be due to a reduction in their 
migration in the absence of CCR6:CCL20 interactions. To address this the MC903 model was 
combined with WT Kaede and Ccr6-/- Kaede mice and cell migration analysed between D2 and 
D5. Upon assessment of the auLN, the number of Kaede Red CD45
+
 cells, ILCs and T cells 
migrating from the ear to draining auLN was comparable between the WT Kaede and Ccr6-/- 
Kaede MC903 treated mice (Figure 6.24a-f). However, within the time frame assessed, there 
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Figure 6.22. Ccr6-/- The expansion of ILC2s within the auLN of MC903 treated mice is CCR6 
dependent 
Tissues from WT mice were compared to Ccr6-/- mice. 4 nmol of MC903 dissolved in absolute 
ethanol was topically applied to the dorsal and ventral sides of the ear on D0-D4 (WT MC903, 
Ccr6-/- MC903). Mice were culled on D5, 24 hours post final dose. Cells were isolated from the 
auLN as described in methods. 
Each data point represents 1 auLN from one mouse. Data pooled a minimum of 2 experiments. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, CD123, 
Gr1, F4/80, FceRI and F4/80. ILCs were gated on negatively for iCD3e. 
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 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) in the auLN of WT 
(top) and Ccr6-/- (bottom) MC903 treated mice.  
b) Percentage of ILCs, ILC1s, ILC2s, ILC3s and TrN cells in the auLN of WT (n=14) and Ccr6-/- 
(n=10) MC903 treated mice. 
c) Number of ILCs, ILC1s, ILC2s, ILC3s and TrN cells in the auLN of WT (n=14) and Ccr6-/- (n=10) 
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Figure 6.23. The expansion of ILC2s within the ear of MC903 treated mice is CCR6 dependent 
Tissues from WT mice were compared to Ccr6-/- mice. 4 nmol of MC903 dissolved in absolute 
ethanol was topically applied to the dorsal and ventral sides of the ear on D0-D4 (WT MC903, 
Ccr6-/- MC903). Mice were culled on D5, 24 hours post final dose. Cells were isolated from the 
ear as described in methods. 
Each data point represents 1 ear from one mouse. Data pooled a minimum of 2 experiments. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, CD123, 
Gr1, F4/80, FceRI and F4/80. ILCs were gated on negatively for iCD3e (gating strategy not 
shown). 
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 IL-7Ra+ iCD3e- RORgt- GATA-3- T-bet-) in the ears of WT 
(top) and Ccr6-/- (bottom) MC903 treated mice.  
b) Percentage (of ILCs, ILC1s, ILC2s, ILC3s and TrN cells in the ears of WT (n=14) and Ccr6-/- 
(n=10) MC903 treated mice. 
c) Number of ILCs, ILC1s, ILC2s, ILC3s and TrN cells in the ears of WT (n=14) and Ccr6-/- (n=10) 
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Figure 6.24. ILCs migrate from the inflamed skin into the draining LN independently of CCR6 
Tissues from WT Kaede mice were compared to Ccr6-/- Kaede mice. 4 nmol of MC903 dissolved 
in absolute ethanol was topically applied to the dorsal and ventral sides of the ear on D0-D4 
(WT MC903, Ccr6-/- MC903). Photoconversion of the ear occurred on D2 and mice were culled 
on D5. Cells were isolated from the ear and auLN as described in methods.  
Each data point represents 1 auLN from one mouse. Data pooled a minimum of 2 experiments. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, 
F4/80, FceRI and F4/80. Populations were previously gated on Live CD45+ cells, then identified 
as Kaede Red, before being identified as a T cell (CD3e+) or ILC (Lineage- IL-7Ra+). 
a) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in the auLN of WT (left) and Ccr6-/- (right) MC903 treated mice.  
b) Number of Live CD45+ Kaede Red cells in auLN of WT (n=10) and Ccr6-/- (n=9) MC903 
treated mice. 
c) Representative flow cytometry plots showing Kaede Red ILCs in the auLN of WT (left) and 
Ccr6-/- (right) MC903 treated mice.  
d) Number of Kaede Red ILCs in auLN of WT (n=10) and Ccr6-/- (n=9) MC903 treated mice. 
e) Representative flow cytometry plots showing Kaede Red T cells in the auLN of WT (left) 
and Ccr6-/- (right) MC903 treated mice.  
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 was a decrease in the number of Kaede Green CD45
+
 cells within the ear of the Ccr6-/- Kaede 
mice compared to the WT Kaede mice and this was similar in the numbers of Kaede Green 
ILCs (Figure 6.25a-d). Kaede Green T cells, on the other hand, within the ear were comparable 
in numbers between the two mice (Figure 6.25e-f). This would suggest that ILC recruitment 
into the MC903 inflamed ear is dependent on CCR6:CCL20 interactions, however these are 
not required for the migration from the ear into the draining LN. 
Overall these data have shown that ILCs are able to migrate via the draining lymphatics from 
the ear skin into the draining auLN under inflammatory conditions. Furthermore, ILCs are 




Figure 6.25. The migration of ILCs into inflamed skin is dependent on CCR6 
Tissues from WT Kaede mice were compared to Ccr6-/- Kaede mice. 4 nmol of MC903 dissolved 
in absolute ethanol was topically applied to the dorsal and ventral sides of the ear on D0-D4 
(WT MC903, Ccr6-/- MC903). Photoconversion of the ear occurred on D2 and mice were culled 
on D5. Cells were isolated from the ear and auLN as described in methods.  
Each data point represents 1 ear from one mouse. Data pooled a minimum of 2 experiments. 
Values on flow cytometry plots represent percentages, bars on scatter plots represents the 
median, which is also shown numerically. Statistical significance was tested using an unpaired, 
non-parametric, Mann-Whitney two tailed T test: *p≤0.05, **p≤0.01, ***p≤0.001. When 
gating on ILCs lineage markers include; B220, CD11c, CD11b, CD3, CD5, CD19, Ter119, Gr1, 
F4/80, FceRI and F4/80. Populations were previously gated on Live CD45+ cells, then identified 
as Kaede Green, before being identified as a T cell (CD3e+) or ILC (Lineage- IL-7Ra+). 
a) Representative flow cytometry plots showing Kaede Green and Kaede Red expression of 
Live CD45
+
 cells in the ear of WT (left) and Ccr6-/- (right) MC903 treated mice.  
b) Number of Live CD45+ Kaede Green cells in the ear of WT (n=8) and Ccr6-/- (n=9) MC903 
treated mice. 
c) Representative flow cytometry plots showing Kaede Green ILCs in the ear of WT (left) and 
Ccr6-/- (right) MC903 treated mice.  
d) Number of Kaede Green ILCs in the ear of WT (n=8) and Ccr6-/- (n=9) MC903 treated mice. 
e) Representative flow cytometry plots showing Kaede Green T cells in the ear of WT (left) 
and Ccr6-/- (right) MC903 treated mice.  
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6.3 SUMMARY 
In this chapter Kaede mice were used to dissect the migration of ILCs and other immune 
populations between the ear and its draining LN. Under steady state, migration of ILCs from 
the ear to the draining LN is undetectable in comparison to T cells and LCs, however a clear 
but modest ILC population can be identified moving into the ear. To determine whether ILC 
migration was affected under inflammatory conditions, skin inflammation models were 
established resulting in an increased number of ILCs within the draining auLN and were 
therefore useful in the assessment of ILC migration. The number of ILCs tracked migrating 
from the ear to the auLN were significant but not equivalent to the increase in numbers 
observed within the auLN. Therefore, proliferation of ILCs was assessed and it was concluded 
to be an important factor in the increase of ILCs within the auLN. Alongside proliferation, 
blocking S1P dependent migration of ILCs suggested that ILCs S1P dependent tissue egress 
was important in contributing to increase in numbers of ILC3s within the auLN. Upon assessing 
Kaede Green cells within the inflamed ear, it was determined that ILCs were also able to 
migrate into the inflamed skin, from the periphery. After exploring the migratory properties 
of ILCs, the mechanism of migration was also studied. Through the use of Ccr6-/- and Ccr6-/- 
Kaede mice it was discovered that the increase in ILC numbers under skin inflammation within 
the ear and auLN was dependent on CCR6 expression. However, only ILC migration into the 
ear was directly dependent on CCR6. In summary, the data presented here shows that under 
skin inflammation ILCs are able to migrate from the ear into the auLN, alongside ILC 
proliferation and accumulation from the periphery contributing to the increase in ILCs within 
the auLN. Furthermore, ILC migration into inflamed skin occurs in a CCR6 dependent manner, 
unlike ILC migration into the auLN. 
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Direct assessment of migration in vivo through photoconversion of the whole ear from Kaede 
Green to Kaede Red formed the basis of these experiments, enabling the migratory kinetics 
of ILCs within the skin and draining LN to be assessed. Based on previous reports by Strid et 
al., assessment of IL-13 production by T cells 2 hours post violet light exposure concluded that 
the method of photoconversion had not elicited immediate damage to the ear (340). 
Therefore, migration could be assessed under steady state conditions. However, studies 
conducted by Strid et al., analysed IL-13 mRNA rather than protein expression (340). 
Therefore, it is possible that exposure to violet light has resulted in undetected damage. 
Further hallmarks of violet light skin damage, that could have been assessed, include 
epidermal hyperplasia, thickening of the stratum corneum and keratinocyte proliferation 
(363). Despite not exploring these specific effects, upon comparing migration between the 
‘steady state’ and MC903 model, which causes overt damage to the skin, a much larger 
migration of hematopoietic cells was detected in the damage model. This suggests that the 
lack of overt migration in the ‘steady state’ model is consistent with minimal damage due to 
the lack of a substantial recruitment of cells one might expect with skin damage. 
The inflammatory response elicited by the MC903 model within the ear and draining auLN 
resulted in an increased migration of ILCs from the ear to the auLN. As discussed, it was clear 
that the migration of ILCs from the ear was not the sole contributing factor to the large 
increase in ILC numbers within the auLN of MC903 treated mice. ILC proliferation was also 
shown to contribute to the expansion of ILCs within the auLN, via increased levels of Ki-67 
expression. However, this is one method of identifying proliferating cells and further 
experiments such as using in vivo bromodeoxyuridine (BRDU) incorporation would need to be 
conducted to support these findings. As shown, ILC proliferation within the auLN increases 
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within the MC903 model, however, these data do not define which population of ILCs are 
proliferating. ILCs could potentially migrate into the auLN from the ear and then undergo 
proliferation. DCs traffic to the draining LN to stimulate the maturation and proliferation of 
effector Th2 cells within the MC903 model, it is therefore possible they interact with ILCs 
stimulating their proliferation, however ILCs may also respond to soluble factors arriving 
within the LN or produced from other cells (391). If Kaede Red migratory ILCs, entering the 
auLN from the ear, underwent rapid proliferation within the LN they would lose their Kaede 
Red expression and be identified as Kaede Green. Therefore, it is possible that ILC migration 
is underestimated within these data. ILC migration is only assessed within these experiments 
from the inflamed ear to the draining auLN, however, it was clear that after MC903 
application, grooming lead to the spreading of MC903 to both ears and to the head. The 
observation of a Kaede Red hematopoietic population migrating from the head skin to the 
auLN shows that other regions of inflamed skin also drain to the auLN contributing to the 
expansion of hematopoietic cells in the auLN. If only the ear was photoconverted then 
migration from other areas of skin wouldn’t be detected, indicating ILC migration from the 
skin was underestimated. To combat this, upon ear MC903 application, the ear and the head 
skin could be photoconverted simultaneously to visualise ILC migration to the auLN from a 
larger area of skin.  
ILC3 accumulation within the MC903 treated auLN was decreased under S1P dependent 
egress block. This suggest that ILC3s are able to egress from tissues, including peripheral LNs, 
and travel through the blood and accumulate within the inflamed auLN. No affects were 
observed on any other ILC population, indicating that ILCs main mechanism for expansion 
within the MC903 treated auLN is via proliferation. However, FTY720, as previously discussed, 
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does not block all S1PRs. Within the bLN experiments it was clear that not all ILC migration 
had been prevented by FTY720 administration, with the presence of Kaede Green ILCs 
migrating into the bLN, suggesting that within these experiments all ILC migration may not be 
blocked under FTY720 administration. Further experiments with the administration of 
substances that block all S1P receptors would be useful in determining whether ILCs migrate 
into and accumulate within the inflamed auLN.  
Within this investigation ILCs are observed to migrate into the ear and from the ear to the 
auLN under inflammatory conditions of AD, however, what functions or roles do these 
migratory ILCs have? Kim et al., reports that in AD ears ILC2s produce IL-5 and IL-13 
contributing to type 2 inflammation within the skin (112). However, the reason for increased 
ILC migration into auLN is less understood. ILCs may potentially become activated within the 
LN and contribute to cytokine production or provide survival signals to T cells, potentially 
skewing their differentiation, as previously discussed. ILCs may also provide survival signals 
for themselves, for example ICOS:ICOSL interactions between ILC2s supports ILC2 survival and 
cytokine production within the lung (262). Furthermore, MHCII expressing ILC2s and ILC3s are 
able to process and present antigen, suggesting that ILCs may have a role in the transportation 
of antigen from skin to draining LN and activation of naïve T cells, similar to DCs (163, 164). 
However, the understanding of in vivo ILC antigen uptake is limited and robust experiments 
would be needed to further test this. 
Migration into the ear under MC903 induced inflammation partly originated from adjacent 
skin, including the head skin. However, this contribution is very small and mainly just consists 
of gd T cells. Effector and memory T cells are known to recirculate through the lymphatics and 
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the blood to lymphoid and non-lymphoid tissue (35, 392). It is therefore possible that the 
influx of T cells may originate from other LNs. Similar to T cells, ILCs egress from the LN and 
have the ability to recirculate to contralateral draining LNs. Therefore, ILCs may be able to exit 
the LN and recirculate into non-lymphoid tissue, suggesting that peripheral LNs may be a 
source of migratory ILCs entering the ear. Interestingly ILCs have been shown to migrate from 
skin draining LNs into the skin upon activation and CCR10 upregulation (226). It would 
therefore be interesting to assess ILC migration from the auLN to the ear, however, due to the 
location of the auLN near the throat, the surgical procedure required to expose the LN for 
photoconversion would be too hazardous for the mouse. A method where surgery was not 
required could be developed with the correct light source photoconverting the auLN through 
the skin. Furthermore, upon inflammation within the skin, immature LCs are recruited from 
the BM to replace LCs that have migrated to the draining LN, suggesting another potential 
mechanism of ILC entry into the ear (387). With experiments conducted using a BM chimera 
with allotype marked BM and sublethal irradiation, the question could be asked whether the 
populations in the skin and auLN contained anything from the new BM, suggesting migration. 
ILC migration was assessed as a whole population when analysing migration between the ear 
and auLN. Within the bLN, cell surface markers were used to identify the individual ILC 
subgroups migrating within the Kaede mice. Unfortunately, identification of ILCs without the 
use of TFs was unable to be established within the ear, partly due to the ear digestion process 
effecting surface protein expression, and therefore tracking of ILC subsets from the ear to 
auLN was not possible. It would have been interesting to determine whether the migratory 
properties of ILC2s were different within the inflamed ear skin, compared to the bLN. In the 
peripheral LNs ILC2s were identified as a mainly tissue-resident population, however, the 
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MC903 model drives type-2 inflammation and the recruitment of ILC2s, potentially meaning 
under inflammatory conditions ILC2s may be able to migrate. This was supported by Huang et 
al., who observed minimal migration of ILC2s within the steady state, however, upon IL-25 
stimulation or helminth infection a clear migratory ILC2 population was identified (254). 
The data here strongly suggests that CCR6 is important for the migration of ILCs into the 
inflamed ear skin. The reduction of Kaede Green ILCs within the ear in the absence of CCR6, a 
chemokine receptor important in cell migration, further supports that ILCs are truly migratory, 
rather than a proliferating resident population. The ILC subset reduced within the inflamed 
ears of Ccr6-/- mice was ILC2s, therefore the dominant population migrating into the ear in a 
CCR6 dependent manner may be ILC2s. The decrease in ILC2s within the MC903 treated ears 
and auLNs of Ccr6-/- mice may in turn lead to protection against the development of AD. AD 
lesions and scabbing can be observed within the ears of mice treated with AD for up to 17 
days. Increasing the duration of MC903 application may determine whether these symptoms 
are clearly reduced in Ccr6-/- mice. To further determine whether this is due to a reduction in 
ILC recruitment CCR6 could be conditionally knocked out of ILCs, or more specifically ILC2s. As 
discussed previously, it is believed that ILC migration into the auLN from the skin is 
underestimated with potential migration of a hematopoietic cells from the surrounding areas 
of skin. It would therefore be interesting to determine whether migration from different areas 
of skin into the auLN was dependent on CCR6. This could be conducted by converting different 
segments of skin, such as the head skin, and observing the migration of ILCs from the selected 
area to the auLN compared between WT and Ccr6-/- mice. 
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The ability of ILCs to migrate into the inflamed ear skin, which was initially observed within 
the MC903 model, was further supported by an increase in ILC migration into the ears of the 
Aldara mice. Time permitting, the confirmation of a true migratory ILC population within the 
Aldara ears, rather than a rapid proliferating resident ILC population would have been 
assessed. Within the Aldara model, reports have published the VC in which the IQM is 
transported in may contribute to the pathogenesis of psoriasis (383). Therefore, using Aldara 
cream excluding the IQM would have been a more suitable control. 
Tomura et al established through the use of a skin irritant applied to the abdominal skin of 
Kaede mice that LC migration from the skin to the draining LN does not increase over a 4 day 
period, instead dermal DC migration is the main population of migratory DCs (247). However, 
this contradicts other reports showing that LC migration from inflamed skin to draining LN is 
paramount in the cross presentation of processed antigen and therefore activation of naïve T 
cells (366, 368, 393). This is demonstrated in the MC903 model where the depletion of LCs 
shows a defect in the development of AD-like symptoms (366). This investigation showed that 
LC migration into the auLN does increase upon ear inflammation, supporting the increased 
migratory properties of LCs over a 5 day period. The difference in skin irritants used, time 
periods observed, with dermal DC migration into the LN peaking at 24 hours and LCs at 4 days 
post skin irritant application, and areas of skin assessed may elude to the varying results of LC 
migration (247, 365).  
T cell migration into the skin is unaffected within Ccr6-/- Kaede mice, although publications 
report this migration to be CCR6 dependent (386). This may due be to other mechanisms 
contributing to T cell recruitment into the ear overriding the deficiency of CCR6 dependent 
 212	
migration. For example, memory T cells recirculating within the blood express the skin homing 
receptor CCR10 (392, 394). CCL27, the ligand for CCR10, is produced by keratinocytes within 
naïve skin and is upregulated in inflammatory conditions such as AD and psoriasis (394, 395). 
However, effector T cells infiltrate inflamed skin in a CCR10 independent manner (394). This 
suggests different mechanisms controlling the recruitment of T cells into the MC903 treated 
ear suggesting why T cell migration into the ear isn’t disturbed in Ccr6-/- Kaede mice. It would 
have therefore been interesting to investigate ILC and T cell migration in MC903 treated 
Ccr10- /- Kaede mice, focusing on identifying naïve, effector and memory T cell subsets. 
Regarding comparable numbers of migrating hematopoietic cells between WT and Ccr6-/- 
auLN of MC903 treated mice, CCL20 expression was only previously assessed in gut draining 
LNs, rather that peripheral skin draining LNs. It would therefore be interesting to investigate 
the expression of CCL20 within the skin draining LNs, or to again examine a different migratory 
mechanism such as CCR7 dependent migration. 
These findings, summarised in Figure 6.26, support that ILCs are not a solely tissue-resident 
population and are able to drain through the lymphatics into the auLN from the ear skin under 





Figure 6.26. Summary Diagram of ILC migration between the skin and draining LN 
Under steady state conditions there was a presence of a small migratory population of ILCs 
migrating into the ear, however, migration from the ear to draining auLN was undetectable. 
Under the AD-like skin inflammatory model, established via MC903 application for 5 days, ILC 
migration into the ear increased and a population of ILCs could now be observed to migrate 
from the ear into the draining auLN. ILCs were shown to migrate into the ear in a CCR6 
dependent mechanism, through the use of Ccr6-/- mice, whereas ILC migration into the auLN 
was independent of this mechanism. 
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Chapter 7.   DISCUSSION 
This project aimed to develop a better understanding of the relationship between ILCs located 
within lymphoid and non-lymphoid tissues. Through these studies ILC populations have been 
characterised within different anatomical compartments. This reveals a simple approach to 
identify ILCs without the reliance of surface markers, which show substantial variation 
depending on location. Using this identification method, the requirement of ICOS:ICOSL 
interactions in ILC biology was assessed, testing the effect on ILCs of a classic co-stimulatory 
interaction that regulates the behaviour of B and T cells. The lack of any clear evidence for a 
role for ICOS:ICOSL in the development and maintenance of ILCs led to a change in direction 
of the projects aims, prompting the investigation of whether ILCs are able to migrate between 
barrier sites and SLTs. Currently this is a poorly understood facet of ILC biology with important 
implications for their function. Photoconvertible Kaede mice were used to clearly show, for 
the first time,  the presence of a migratory population of ILCs traveling through the blood and 
lymphatics to peripheral LNs. Collectively these studies have revealed several important new 
aspects of ILC biology, supporting studies of ILCs by other researchers.   
7.1 ILCS ARE DISTRIBUTED THROUGHOUT LYMPHOID AND NON-LYMPHOID TISSUES 
ILCs are a population of innate cells that are similar to Th cells in their cytokine production and 
TF expression, however, they belong to the innate side of the immune system. They are 
located within non-lymphoid and lymphoid tissue around the body, being more abundant at 
barrier sites such as the SI LP, lung and skin compared to SLTs such as LNs. Through the use of 
a simple but robust staining panel, ILCs were detected across lymphoid and non-lymphoid 
tissues with the proportions of ILC subgroups being distributed differently in various tissues, 
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reflecting tissue specific functions. Using a consistent method to compare ILC subgroups 
across the analysed tissues revealed that not all ILC2s share the same phenotype. Markers 
that are commonly used to identify ILC2s were not found to be expressed in certain tissues. A 
robust method for the identification of ILCs that can be used across tissues is required due to 
the frequency of ILCs varying within the tissues. This establishes them as a separate population 
from T cells and other common innate cells. Key to this was a suitable lineage dump channel 
enabling a clear population of ILCs to be identified within most tissues, consistent with them 
being a separate population from other established cell types. 
7.1.1 TF are a useful tool in the efficient identification of ILC subsets 
Within the field, rapid progress has been made in identifying the different functions of ILCs 
within a variety of tissues, based on the expression of specific surface markers. This makes it 
difficult to keep up to date with varying phenotypes used to identify different subgroups, 
within various tissues under certain conditions. This has led to a variety of proposed methods 
in identifying ILCs and their subsets across different tissues, complicating the identification of 
ILC subsets. It is therefore important within the field that there is a consistent identification 
method for ILC subsets, to  enable a better understanding of their function and their 
relationships between different tissues. TF staining is a robust method in identifying ILC1s, 
ILC2s and ILC3, through the use of T-bet, GATA-3 and RORgt (28). Furthermore, the TFs T-bet, 
EOMES and RORgt are a more reliable method of separately identifying IFN-g producing ILCs 
such as ILC1s, cNK cells and NCR
+
 ILC3s, where they share surface markers such as NK1.1, 
NKp46 and CD49b (27, 130, 135). However, staining for TFs may not always be the most 
appropriate method of identification, depending on the tissue being analysed and the 
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experiments being conducted. ILCs are a rare population in some tissues, such as the human 
blood. Where tissues contain low frequencies of ILCs, the process of fixation and 
permeabilisation can substantially reduce the cell yield obtained due to longer protocols 
having increased cell loss. This low frequency of ILCs can be combated by merging samples, 
which may be more appropriate for murine experiments rather than human. Furthermore, if 
the experiment conducted requires the cells to remain viable, or their cell membrane to 
remain intact, for example cell sorting or analysing Kaede expressing cells, then staining for 
TFs would not be appropriate. Under these circumstances surface markers are more suitable, 
however, as shown within Chapter 3, surface markers are not a consistent method for 
identifying ILC subsets between tissues. When surface markers need to be used as a method 
of ILC subset identification, initially confirming the identification of the subset through TF 
staining and then assessing the surface marker expression is an appropriate method to use. 
Subsequently, upon assessing the appropriate surface markers, ILCs can be identified without 
the use of TFs, as shown in Chapter 5. 
7.1.2 The digestion protocol affects the identification of ILC subsets 
Although ILC subset identification is best achieved through the use of TFs, the digestion 
protocol, as well as affecting cell surface markers, also affects the expression of TFs. Previous 
publications have reported the loss of surface proteins due to different digestion protocols, 
however, it was slightly surprising when TF expression was also observed to be affected (266). 
These data clearly showed a reduction in the expression of T-bet and GATA-3 under a harsher 
digestion protocol, potentially reflecting the ‘wellbeing’ of the cells after an extensive 
digestion protocol. The importance of understanding the effect of different enzymes, 
incubation periods and temperatures on the cells being analysed, is key in the correct 
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identification of any population. Certain digestion protocols may skew the identification of 
different subsets by affecting key proteins used in their analysis. For example, CD4 and CD8 
expression is lost under a longer digestion with a higher enzymatic concentration, effecting T 
cell subset identification. This may potentially lead to the misidentification of a population or 
the increased presence of a population that does not fit into the current literature, such as 
the TrN ILCs described here. The TrN ILC population was shown to have similarities with the 
ILC population beyond just being identified within the Lineage
-
 IL-7Ra+ gating. This suggests 
that they were potentially a new subset of  ILCs not currently classified within the normal 
nomenclature. However, due to the digestion protocol directly affecting the number of TrN 
ILCs, it was a concern that this population was mainly comprised of ILC1s and ILC2s, that had 
lost either T-bet or GATA-3 expression, respectively. Further phenotyping of this TrN ILC 
population may help in identifying the proportional contribution of ILC1s and ILC2s that have 
just lost their TF expression due to the digestion protocol. The lack of knowledge regarding 
the phenotype of TrN ILCs makes it difficult to separate them from ILC subsets that have 
downregulated TFs. Culturing single cell suspensions, post digestion, may revive TFs or surface 
proteins expression which may have been lost due to the stressful conditions of a harsher 
digestion protocol. CD90 expression could also be assessed to further clarify their 
identification as an ILC population, alongside observing whether they are present within Rag- /- 
and Rag-/- γc-/-mice, which lack all ILCs. 
In conclusion digestion protocols and phenotypic markers vary between sites and clearly 
understanding these variations is key in obtaining a robust population for the correct analysis. 
This is of great importance when comparing populations across different tissues, which have 
different digestion protocols. 
 218	
7.2 ICOS EXPRESSION IS NOT REQUIRED FOR ILC MAINTENANCE UNDER STEADY STATE 
CONDITIONS 
ILC2s and ILC3s have been shown to interact with T cells, via presentation of antigen via MHCII, 
contributing to the regulation of the adaptive immune response (114, 162, 164). Co-
stimulatory molecules are important in facilitating these interactions, with it being suggested 
that the presence or absence of the co-stimulatory molecules CD80 and CD86, can affect 
whether ILC3s are able to stimulate or inhibit T cell activation (114, 162). However, data on 
the role of co-stimulatory molecules in ILC biology was limited, particularly when this study 
was started. ILCs have been described to express ICOS, ICOSL, OX40L, programmed cell death-
1 (PD-1), CD80 and CD86. These co-stimulatory molecules may aid ILC interactions with T cells 
or be important in T cell independent ILC functions (25, 114, 164, 262, 396, 397). Upon 
commencing this investigation co-stimulatory molecules role in ILC biology was still unclear, 
compared with T cell biology where their function is well documented. Within these studies 
the role of the co-stimulatory molecule ICOS was chosen to be analysed on ILCs due to it being 
highly expressed on ILC2s. At the time, ICOS expression had also been detected on ILC3s lab 
unpublished (Withers lab unpublished observations). Thus, it was interesting to use 
ICOS:ICOSL interactions as a model of co-stimulation which was hypothesised to be important 
in ILC biology.  
7.2.1 Differences in mouse biology as a result of differing animal facilities 
Within Chapter 4 it was concluded that the development and maintenance of ILCs was not 
dependent on ICOS:ICOSL interactions. This was controversial compared to publications by 
Paclik et al., who determined that ICOS is required for the expansion of ILC2s under steady 
state conditions (306). Differing results between these two studies may be explained by the 
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differences in animal facilities. One factor which differs between mice, even within the same 
facility, is their microbiota (307). ILCs are efficient at sensing the environment and responding 
to signals that reflect the microbiome state and composition, such as NCR
-
 ILC3s within the 
gut, and therefore changes in the microbiota may affect their homeostasis (162). Studies have 
focused specifically on the effect of the gut microbiota on many different biological factors 
including digestion, obesity and the immune system (308, 398). Even though mice may be 
genetically identical, gut microbiota, which is influenced by a variety of factors, may differ 
between mice in different facilities, in turn effecting animal health and potentially 
experimental results (307). For example, mice with different diets and therefore microbiota, 
respond differently to induced inflammatory diseases, such as dextran sodium sulphate 
induced colitis, with altered diets abrogating the disease (399). Therefore, variations in 
husbandry related factors such as diet, cleaning, handling and circadian cycles will result in 
differentiation between the gut microbiota and in turn, potentially affect the biology of the 
mouse including their immune system (307, 399-402). Different murine strains and suppliers 
will also have a different microbiota composition, which was shown to affect the ability of 
professional APCs to induce T cell responses (309, 403). This may specifically effect 
experiments if comparing inbred mice with out-sourced genetically modified mice.  
7.2.2 Publication of negative results is required within the scientific field 
Within Chapter 4 ICOS:ICOSL interactions were suggested to be redundant within the 
maintenance and development of ILCs under steady state conditions. Although these data are 
not necessarily of high impact, their results are still relevant within ILC research. Chapter 3 
contained a large amount of data characterising ILCs within different tissues. This robust data, 
whilst descriptive in nature, makes a useful contribution to the field, serving as a resource to 
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others, particularly people new to studying ILCs. The publication of negative data is important 
in streamlining and aiding future work within different groups, preventing the repetition of 
experiments that may show redundant functions of certain molecules.  
7.2.3 Co-stimulatory molecules are required for ILC function 
Combining the results from this investigation alongside the publications by Paclik et al., and 
Maazi et al., suggests that there is redundancy of co-stimulatory molecules expressed on ILCs 
under certain conditions and that other environmental stimuli may affect this. There may be 
roles for different co-stimulatory molecules in specific situations in which they should 
facilitate certain interactions between cells. It can be difficult to tease apart the importance 
of these co-stimulatory molecules on ILCs when other more dominant populations also 
express the same molecule. Conditional knock out mice would help, however, currently within 
the ILC field there is a lack of robust and specific ILC knock outs.  
Other co-stimulatory molecules that have been explored on ILCs includes PD-1, another 
member of the CD28 family. PD-1, which bind to its ligands PD ligand-1 (PDL-1) and PDL-2, is 
expressed on activated T cells and signalling through PD-1:PDL interactions prevents T cell 
proliferation and induces Treg development (404-406). This is a similar mechanism by which 
ILCs are regulated by PD-1. KLRG1
+
 ILC2s express PD-1 and through the use of anti-PD-1 or 
genetically modified mice lacking PD-1, Taylor et al., showed that in the absence of PD-1:PDL 
interactions, KLRG1
+
 ILC2s were increased in number and their function enhanced (407). 
Clinical studies are currently working on PD-1 as an immunotherapy target, due to tumours, 
viruses and bacteria being able to evade the host immune response through manipulating the 
PD-1 pathway (408-410). Together, these studies suggest that co-stimulatory molecules as 
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well as regulating T cell responses are important in the regulation of ILC populations, with the 
potential of being an immunological target in cancer therapies.   
Overall, the differences in mouse gut microbiota can affect the immune response and 
therefore analysis of immune populations within the assessed mice. Understanding these 
changes and adapting experiments to minimise these differences, may help in reducing 
variations across publications. For example the gut microbiota can be normalised after 
accommodation in a new housing facility, therefore, leaving new bought strains to acclimatise 
minimises gut flora variation (411). Furthermore, when analysing the function of a molecule 
on a cellular population, assessing its role under different conditions is important in observing 
its true function, as protein interactions may have specific roles under different conditions.  
7.3 ILCS MIGRATE UNDER STEADY STATE CONDITIONS IN PERIPHERAL LNS 
The continued exploration in the literature, focusing on the role of ICOS and ICOSL on ILCs 
under inflammatory conditions and the reduced impact on continuing this line of research, 
the focus of these studies was changed. Instead, the challenging and novel question of the 
relationship between ILCs within non-lymphoid tissue barrier sites and SLTs was pursued. Due 
to the availability of photoconvertible Kaede mice, in which in vivo cell migration can be 
directly tracked and other work in the lab utilising these mice to assess T cell residency, it was 
considered that the migration of ILCs between these two sites could be uniquely explored. 
During these studies a 6 month placement at MedImmune drove an interest in understanding 
the role of ILCs within ear skin and their relationship with the draining peripheral LN, 
particularly when inflammation was induced. Within the literature, parabiotic mice had 
recently been used to establish that ILCs were a tissue-resident population. However, 
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analysing migration within the peripheral LN of Kaede mice was believed to be able to address 
different questions which were not answered within the parabiotic models (248, 249). Two 
models were then established to track ILC migration within peripheral LNs. Initially the bLN 
model, which would be able to track cell migration into and out of the LN, and then the ear 
and auLN model, which was able to directly track migration of ILCs into the ear and from the 
ear to the auLN via the draining lymphatics. 
Establishment of the bLN Kaede model enabled simple questions to be answered concerning 
ILC movement within LN, such as their ability to enter or egress and the mechanisms behind 
this. ILCs were discovered to not comprise solely of a tissue-resident population, with 
migration being observed into and out of the LN under steady state conditions. Migration into 
the LN was dependent on CCR7, and ILC1s seemed to be entering from the blood, suggested 
by their duel expression of CCR7 and CD62L. ILC egress from the LN was also detected and 
shown to be dependent on the S1P gradient between the LN and the efferent lymphatic 
vessel. ILC migration was tracked to recirculate through the blood into contralateral LNs, 
suggesting they are able to re-enter secondary LNs, upon egress of a primary LN. However, 
this model alone was unable to sufficiently answer whether ILCs were able to migrate 
between non-lymphoid and lymphoid tissues via draining lymphatics. Therefore, the ear and 
auLN Kaede model was used to assess ILC migration from skin to the draining peripheral LN, 
which was observed to be limited. Together these models suggest a migratory population of 
ILCs that are able to enter into and egress from peripheral LNs. 
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7.3.1 ILC1s possess similarities in migratory properties to cNK cells 
Initial experiments clearly identified that ILC populations within the bLN change over time, 
highly suggestive of migration. ILCs however, had only been assessed as a whole population, 
therefore, the migratory properties of individual ILC subsets needed to be assessed. This key 
experiment identified ILC1s as the most migratory ILC subset within the bLN. ILC1s are closely 
related to the migratory population of cNK cells, with both subgroups being dependent on 
T- bet expression, sharing the expression of NCRs and being able to produce IFN-g and TNF-a 
(272). Therefore, the two populations migratory abilities were compared. Both populations 
express CD62L and CCR7 within the blood and were shown to recirculate through contralateral 
LNs (116). This indicated that ILC1s were similar to cNK cells in their ability to migrate within 
the blood and recirculate through SLT, suggesting that they may also have functional and 
behavioural similarities in ability in scanning SLT (115-117). Furthermore, although the 
migratory abilities of cNK cells through the blood have been explored before, this assessment 
of cNK cell migration was new data directly assessing their ability to recirculate, for which the 
Kaede model was required. Lucas et al., have shown that cNK cells recirculating SLTs are able 
to be primed within LNs, via DCs, and re-enter the blood with enhanced effector function 
(346). This suggests that if ILC1 migrate in a similar manner to cNK cells, then they may also 
be primed within LNs. Therefore, the assessment of activation markers on migratory ILC1s 
compared to tissue-resident ILC1s would be interesting to compare. These studies conducted 




, which does not specifically exclude ILC1s 
from this analysis, suggesting that part of this cNK cell priming may also include ILC1s (346).  
cNK cells are also able to migrate through the blood into non-lymphoid tissues such as the gut, 
however, Gasteiger et al., showed that ILC1s did not possess the ability to do this (249). 
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Migratory cNK cells, within human blood, can be subdivided into two groups based on their 
migratory abilities. CD161
+ 
cNK cells express chemokine receptors similar to neutrophils, 
suggesting their migration may be directed to acute inflammatory barrier sites (251). This is 
in comparison with CD161
-
 cNK cells, which express molecules important in trafficking into 
LNs, such as CCR7 and CD62L (251). ILC1s may be more similar to the CD161
-
 cNK cell 
population, as they only seem to be able to migrate into SLTs and not non-lymphoid tissues. 
However, these studies were conducted across human and murine samples and further 
studies would needed to be conducted to clarify similarities between subgroups (251).  
Tissue-resident NK (trNK) cells have been identified within the liver, thymus, uterus and skin 
as a separate subset to cNK cells (412). Although ILC1s are the most migratory population of 
ILCs, they still contain a resident population alongside the migratory cells within the peripheral 
LN. This may suggest that ILC1s and potentially other ILC subsets, may specifically consist of 
subsets that are able to migrate and others that are permanently resident, similar to NK cells. 
Detailed analysis of trNK cells compared to cNK cells, has revealed a variety of differences 
between the two populations, including their abilities to produce larger amounts TNF-a and 
IFN-g, respectively (412). Further differences in their NCR expression, cytotoxic abilities and 
TF expression, varies across trNK cells resident in different tissues, suggesting that trNK cells 
have tissue specific functions (413). ILC1s have also been identified with varying phenotypes 
within the salivary gland, liver and gut (135). This further supports previous data that ILCs 
phenotypes are not consistent across tissues and that TFs are a more robust method in 
analysing ILC subgroups. It may therefore be suggested that a migratory population of ILC1s 
exist, similar to cNK cells, alongside a population of tissue-resident ILC1s, in which the 
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phenotype varies depending on the tissue they reside in, similar to trNK cells. Assessing tissue-
resident ILC1s over a longer time frame than 72 hours would be useful in confirming that they 
are a long term resident population. 
Within this investigation, the identification of ILC1s within the bLN Kaede model does not 
exclude the potential to contain ex-ILC3s, which conceivably may possess distinct migratory 
properties. Indeed, the differences if any between ILC1 and ex-ILC3 remains poorly 
understood. It would therefore be interesting to observe the migratory abilities of ex-ILC3s to 
determine whether they acquire a more migratory phenotype, or whether they become part 
of the tissue-resident ILC population. Unfortunately, due to the fate mapping RORc cre mice 
using a fluorochrome that is already used within the Kaede mice, these mice could not be 
crossed and fate mapped and the migration of ex-ILC3s analysed.  
ILCs migrate into the bLN in a CCR7 dependent manner, however, it was not made clear by 
these studies whether ILCs migration into the LN depended on CCR7 directly, or on other CCR7 
dependent cells. This dependency may also change under certain inflammatory models. For 
example, under steady state conditions cNK cell migration into SLT is dependent on CCR7, 
whereas in activated LNs CCR7 becomes redundant and cNK cells migrate into the LN in a 
CXCR3 dependent manner(116). This may, however, be specific to the type of infection. 
Studies examining the migratory properties of ILC1s in Kaede mice, under steady state, or 
inflammatory conditions would be important in further understanding of the biological 
similarities and differences between ILC1s and cNK cells.  
cNK cell egress from the LN is dependent on the expression of S1PR5 (326). Within these 
experiments FTY720 was used to block S1PR, however, FTY720 does not have a strong affinity 
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to S1PR2 or S1PR5 (254, 261, 344). The migratory population of ILCs observed to still be 
entering the bLN under FTY720 block, may be comprised of ILC1s which egress from previous 
tissues in an S1PR5 dependent manner, similar to cNK cells. S1PR5 expression on cNK cells is 
directly regulated by T-bet, with mice deficient in T-bet having reduced levels of S1PR5 and in 
turn accumulating within the BM and LNs (344). This direct link between T-bet and S1PR5 
further suggests that ILC1s may be able to migrate within an S1PR5 dependent manner, which 
was not blocked in the experiments conducted within this investigation. 
cNK cells are able to be recruited from the blood and migrate into draining activated LNs 
producing IFN-g necessary for Th1 cell differentiation (116). Due to migratory ILC1s sharing 
similarities with cNK cells they may also be able to contribute to the polarisation of Th cell 
development in a similar manner. To explore this, Kaede mice could be immunised and the 
ability of migratory ILC1s, compared to tissue-resident ILC1s to produce the cytokines such as 
IFN-g and TNF-a to be assessed. Therefore, understanding the migratory properties of ILCs 
within peripheral LNs may lead to a clearer understanding of their function within SLTs. These 
data suggest that ILC1s are migratory under steady state and that they may actively seek out 
infected cells, in a similar manner to cNK cells.  
7.3.2 ILC2s and ILC3s are mainly tissue-resident under steady state 
In comparison to naïve T cells and cNK cells, the helper ILC population clearly has a larger 
proportion of tissue-resident cells over the time frame analysed. This population is mainly 
comprised of ILC2s and ILC3s. Parabiotic mice established for 3 months and 8 months have 
been used to show that under steady state conditions ILC2 migration occurs but is minimal 
and the biological relevance was questioned (249, 254). Similar to these parabiotic 
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experiments, ILC2s within the peripheral LN are comprised of a larger tissue-resident 
population than migratory. This was, however, only observed over a 72 hour period and longer 
time frame would be needed to determine long term residency. A recent publication has 
shown that an inflammatory subset of ILC2s possess the ability to migrate from the gut into 
tissues such as the lung, spleen and mLN under IL-25 stimulation or helminth infection through 
the use of parabiotic mice (254). This suggests that at least some ILC2s within the assessed 
peripheral tissues, may possess the ability to migrate under certain conditions, but that under 
steady state conditions they are mainly a tissue-resident population. Huang et al., show that 
iILC2 propagation from the gut may occur due to iILC2s not being present within the lung and 
mLN (108, 254). iILC2s can specifically provide quick sources of IL-13 compared to resident 
ILC2 populations, which are slower at cytokine production, to help combat infections (108, 
254). This therefore possibility that the peripheral LN may mainly contain tissue-resident ILC2s 
and that under certain inflammatory conditions iILC2s may specifically need to be recruited 
from other tissues into the LN. It would be interesting to assess ILC migration in peripheral 
LNs when mice were infected with different helminths, to determine if this changed ILC2 
migration and more specifically which ILC2 populations.  
Parabiotic mice have also been used to show that ILC3s are mainly tissue-resident under 
steady state conditions, more so than ILC2s (249, 254). Within the peripheral LNs ILC3s 
migratory abilities seemed to be similar to ILC2s, with a predominant ILC3 resident population 
within the bLN. Again, the time frame in which migration was assessed is a limitation in 
confidently defining Kaede Red ILC3s as permanently resident. Preliminary unpublished data 
within the lab has analysed the composition of ILCs within the bLN of Kaede mice 1 week after 
exposure, and observed a similar 50:50 ratio of Kaede Green to Kaede Red expression (Withers 
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Lab Unpublished Observations). Recent publications using Dendra mice have defined gd T cells 
as resident after observing their retention within the LN over a 4 week period (350). Using 
these mice and analysing tissue residency after a similar time frame would help to determine 
whether ‘resident’ ILCs are a long term tissue-resident population. Within embryonic 
development ILC3s, mainly LTi cells, are paramount in providing LTa1b2 signals for the 
development and maturation of LNs (111, 137, 414). The ILC3 population within adult LNs is 
mainly comprised of LTi-like cells, which are closely linked to the repair and maintenance of 
SLTs (244, 245). IL-7 promotes ILC3s in their ability to maintain the function of LNs, enabling 
normal T and B cell ingress (245). Stromal cells, such as LECs, have been shown to be an 
important source of IL-7, specifically in the remodelling of the LN after infection (415). 
Furthermore, within the adult ILC3s colocalise with specific stromal cells called marginal 
reticular cells, forming a particular niche for ILC3s (285). This close relationship of ILC3s with 
stromal cells within the developing LN, may be maintained within adult life, suggesting why 
ILC3s are mainly tissue-resident within the peripheral LN under steady state conditions. 
However, the data presented in Chapter 5 indicates that ILC3s are not solely tissue-resident 
and do contain a smaller migratory population. The studies of Mackley et al., supports the 
migratory properties of LTi-like cells from the gut to the draining mLN (243). This migration 
was assessed under a laparotomy and the labelling required substantial handling of the 
intestine tissue (243). This is an invasive procedure, potentially resulting in tissue damage and 
therefore increasing migration into the draining mLN (243). Overall, assessing the migration 
of ILC1s, ILC2s and ILC3s suggests that ILC1s are able to recirculate scanning for infected cells 
and that ILC2s and ILC3s are more resident under steady state conditions. As discussed, 
analysing the migration over a longer period of time and in the context of different responses 
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would help to further establish whether the resident populations observed after only a few 
days are really long term non-migratory cells. 
The challenges of retaining robust Kaede expression combined with convincing detection of 
TF expression meant that surface markers were used to identify ILC1s, ILC2s and ILC3s within 
the Kaede mice. As discussed previously, a caveat of this method was the inability to identify 
all subsets, with a proportion of each subset falling within the ungated population. Therefore, 
these results are representative for each subgroup, with some ILCs remaining unanalysed. For 




 ILC3s fell within the ungated population due 
to them being unable to be identified separately from ILC1s. Therefore, CD4
-
 ILC3s may have 
a different migratory profile compared to CD4
+
 ILC3s, although no differences have previously 
been observed amongst these populations, including chemokine receptor expression (416). 
These results do however, provide a simple model in which ILC migration can be assessed in 
LNs and shows that ILC subsets have different migratory abilities under steady state 
conditions.  
7.3.3 Do migratory and tissue-resident ILCs possess different functions? 
Through the use of Kaede mice a population of ILCs were identified that migrate into the LN 
and a population that remain resident over the time period assessed. A key unanswered 
question from these studies is, what is the functional significance of ILC migration through 
LNs? Further work is required to establish whether migratory ILC subsets possess altered 
functions, compared with those that appear to be more tissue-resident. 
Within this investigation the ability of ILCs to present processed antigen via MHCII was not 
assessed. However, ILC3s and ILC2s have been shown to possess the ability to directly 
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communicate with T cells via TCR:MHCII-antigen interactions (114, 162, 164). It would 
therefore be interesting to assess the expression of MHCII alongside co-stimulatory molecules 
compared between migratory and resident populations. It is, however, unlikely that the 
population of migratory ILC2s and ILC3s within the bLN are APCs, due to them being small 
population compared to professional APCs, such as LCs. Studies exploring ILC:T cell 
interactions have mainly focused their studies within the gut and mLN (114, 162, 164). 
Exploring the migratory properties of ILCs within the mLN, compared to the peripheral LNs, 
would be another manner in which ILC migration could be assessed. This may be beneficial 
due to the mLN being a larger LN and draining the gut which is a large barrier site, suggesting 
that it may be easier to identify a bigger population of migratory ILCs. However, ILC migration 
could not be assessed through the blood under steady state, as shown by ILC tissue residency 
in the mLN and gut of parabiotic mice, and a more invasive procedure would be required to 
photoconvert the mLN (243, 249). 
A useful method to examine a variety of features that may differ between migratory and 
resident ILCs would be ribonucleic acid (RNA) sequencing. This would screen for a large 
number of genes expressed, helping to assess the differences between the populations. For 
example, different chemokine receptors and integrins involved in migration, as well as 
different surface receptors which may be required for different functions. A caveat of this 
Kaede model, is the size of the ILC population identified within the peripheral LN. Samples 
would have to be combined to collect enough ILCs to sort into Kaede Green and Kaede Red 
before analysis. This would, however, be an efficient manner in which the properties of 
migratory and resident ILCs could be compared. 
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In summary, the Kaede model established has provided basic migratory data of ILCs under 
steady state conditions within the peripheral LNs. Understanding the biology of ILC migration 
has helped in further understanding different functional aspects of the ILC subgroups. This 
model could be used to simply analyse migratory properties of other populations in different 
tissues analysing mechanisms behind influx and egress.  
7.4 ILC MIGRATION UNDER INFLAMMATION 
Minimal ILC migration from the ear to the auLN was observed under steady state, showing 
that within the assessed tissues ILCs do not efficiently migrate through the draining lymph 
from non-lymphoid tissues. This posed the question of whether ILCs are only able to migrate 
in the blood, or whether certain inflammatory conditions can drive the migration of ILCs within 
the draining lymphatics. The well characterised model of AD, induced through applying 20 µL 
of MC903 to the ear, was chosen as the main model of skin inflammation due to its 
reproducibility. Other models, such as the house dust mite model (HDM), which was the initial 
skin inflammation model examined within the MedImmune placement, contained variabilities 
between batches, potentially leading to inconsistencies between experiments. This model has 
also been used less widely and takes several weeks to run, potentially limiting the progression 
of the work. Furthermore, the reproducible application process of MC903 was more accurate 
compared to the HDM and the Aldara model, in which the HDM was applied using a cotton 
swap and the Aldara cream being weighed and applied using a spatula. Under the model of 
AD ILC migration was observed to increase from the inflamed ear to the auLN, showing that a 
modest number of ILCs were able to migrate through the lymphatics from barrier sites to 
draining LN. However, this migration was not observed within the Aldara treated mice, 
suggesting that this migration is dependent on stimuli used and the inflammatory condition 
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that develops. Another model, not used within these studies, may be more specific to assess 
the activation and migration of ILCs. 
Upon the induction of skin inflammation ILCs were increased within the ear, accompanied by 
an increase in ILC recruitment from the periphery. ILC migration also increased from the ear 
via the draining lymphatics into the auLN, only with the AD model, consistent with the ability 
of ILCs to enter peripheral LNs via the lymph. Together these data suggest that under 
inflammatory conditions, some ILCs receive activation or chemotactic signals resulting in their 
migration into inflamed skin and draining LNs. Although migration was clearly assessed, 
proliferation of ILCs within the ear and auLN was a contributing factor to the expansion of 
their population. 
7.4.1 ILCs are recruited into the inflamed ear skin 
Unfortunately, due to the challenges in identifying ILCs confidently by surface markers within 
the ear, the different migratory properties of ILC subsets was not assessed within the AD 
model. However, an increase in ILC migration into the ear was identified and it was suggested 
that lymphocytes, mainly gd T cells, were able to redistribute from certain areas of adjacent 
skin into the inflamed ear. Due to the Kaede model being more efficient at tracking migratory 
cells out of a specific photoconverted area, determining the original location of cells migrating 
into the photoconverted ear was more challenging. Another caveat of the Kaede model is the 
ability for resident rapidly proliferating photoconverted cells to dilute out their Kaede Red 
expression and return to a Kaede Green fluorescence, in turn being identified as a migratory 
cell in these experiments. Through assessing the rate of proliferation, it was concluded that 
not all Kaede Green ILCs within the ear showed evidence of proliferation, suggesting at least 
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some ILCs were actively migrating into the labelled tissue. However, it is likely that a large 
factor contributing to the increase in hematopoietic cells, including ILCs was proliferation. 
Upon skin inflammation keratinocytes produce alarmins including TSLP, IL-25 and IL-33 which 
may in turn lead to the activation, proliferation and increase in ILC numbers (1, 112). 
Huang et al., show that iILC2s do not migrate from the gut into the lung upon intranasal 
administration of IL-25, however, do migrate upon i.p. injection of IL-25 (254). Within the 
inflammation models used, the effect of ingesting MC903 or Aldara during grooming was not 
assessed. Potentially the ingestion of these substances activate ILCs within the gut and leading 
to their recruitment in other tissues, such as the ear skin. It would be interesting to determine 
if ILCs were increased in any other tissues, such as the gut, lung and mLN, alongside the ear. 
Within the AD and psoriatic models of skin inflammation ILC2s and ILC3s, respectively, have 
been shown to contribute to disease pathogenesis by cytokine production (112, 231, 233). 
These publications show an accumulation of ILCs within the ear, however, were unable to 
directly assess ILC migration. Chapter 5 shows that the increase in ILCs within the inflamed ear 
is directly contributed to by the migration of ILCs from the periphery. Understanding that 
migratory ILCs contribute to increased numbers within the inflamed AD ear in a CCR6 
dependent manner, may contribute to the design of therapeutic strategies to limit such 
inflammation. Within the MC903 model the depletion of ILC2s attenuated the pathology of 
AD, suggesting that either targeting the mechanistic migration of ILCs into the ear, via CCR6, 
or targeting their expansion may reduce the disease development (112).  
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7.4.2 ILCs accumulate within challenged peripheral draining LNs 
Under steady state conditions ILCs were not observed to migrate from the ear to the draining 
auLN. To determine whether migration via the lymphatics increased under inflammation, the 
AD model was used to discover that migration of ILCs from the inflamed skin to the draining 
auLN did contribute to the accumulation of ILCs in the auLN. Interestingly, although an 
increase in ILCs is observed within the auLN of Aldara treated mice, their migration from the 
ear is not. This suggests that ILC migration through the lymphatics may be dependent on 
certain forms of inflammation, or perhaps inflammation in certain sites. Inflammation within 
the Aldara model spreads over a larger area of skin, including the head and face, compared to 
the AD model. This may result in the migration of ILCs into an alternative draining LNs such as 
the cLN. Due to the lack of detection of ILC migration into the auLN within the Aldara model, 
this discussion will focus on ILC migration from the ear to the auLN within the AD model.  
Within the draining auLN, proliferation seems to be one of the key mechanisms in which ILCs 
were increasing, compared to migration from the ear. However, other mechanisms of ILC 
entry into the LN have not been explored within these studies. Although lymphocyte migration 
increases from the ear to the auLN a larger number, roughly double, of hematopoietic cells 
can be observed to migrate from the head skin to the auLN. This suggests that the ear skin is 
not the only area draining to the auLN and that other areas of neighbouring skin may also 
drain to the auLN. ILC migration was not assessed from the head skin, however, it could be 
assumed that it may also contribute to the increase of ILCs within the auLN. ILC migration from 
the blood was also not assessed. Under inflammatory conditions egress from the activated LN 
can be prevented, resulting in the accumulation of cells. ILCs migrating in from the blood, may 
therefore accumulate within the auLN, contributing to the increase in number of ILCs. Within 
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these experiments it was shown that ILC1s were the main population within the blood, 
however, Huang et al., show that under IL-25 stimulation and helminth infections, ILC2s are 
also present within the blood (254). Inducing inflammation within the ear may increase the 
migration of other ILC subsets within the blood, therefore resulting in an accumulation of all 
ILC subsets within the auLN, via blood.  
The striking increase in ILC numbers observed within the mild early stage of AD suggests it 
would be interesting to assess further this accumulation under prolonged chronic conditions. 
Assessing whether the increase in ILC numbers is maintained, increased or reduced over 
longer periods of time, may help to identify at which stage in AD development ILC numbers 
peak. If ILC numbers decrease during chronic inflammation it may be clear that they were 
mainly functional within the early stages of infection, however, if they are maintained at high 
levels or increase in number further, they may be more important in interacting with or 
supporting the adaptive immune response. 
In conclusion, it is likely that a combination of proliferation and migration contributes to the 
accumulation of ILCs within the auLN, with the possibility of migratory cells entering the LN 
and then undergoing proliferation.  ILCs were only assessed during the development of this 
early model of AD and assessing the ILC populations under different conditions after this 
application period would be interesting. Extending the AD model was discussed above, 
however, also assessing how quickly ILC numbers return to normal, upon stopping MC903 
application, is also of interest. It is known that ILC3s are important in the maintenance and 
repair of SLTs, suggesting that maybe ILC3 numbers, or another subsets, may take longer to 
return to normal than other ILC groups (244, 245). In addition, it could be considered what 
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might occur upon a second course of MC903 application, after recovering from the first. As 
ILCs are part of the innate immune system, one may assume that they would react in a similar 
manner to the first MC903 exposure, however, this could be easily assessed within this model. 
7.4.3 Accumulation of ILCs within the LN suggests a role in crosstalk with the adaptive 
immune system 
ILCs function within the inflamed ear has been previously reviewed in other publications, with 
this investigation confirming their direct migration into the ear (112, 231, 233). On the other 
hand, why ILCs migrate into the draining LN is less clear. Multiple studies have shown the 
ability of ILCs to interact with the adaptive immune system. The clearest role for ILCs is in the 
intestine, where there is evidence that they limit CD4
+
 T cell responses in an MHCII-dependent 
manner (162). Furthermore, ILC2s are suggested to help prime Th2 responses against lung 
helminth infections (164). The evidence supporting TCR:MHCII-antigen interactions between 
ILCs and T cells comes from studies deleting MHCII on ILCs specifically (162, 164). It may 
therefore be suggested that ILC migration into peripheral LNs under inflammatory conditions 
may in turn complement the function of DCs. For example, ILCs may present antigen via 
MHCII, provide co-stimulatory molecules or cytokines to enhance the function of DCs or to 
reinforce or sustain the T cell response. ILCs may transport processed antigen from the 
inflamed ear to draining auLN. However, ILCs expression of MHCII, ability to uptake antigen 
and migrate from the ear to auLN is reduced compared to professional APCs, such as LCs. This 
suggests that ILCs may not primarily function as APCs, as they seem uncompetitive when 
compared to DCs, particularly for initial priming of T cells as they have much lower expression 
levels of CD80 and CD86 (114). ILC2s have also been shown to be able to take and present 
MHCII-antigen from other APCs, called trogocytosis (164). This may be a more effective 
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manner in which ILCs express antigen and this could be a feature that separates migratory and 
resident ILCs. Migratory ILCs may be able obtain antigen and present it via MHCII in the 
inflamed tissue, before migrating into the draining LN. Resident ILCs may be more likely to 
take MHCII-antigen complexes off other cells. There are multiple other possible mechanisms 
in which ILCs may directly interact with T cells within the LN, for example, providing co-
stimulatory signals supporting cell survival. Therefore, further testing is required to specifically 
understand whether migratory ILCs have a different role within the draining LN compared to 
resident ILCs, specifically comparing their expression of co-stimulatory molecules. 
The environment in which T cells are activated can drive the polarisation of Th cell 
differentiation (47, 68, 69). Upon accumulation and proliferation within the auLN, ILCs may be 
activated by soluble factors from the draining lymph and in turn produce cytokines effecting 
Th cell development. This supports the ability of ILCs to communicate and shape the adaptive 
immune response. Further studies would be required to directly link ILC cytokine production 
to the development of certain Th effector responses under different inflammatory conditions. 
ILC specific knock outs would be a key tool in this analysis, however, these are currently still 
being developed within the field. Due to ILCs sharing TFs related to T cells, such as T-bet, 
GATA- 3 and RORgt as well as Id2 being required for the development of other lineages, 
targeting these genes depletes more than just ILCs. 
In conclusion, assessing the increased migration of ILCs within the inflammation models 
indicates that ILCs are required within the ear and the draining auLN during inflammation. 
Migration from the inflamed ear to auLN is detected and potentially this is underestimated. 
ILCs from surrounding tissue, such as the head skin, possibly also migrate into the auLN. 
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However, local expansion within the draining auLN likely plays an important role in the 
accumulation of ILCs, consistent with ILCs providing cytokines to promote T cell development, 
compared with transporting antigen from the inflamed tissue. Photoconvertible models 
provide a key tool through their direct in vivo assessment of migration, enabling the 
deciphering of mechanisms controlling such trafficking. This can be achieved by crossing 
Kaede mice with genetic mice lacking certain chemokine receptors, such as done within this 
investigation with Ccr7-/- Kaede and Ccr6-/- Kaede mice. 
7.5 CONCLUDING REMARKS 
Overall, these studies have addressed fundamental issues in the identification methods of ILCs 
across the current literature, taking into account varying phenotypic marker expression within 
different tissues, alongside the effect of digestion protocols. The requirement for a potentially 
key co-stimulatory molecule, in ILC biology, was tested across a number of tissue 
environments, concluding that development and maintenance of ILC1s, ILC2s and ILC3s under 
steady state was independent of ICOS. However, ILCs dependency on ICOS:ICOSL interactions 
was shown to be dependent under certain conditions, with ILC survival and proliferation in 
the induction of airway hyperreactivity being dependent on these interaction (262, 306). 
These studies provide much needed clarity of the migration of ILCs into SLTs. Under steady 
state ILC1s can be observed to recirculate through the blood and LNs, in a similar manner to 
cNK cells, suggesting that they actively survey for danger signals. In comparison, ILC2s and 
ILC3s are more tissue-resident, consistent with other studies and their migration may instead 
be activated upon immunological challenge. Although the migration of individual ILC subsets 
was not assessed, ILC migration is clearly increased under skin inflammation. With the AD-like 
inflammation model being driven by a Th2 response and ILC2s role within driving 
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pathogenesis, it is highly possible that ILC2s are migrating into the ear of the inflamed mice 
and that this is in turn dependent on CCR6. Through understanding the migratory properties 
of ILCs, this highlights potential biological roles of ILCs and their different subsets under steady 
state and inflammatory conditions.  
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